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INTRODUCTION 
1 Epidemiology 
Although being a rare childhood cancer accounting for 1% of all pediatric neoplasms, 
hepatoblastoma represents 80% of hepatic-related cancers in children. This tumor affects 
approximatively 1:1,000,000 children under the age of 15 and most predominantly between 
6 months and 3 years1, 2.  
It has been reported that the risk of developing hepatoblastoma is increased in subjects that 
are afflicted by several syndromes including Beckwith-Wiedemann syndrome (BWS)3, 
hemihypertrophy or familial adenomatosis polyposis (FAP)4. Previous studies have also 
reported an increased incidence in subjects with low birth weight5. 
2 Clinical presentation, diagnosis 
This tumor is most frequently detected by palpation of an asymptomatic hepatomegaly. 
Other clinical presentations can include jaundice, weight loss, pain and/or fatigue 
depending on the tumor progression. Blood test and imaging such as computed 
tomography scan and magnetic resonance imaging are key for diagnosis. Blood tests often 
reveal high levels of Alpha-Feto-Protein (AFP), a robust marker of hepatoblastoma6. Less 
importantly, in some instances, it reveals a disruption of coagulation homeostasis as 
proteins of coagulation are synthesized in the liver. 
At diagnosis, imaging reveals either an unifocal or multifocal tumor. Synchronous 
metastases are present in 20% of hepatoblastoma and are often localized in the lung. On 
the other hand, metachronous metastases are generally found in the lung as well as the 
brain and bones7. 
3 Histology 
The etiology of hepatoblastoma is still not known but the tumorigenesis is believed to occur 
through a derailed development of immature hepatocytes precursors, which  normally 
differentiate into several cell types, including hepatocytes, epithelial, biliary and 
mesenchymal cells. This explains the cell heterogeneity of the tumor and the different 
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histological subtypes. Hepatoblastoma can be classified in the epithelial (56%) or mixed 
form (epithelial and mesenchymal, 44%). The epithelial form further regroups the pure fetal 
(31%), embryonal (19%), macrotrabecular (3%) and the small-cell undifferentiated (3%) 
subtypes8, the latter being associated with poor prognosis9. 
4 Staging systems 
There are currently four leading childhood liver study groups in the world: the International 
Society of Pediatric Oncology group (SIOPEL) which is located in Europe, the Children's 
Oncology Group (COG) in North America and the national study groups from Germany 
(GPOH) and Japan (JPLT). As mentioned above, techniques such as magnetic resonance 
imaging, computed tomography and blood tests are used to evaluate the PRE-Treatment 
tumor EXTension (PRETEXT), POST-Treatment EXTent of Tumor (POSTTEXT), AFP 
level, tumor histology and metastatic diseases10-13.  Each group has their own staging 
system and treatment strategies although recent efforts are made toward standardization14. 
Here, we will only describe the methodologies instigated by the SIOPEL and COG groups. 
 
4.1 SIOPEL 
The PRETEXT staging system, originally created by the SIOPEL group, is based on 
imaging prior to any treatment to characterize the localization of the tumor using Couinaud's 
system of segmentation of the liver.  
It distinguishes four PRETEXT stages (Figure 1) but also uses other parameters to assess 
the spread of the tumor beyond the liver (lymph node metastases, portal vein involvement, 
involvement of the inferior vena cava and/or hepatic veins, extrahepatic abdominal disease, 
tumor rupture or intraperitoneal haemorrhage disease, distant metastases)15.  
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Figure 1: PRETEXT staging system 
I: one section is involved and the 3 adjoining sectors are free. II: two sections are involved. III: two or three 
sections are involved and no two adjoining sections are free. IV: all sections are involved. Figure taken from 
Kadheri et al.
16
  
 
4.2 COG 
The POSTTEXT staging system was developed by the COG group. The staging 
methodology consists of an initial surgery attempt to completely resect the tumor followed 
by chemotherapy courses. Following the surgery, four groups are distinguished depending 
on the outcome: stage I, corresponds to complete resection; stage II to microscopic 
residual; stage III to macroscopic residual and stage IV to distant metastases.  
5 Molecular alterations in hepatoblastoma 
Different molecular alterations have been identified as being involved in the genesis of 
hepatoblastoma. More particularly, a deregulation of different signaling pathways has been 
described among which the canonical Wnt signaling, Sonic Hedgehog, Notch and 
phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin 
(PI3K/AKT/mTOR)17.  
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5.1 The canonical Wnt signaling pathway 
5.1.1 Description of the pathway 
The canonical Wnt signaling pathway is known to play a vital role in the regulation of cell 
proliferation, survival and differentiation18. In 1982, the mouse mammary tumor virus 
caused tumor development in mice via increased expression of an unknown gene that 
became known as Integration 1 (Int1)19. Simultaneously, the previously discovered 
Wingless (Wg) gene, mutated in fruit flies lacking wings, was found to be a homologue of 
Int120. This led to the description of the Wnt pathway (Wnt is a fusion of Wg and Int1)21. The 
level of conservation also highlights the importance of this pathway in development. 
Currently, we have a good understanding of the mechanisms involved in the Wnt pathway 
(Figure 2): 
Figure 2: Representation of the canonical Wnt pathway 
(a) Wnt off: ubiquitin-dependent degradation of β-catenin in the cytosol by the destruction complex (GSK3β, 
AXIN, CK1α, APC) through phosphorylation processes. TCF transcription factors are repressed by Groucho 
and Wnt target gene expression is inhibited. (b) The binding of the Wnt ligand to its receptor induces the 
sequestration of AXIN, which therefore inactivates the destruction complex. β-catenin subsequently 
accumulates in the cytoplasm and is free to translocate into the nucleus, where it binds to TCF to activate Wnt 
target gene expression. Figure taken from Barker et al.
22
 
 
In the absence of Wnt ligand, cytoplasmic β-catenin is taken up by a destruction complex, 
made up of APC, AXIN and two kinases, namely glycogen synthase kinase 3β (GSK3β) 
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and casein kinase 1α (CK1α), which phosphorylates the N-terminus of β-catenin23. It is then 
ubiquitinated by β-transducin repeat-containing protein and degraded in proteasomes, 
keeping cytoplasmic β-catenin at low levels24. In this state, a molecule called Groucho 
interacts with and inhibits the transcription factors LEF/TCF of this pathway, suppressing 
the expression of the Wnt target genes25. 
However, in the presence of Wnt ligands (19 Wnt ligands have been discovered in 
humans21), they bind to Frizzled receptors and LRP5/6 co-receptors. This results in the 
phosphorylation of LRP5/6 by casein kinase 1γ and the recruitment of the Dishevelled 
protein to the membrane, which causes AXIN translocation to the membrane26. This 
inactivates the destruction complex, disrupting β-catenin phosphorylation, and hence 
stabilizing the β-catenin concentration in the cytosol. Therefore, β-catenin is free to 
translocate to the nucleus, where it displaces the repressive Groucho molecules, forming its 
own complex with LEF/TCF27, resulting in the activation of Wnt target gene expression. 
Many Wnt target genes have been discovered, most importantly the proto-oncogene MYC 
and cyclin D1 involved in cell cycle regulation28. Other target genes include the actual 
components of the Wnt pathway (Frizzled, LRP5/6, AXIN, LEF/TCF) providing a 
mechanism by which this pathway could auto-regulate itself21. 
In the late 1990s, a number of Wnt pathway inhibitors were discovered: secreted Frizzled-
related peptides, Wnt inhibitory factor 1 and Dickkopfs (DKKs)29, 30. One study showed the 
inhibitory effect of one DKK receptor, Kremen, via LRP receptor internalization31. Another 
family of Wnt homologues, the R-spondins, have also been discovered to activate the 
canonical Wnt signaling pathway through interacting with the Frizzled/LRP complex32. 
5.1.2 Role in cell adhesion 
The presence of β-catenin is essential for cell adhesion. It creates a bridge between the 
cytoplasmic part of E-cadherin and the actin cytoskeleton to form adherens junctions, which 
promote lateral cell anchoring33. Interestingly, previous work identified this complex as 
being involved in canonical Wnt signaling regulation. Indeed, the APC protein, β-catenin 
and E-cadherin never seem to associate simultaneously: the complexes APC/β-catenin and 
E-cadherin/β-catenin appear mutually exclusive34. It has been reported that following the 
decrease of E-cadherin expression, the level of free β-catenin increases, which promotes 
its nuclear translocation and subsequently Wnt target gene expression35. 
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The mechanics by which β-catenin and E-cadherin interact is partially uncovered. In the 
endoplasmic reticulum, E-cadherin is specifically phosphorylated allowing its binding to     
β-catenin and at the same time, preventing its degradation36. Once at the membrane, 
phosphorylation of β-catenin at distinct sites by several kinases, can regulate the complex 
association37. For example, the hepatocyte growth factor triggers phosphorylation of          
β-catenin at tyrosine 654 and tyrosine 670 in hepatocytes, which induces the disruption of 
the complex and nuclear translocation of β-catenin38. 
5.1.3 Role in the liver 
It is well established that canonical Wnt signaling plays an important role in liver 
homeostasis: from embryonic liver to its functional maturation, which reinforces its role in 
hepatoblastoma tumorigenesis39-41. However, in the adult liver, canonical Wnt signaling is 
not activated except in the centrizonal region of the hepatic lobule as proved by positive 
nuclear and cytoplasmic β-catenin in this area41. This was associated with the regulation of 
genes involved in ammonia and xenobiotic metabolism.  
Importantly, reactivation of this pathway also occurs during liver regeneration in adults42. It 
is a really unique process allowing for instance spontaneous regrowth of the liver after 
partial hepatectomy43. This process is known to occur through the proliferation of mature 
cells, including hepatocytes, and doesn't cause any inflammation to the surrounding 
tissues44. At the molecular level, Wnt signaling is quickly activated through inhibition of      
β-catenin degradation resulting in an increase of the protein by 2.5 fold and its nuclear 
translocation42. In the nucleus, β-catenin induces proliferation through positive regulation of 
genes implicated in cell cycle regulation such as cyclin D141, and protein level returns back 
to normal 48 hours post resection42.  
5.1.4 Alterations of canonical Wnt signaling in cancer  
Mutations in the canonical Wnt signaling pathway have been shown to deregulate the cell 
cycle, resulting in the development of human cancers. For example, CTNNB1 (the             
β-catenin gene) mutations are found in numerous cancers, including colorectal, 
hepatocellular, ovarian cancers and notably hepatoblastoma45. The majority of these 
mutations result in the deletion/alteration of the N-terminal fragment of β-catenin, and hence 
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its degradation in the cytosol45. Therefore, excess β-catenin translocates to the nucleus and 
binds to LEF/TCF, resulting in the overexpression of Wnt target genes.  
However, the most famous mutation of the Wnt pathway concerns APC, located at the 
5q21-22 locus46, which is mutated in FAP patients, an inherited disease associated with the 
development of thousands of benign polyps in the colon, of which a few inevitably become 
malignant47, as well as in patients with sporadic colorectal cancers47. 
The APC protein contains a region of SAMP repeats (three repeats of a specific sequence 
of amino-acids) that are vital for its successful binding to both AXIN and β-catenin48, 49. 
However, in colorectal cancer, numerous types of mutations (frameshift, nonsense and 
splice-site) build up prior to this region, leading to the truncation of 50% of the APC 
proteins45. This disrupts the destruction complex, which allows an increase of 
cytoplasmic/nuclear β-catenin and thus an overexpression of Wnt target genes. 
5.1.5 Deregulation of canonical Wnt signaling in hepatoblastoma 
High frequency of point mutations and deletions in exon 3 of CTNNB1 was first reported by 
Koch et al.50 and confirmed by others (49%-89%)51 indicating a crucial role of this pathway 
in hepatoblastoma. Subsequent immunohistochemistry experiments confirmed an aberrant 
cytoplasmic/nuclear localization of β-catenin in the majority of hepatoblastomas52-54. Other 
members of the pathways have been screened for mutations in sporadic hepatoblastoma 
such as AXIN1, AXIN2 or APC. Although some discrepancies exist between studies, AXIN1 
was found mutated in 1.6%55 or 7.4%56, whereas AXIN2 was found mutated in 5.4%57 of 
the cases investigated. Furthermore, germline mutations of APC were reported in 10%58 
and somatic mutations in 61.5%59 of sporadic hepatoblastoma. 
Apart from this, one study focusing on Wnt antagonists revealed a transcriptional up 
regulation of this particular class in hepatoblastoma cells. The fact that Wnt signaling is 
constitutively expressed in Wnt mutated cells despite the high level of antagonists, indicates 
the presence of a complex regulation mechanism of β-catenin within these cells60.  
Finally, previous studies have found no correlation between elevated Wnt activity and MYC 
expression in normal liver cells as well as hepatoblastoma cells, which implies that this 
gene is most likely not a Wnt target gene in this context53, 61, 62. 
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5.2 PI3K/AKT/mTOR axis 
The PI3K/AKT/mTOR signaling pathway is involved in the regulation of many cellular 
functions, such as metabolism, proliferation, survival and motility63. This pathway is often 
deregulated in cancer cells, such as hepatoblastoma64, as most of its proteins are tumor 
suppressor genes or proto-oncogenes whose mutation or anarchic expression can promote 
the development of a tumor65, 66. Therefore, this pathway constitutes an interesting 
therapeutic target67. 
5.2.1 Receptor Tyrosine Kinase (RTK)  
The PI3K/AKT/mTOR pathway is most often activated through a RTK, itself stimulated by 
multiple ligands (growth factors such as IGF, EGF or cytokines). It induces the activation of 
many intracellular proteins through cascades of phosphorylations68. Numerous human RTK 
have been characterized today constituting 20 subfamilies illustrated in Figure 3. Of note, 
the epidermal growth factor receptor (EGFR) was the first RTK characterized and found 
mutated in cancer69. 
 
Figure 3: Illustration of the subfamilies of human RTK 
RTK are grouped into 20 subfamilies, all characterized by intracellular domains containing the tyrosine kinase 
(red rectangles). Members of each subfamilies are shown under each receptors. Figure taken from Lemmon 
et al.
68
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More precisely, following the binding of the ligand, the receptor is activated through 
dimerization and transphosphorylation of its intracellular portion mediated by conformational 
changes, corresponding to the activation of the tyrosine kinase domain70. Several signaling 
pathways have been described to be activated following the activation of a RTK, the most 
described being the PI3K/AKT/mTOR, RAS/Raf/MAPK, JAK/STAT3 and Src/PLCγ 
pathways70. Here, we will focus on the PI3K/AKT/mTOR pathway. 
5.2.2 PI3K kinases 
PI3K are lipid serine/threonine kinases constituted of 2 subunits: p85 (regulatory subunit) 
and p110 (catalytic subunit), the latter being activated by RTK. PI3K can be grouped in 
three different classes (I, II, III)71. PI3K from class I-A, a particular subgroup of class I, are 
the most commonly found in cancer. The regulatory subunit p85 contains a SH2 domain, 
recognizable by the phospho-tyrosine of the activated RTK as well as by adaptor proteins 
such as the insulin receptor substrate family of adaptors (IRS)72.  
In any cases, upon activation, PI3K phosphorylates the phosphatidylinositol-4,5-
bisphosphate (PIP2) at the membrane through its catalytic subunit p110, to form the 
phosphatidylinositol-3,4,5-triphosphate (PIP3)73. At the membrane, PIP3 can further recruit 
proteins with Pleckstrin Homology (PH) domain such as Phosphoinositide-Dependent 
Kinase-1 (PDK1) and AKT. PIP3 is thus a phospholipid second messenger, which is 
mandatory for AKT activation74. Phosphatase and tensin homologue (PTEN) catalyzes the 
dephosphorylation of PIP3 into PIP2, which abrogates the signal (Figure 4).  
 
 
Figure 4: Mechanisms of activation of PI3K from class IA 
PI3K from class IA can be activated by RTK or by adaptors through the SH2 domain of its regulatory subunit 
(p85), which recognizes and docks to phosphorylated tyrosines. Catalytic subunit of PI3K (p110) subsequently 
phosphorylates PIP2 at the membrane to form PIP3. Negative regulation of this pathway is mediated by the 
phosphatase PTEN, which dephosphorylates PIP3 into PIP2. Figure taken from Engelman et al.
75
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5.2.3 AKT  
AKT is a serine/threonine kinase whose activation is subsequent to its binding to PIP3 at 
the membrane through its PH domain76. There are different isoforms of AKT kinases, which 
are encoded by the AKT1, AKT2 and AKT3 genes. AKT1 is found ubiquitously in human 
tissues and is characterized by two phosphorylation sites: threonine 308 (T308) and serine 
473 (S473), which are essential for its activation. The association of AKT to PIP3 is 
followed by conformational changes leading to the exposure of AKT phosphorylation sites 
at T308 and S473. PDK1, another substrate of PI3K localized at the membrane, is 
responsible for the phosphorylation at threonine 30877, 78, whereas the phosphorylation at 
S473 is performed by the complex mTORC279 (see 5.2.5).  
AKT has several biologically relevant roles. For instance, it modulates the activity of 
Forkhead box O (FOXO) transcription factors (FOXO1, FOXO3a), which regulate the 
expression of genes implicated in stress, cell-cycle and metabolism80. Furthermore, AKT 
can also inhibit GSK3β by phosphorylation (serine 9), a member of the Wnt pathway81. 
Other important regulations concern the apoptosis process: AKT phosphorylates Bcl-2, a 
pro-apoptotic marker, which inactivates it and in turn promotes cell survival82. 
5.2.4 The mTORC1 complex 
mTOR is a 289 kDa serine threonine kinase, highly conserved between species, which 
belongs to the phosphatidylinositol 3-kinase-related kinase (PIKK) family. Its association 
with various proteins forms two distinct complexes: mTORC1 and mTORC2 implicated in 
fundamental biological processes, which monitor amino acid, glucose, oxygen, energy and 
growth factor levels (Figure 5). 
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Figure 5: Schematic representation of PI3K/AKT/mTOR pathway 
Upon activation, AKT phosphorylates TSC2, which inhibits its GAP (GTPase activating protein) activity and 
ultimately the TSC2/TSC1 complex. Therefore, Rheb remains in its active GTP conformation and mTORC1 
complex is activated. mTORC1 regulates autophagy and angiogenesis as well as protein translation and cell 
proliferation through the modulation of p70S6K and 4EBP1. mTORC2 complex is involved in cytoskeleton 
organization and is negatively regulated by p70S6K. AKT also regulates fundamental processes via 
alternative pathways such as apoptosis and cell proliferation. Figure taken from Ashworth et al.
83
 
 
The mTORC1 complex, which is rapamycin sensitive, consists of 5 components, namely 
mTOR, mammalian Sec13 protein with lethal 8 (mLST8), Regulatory-Associated Protein to 
mTOR (RAPTOR), Proline-Rich AKT Substrate of 40kDa (PRAS40), DEP domain-
containing mTOR-interacting protein (DEPTOR) and FKBP38. This complex is a global 
regulator of cell metabolism through modulation of anabolic and catabolic processes (such 
as autophagy), and of cell growth through control of protein synthesis. Its activity is thus 
related to the presence of growth factors and nutrient availability and is mediated by the 
regulation of its downstream proteins such as p70 ribosomal S6 kinase (p70S6K) and 
Eukaryotic Translation Initiation Factor 4E Binding Protein 1 (4E-BP1)84, 85.  
The mechanism by which this complex is regulated is partially elucidated. mTORC1 is 
negatively regulated by some of its constitutive components, namely PRAS40 and 
DEPTOR. These two proteins inhibit the complex by direct physical interaction85, 86.  
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Furthermore, mTORC1 can also be inhibited by GDP conformation of Ras homolog 
enriched in brain (Rheb) through the activation of the Tuberous Sclerosis complex 1/2 
(TSC1/TSC2). Indeed, TSC2 is a GTPase-activating protein, which changes the state of 
Rheb from GTP (active) to GDP (inactive). On the contrary, when fully activated, AKT can 
inactivate TSC2 by phosphorylation, which results in Rheb-GTP conformation and 
promotes mTORC1 activity87. The  role of mLST8 remains unclear. 
 
mTORC1 is an important regulator of protein synthesis as it is responsible for the 
phosphorylation of p70S6K, a kinase belonging to the AGC family. The activation of 
p70S6K triggers the phosphorylation of eIF4B, which promotes the cap-dependent 
translation and elongation by enhancing the RNA helicase activity of eIF4A84. The 
regulation of p70S6K involves a complex interplay of phosphorylations88.  
The 14 kDa protein 4EBP1 is another key regulator of protein synthesis. Its phosphorylation 
by mTORC1 enables the activation of eIF4E, which permits the translation of mRNA by 
activation of eIF4F complex89 (Figure 6).  
 
 
Figure 6: Regulation of cap-dependent translation by 4E-BP 
eIF4F complex is composed of eIF4E subunits, which binds to the 5' cap, eIF4G a scaffold protein, MnK1 
(Mitogen-activated protein kinase-interacting kinase 1) an EIF4E kinase and eIF4A an RNA helicase. a: Active 
mTORC1 phosphorylates and inactivates 4E-BP, therefore enabling the association of eIF4F complex and 
cap-dependant translation. b: In its dephosphorylated form, 4E-BP binds to and sequesters eIF4E inhibiting 
eIF4F formation. Figure taken from Buchkovich et al.
90
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5.2.5 The mTORC2 complex 
Comparatively to mTORC1, little is known about mTORC2. It is composed of different 
proteins, namely mTOR, Rictor (rapamycin-insensitive companion of TOR), SIN1 (stress-
activated map kinase-interacting protein 1), mLST8 (also named GβL), DEPTOR and 
PPR5/PROTOR. Unlike mTORC1, it is relatively insensitive to rapamycin91. It is also 
involved in critical processes such as cytoskeleton organization, metabolism, cell survival 
and proliferation.  
Previous studies have shown that Rictor and SIN1 were essential for mTORC2 activation 
and could have the same function as RAPTOR, that is complex stabilization and substrate 
recruitment92. Other studies have also linked TSC1/TSC2 to the activation of mTORC293.  
Moreover, experiments of mLST8 knockout have shown that this protein was mandatory for 
optimal mTORC2 activity94. On the other hand, inhibition of mTORC2 activity was shown to 
be mediated partially by DEPTOR85 and as far as is currently known, it is the only 
characterized endogenous direct inhibitor of this complex. The protein p70S6K was also 
shown to inhibit mTORC2 through inhibition of Rictor95. 
mTORC2 allows the activation of AKT as it is responsible for S473 phosphorylation. Other 
mTORC2 targets include members of the AGC kinase family such as protein kinase Cα 
(PKCα) and serum and glucocorticoid-induced protein kinase 1 (SGK1)96. Of note, a 
negative feedback has been described between mTORC1 and mTORC2. Upon activation, 
mTORC1 inhibits mTORC2 activity via activation of p70S6K, which phosphorylates Rictor 
decreasing subsequently AKT phosphorylation at S47397. Another negative feedback 
involves IRS proteins which abrogate PI3K dependent activation of AKT98. 
5.2.6 Deregulation of PI3K/AKT/mTOR axis in cancer 
Several alterations of the pathway have been characterized such as in RTK, PI3K, PTEN or 
AKT inducing a constitutive activation of the pathway. These alterations can be due to 
chromosomal translocation, overexpression or gain of function mutation. In any cases, this 
leads to the breaking of the fragile balance between cell death and cell survival promoting 
the oncogenesis process. 
PTEN is often found mutated in cancer and the result of these mutations is most often a 
truncated protein with loss of function. This leads to an accumulation of PIP3 and thus 
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activation of the pathway. PTEN can also be altered due to epigenetic modifications as 
previously described in colorectal cancers. For instance, Goel et al. reported that 
hypermethylation of PTEN promoter correlated significantly with decrease or complete loss 
of PTEN protein expression in sporadic colorectal cancer with microsatellite-instability99. 
Somatic mutations of the gene encoding the catalytic subunit of PI3K have also been 
identified in many solid tumors100 as well as mutations of the kinase domain, which become 
constitutively active100. 
Finally, mutations in genes encoding AKT isoforms have been reported for instance in the 
PH domain, which confers a membranous localization independently of PIP3. Therefore, 
AKT become constitutively activated by phosphorylation mediated by PDK1 and 
mTORC2101. 
5.2.7 Alteration of PI3K/AKT/mTOR pathway in hepatoblastoma 
A study conducted by Hartmann et al.64 revealed that point mutation of PI3KCA (p110α 
subunit of PI3K) was present in 2% of the tumors investigated, resulting in a gain of kinase 
activity. Moreover, they found that PI3K/AKT/mTOR activation was actually central for 
hepatoblastoma survival as demonstrated by PI3K inhibition in vitro and subsequent 
reduction of AKT and GSK3β phosphorylation64. Further, the insulin like growth factor (IGF) 
axis was also shown to be implicated in hepatoblastoma growth102. This pathway was found 
to be over activated as a result of IGF2 ligand overexpression, confering a constant anti-
apoptotic signal to the cells mediated through the insulin-like growth factor 1 receptor 
(IGF1R)103. An epigenetic mechanism was shown to be responsible for this alteration. 
Indeed, IGF2 expression is normally restricted to the paternel allele as the maternal copy is 
epigenetically silenced (genomic imprinting). However, loss of imprinting was described for 
IGF2 ultimately leading to a biallelic expression which is responsible for its 
overexpression104. Finally, regulators of this axis have also been implicated in 
hepatoblastoma growth namely the insulin-like growth factor binding proteins (IGFBP). The 
function of these proteins is to repress ligands by physical interaction in order to prevent 
their binding to the receptor. In hepatoblastoma, altered expression of IGFBP-1 and IGFBP- 
2 has been described105-107. 
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5.2.8 Other molecular alterations described in hepatoblastoma  
The two other embryonic pathways, Hedgehog and Notch, have been described to be 
altered in hepatoblastoma as well. A recent study has shown an overexpression of 
Hedgehog ligands, which contributes to the activation of the pathway and the expression of 
target genes mediated by the activation of the transcription factor GLI108. These target 
genes, particularly implicated in cell cycle regulation, participate therefore in the 
tumorigenesis process and inhibiting this pathway with cylopamine induces a striking 
growth inhibition of hepatoblastoma cells108. On the other hand, activation of Notch 
signaling was more observed in fetal subtypes. Immunohistochemistry experiments 
revealed an overexpression of the receptor NOTCH2 in 92% of the tumors compared to 
normal liver tissues109, which was associated with an upregulation of its downstream target 
HES1110.  
Other anomalies have been described at the epigenetic level. More particularly, several 
tumor suppressor genes have been shown to be altered through DNA methylation in their 
promoter sequence, which in turn inactivates them. For instance, secreted frizzled-related 
proteins (SFRP) are negative modulators of the Wnt pathway by competing with the actual 
ligands. Therefore, loss of expression results in enhanced Wnt activity. Similarly to SFRP, 
Hedgehog-interacting proteins (HHIP) which are negative modulators of the Hedgehog 
pathway, are also altered through hypermethylation108. Finally, silencing of APC through 
hypermethylation has been described in about 30% of hepatoblastoma111. 
Genetic aberrations in several chromosomes have been identified such as gains of 
chromosomes 1q, 2q, 2p, 6q, 8q, 17q and 20, and losses on chromosomal region 4q112. 
Interestingly, gains on chromosomes 8 and 2 were found to be associated with a so called 
C2 subclass of hepatoblastoma introduced by Cairo et al.55.  
Using gene expression profiling this group identified two subclasses of hepatoblastoma 
tumors namely C1 and C2, which exhibit similarity with distinct phases of liver development. 
The C2 subclass, which conforms to an embryonal histotype was found to proliferate faster 
than the fetal-like C1 subclass. In accordance, the C2 tumors highly expressed cell cycle 
related genes such as CDC2 and DLG7, and displayed intense nuclear accumulation of β-
catenin. Importantly, they described a 16-gene signature, which corresponds to the 16 most 
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differentially expressed genes between C1 and C2, and therefore allows classification of 
the tumors between these two subclasses55.  
From a clinical perspective, the tumors with a C2 signature were shown to be associated 
with poor prognosis for the disease with a more advanced tumor stage (metastasis, 
vascular invasion). The 2 years overall survival was 44% for patients with C2 tumors 
against 92% for patients with C1 tumors55.  
6 Treatment strategies 
During the last 30 years, several clinical trials have been conducted in order to increase the 
survival of children with hepatoblastoma. One of the major breakthroughs is the use of 
platinum based chemotherapeutic agents (such as cisplatin and carboplatin), which greatly 
improved the survival in children from 30% to 70%2. 
Cisplatin alone16 or in combination with other cytostatics (5-fluorouracil, vincristine, 
doxorubicin, carboplatin) remains the first choice for chemotherapy courses in all four liver 
study groups. The chemotherapy recommendations depend on the stage of the tumor and 
differ between the four liver study groups113, 114, although all four groups adopted recently 
PRETEXT staging system115. For instance, SIOPEL recommends preoperative 
chemotherapy with the ultimate goal to shrink the tumor to allow tumor resection, which is 
the only way to achieve a definitive cure116. In some cases, such as in patients with a fetal 
histology tumor, chemotherapy is not advised and only surgery is advocated as being 
curative by itself117. However, in children with unresectable tumors, orthotopic liver 
transplantation is the main choice for treatment118, 119.  
Despite the progresses witnessed in hepatoblastoma treatment evoked above, there 
remains a large margin for progression, both in terms of the effectiveness of the treatments 
and of the severity of their side effects. For instance, high risk patients (SIOPEL PRETEXT 
IV or COG stage IV) have a 5-year overall survival rate in between 30.9% and 39.3% 
depending on the staging system120. Furthermore, one limitation of chemotherapy treatment 
is multidrug resistance (MDR), which often occurs after four cycles of chemotherapy120. It is 
associated with an increased expression of the MDR gene coding for P-glycoprotein121. 
This protein is a transmembrane receptor, which acts as an ATP-reliant pump allowing the 
evacuation of drugs or other molecules122. Another downside with the use of 
chemotherapeutic agents is the strong toxicity induced by these molecules. For instance, 
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cisplatin is responsible for ototoxicity and nephrotoxicity after several courses123, whereas 
doxorubicin is higly cardiotoxic124. 
New treatment strategies are needed that tackle the limitations and downsides of the 
aforementioned methods. A promising target for innovative approaches to hepatoblastoma 
treatment is the Substance P (SP)/Neurokinin-1 receptor (NK1R) complex. 
7 SP/NK1R complex  
7.1 Description 
Currently, there are three main classes of neurokinin receptors characterized in human: 
neurokinin-1 receptor (NK1R), neurokinin-2 receptor (NK2R) and neurokinin-3 receptor 
(NK3R), which are encoded by TACR1, TACR2 and TACR3 genes, respectively. These 
three receptors, which are G-protein coupled receptors (GPCRs), have high sequence and 
structure homologies but are differentially expressed within human tissues. NK1R is  
expressed in the central nervous system as well as in the periphery, while NK2R is mainly 
expressed in peripheral tissues such as the gastrointestinal system, lungs, bladder and the 
uterus. NK3R is found in the central nervous system but its expression is also detected in 
some peripheral tissues such as the liver and lungs 125-129. 
The neurokinin receptors regulate a variety of fundamentals biological processes: 
regulation of neuronal activity, cell proliferation, nociception, endocrine and exocrine 
secretions, vasodilatation, inflammation and regulation of the immune system125, 130-132. The 
ligands of these receptors belong to the tachykinin family and each ligand has a specific 
affinity for the three receptors. For instances, neurokinin A binds preferentially to NK2R, 
neurokinin B to NK3R and SP to NK1R125. We will now focus on NK1R.  
7.2 The NK1R, truncated and full length forms 
In humans, the TACR1 gene is located on the chromosome 2 and is constituted of five 
exons. In its full length form, NK1R is a protein of 417 amino acids133. It belongs to the class 
I of GPCRs and can be coupled to several groups of G proteins: the Gαq, Gαs and the 
Gαi134, 135. The receptor conformation and the types of ligands have been shown to 
determine the specificity of the response through the activation of a specific G protein136, 137. 
Indeed, these proteins differ in their signaling pathway and effectors that they activate. For 
example, the coupling with the Gαq protein results in the activation of phospholipase Cβ 
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(PLCβ), which causes an increase of PIP3. The activation of PLCβ also induces the release 
of diacylglycerol (DAG), which ultimately induces an increase of intracellular calcium138. 
The coupling with Gαs activates the enzyme adenylate cyclase (AC) and thus stimulates 
the production of cyclic adenosine monophosphate (cAMP). An increased concentration of 
cAMP activates the protein kinase A (PKA), which phosphorylates specific substrates139. 
Finally, coupling with Gαi inhibits AC decreasing thereafter the concentration of cAMP in the 
cell140, 141. In any cases and most importantly, these cascades lead to a specific 
physiological response via the transcription of specific genes. 
The NK1R, like other GPCRs, undergoes a rapid desensitization and internalization through 
phosphorylation processes, with a subsequent recycling at the membrane142. More 
precisely, this mechanism is relying on β-arrestin/clathrin proteins and endocytosis143. 
Interestingly, Roosterman et al. showed that NK1R internalization is dependant on the SP 
concentration: at low concentrations (1 nM) the receptor is internalized and quickly recycled 
at the membrane, whereas at high concentrations (10 nM), the process takes more time 
with an endocytosis into perinuclear endosomes144. 
Recently, the description of a truncated form of the NK1R was reported (NK1R-tr) (Figure 
7). This isoform is produced by alternative splicing: the intron between exons 4 and 5 is not 
removed and, therefore, a premature stop codon appears resulting in a protein lacking 96 
amino acids at the C-terminus part145, 146. Importantly, the loss of this specific part was 
associated with a loss of internalization147.  
 
Figure 7: Representation of truncated and full length NK1R  
(a) Full-length NK1R is a GPCR of 407 amino acids, whereas (b) the truncated isoform is lacking 96 amino 
acids at the C-terminus. Figure taken from Tuluc et al.
148
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NK1R-tr expression was detected in specific regions of the brain or the spinal cord and in 
the central nervous system. It is also abundant in peripheral tissues such as the prostate, 
adipose tissue, heart, lungs and spleen. Functional differences between the long (NK1R-fl) 
and the truncated form of NK1R have been described. Firstly, as mentioned above, NK1R-
tr is resistant to desensitization. Secondly and contrary to NK1R-fl, the truncated form is 
able to induce a rapid but sustained calcium response147. This difference could be 
explained by a lower affinity of SP for the truncated form and by the absence of a rapid 
desensitization, which therefore promotes a prolonged activity145.  
7.3 NK1R antagonists 
The first generation of antagonists was developed from the modification of the SP 
sequence. However, these peptides were particularly unstable and toxic149. A breakthrough 
in the development of NK1R antagonists, achieved by random screening of chemical 
libraries, was the discovery of non-peptide compounds such as L-733.138, L-733.060 and 
L-703.606, which showed a great affinity for the NK1R. By improving the pharmacokinetic 
properties of L-733.060, Merck Frosst developed the molecule MK860 or aprepritant150. 
Aprepritant, or its commercial name Emend®, is the first NK1R antagonist approved by the 
Food and Drug Administration (FDA) and Health Canada in 2009 for its antiemetic 
properties. More precisely, it is used at low doses in triple therapy for the prevention of 
chemotherapy-induced nausea and vomiting in adults only151. Previous studies have 
unveiled other very interesting properties of these antagonists depending on the dose at 
which they are used. At medium doses, they can treat depression or pain, whereas at high 
doses, a potent anticancer effect has been shown152, 153.  
8 Goal of the study 
In this study we investigated the SP/NK1R complex in hepatoblastoma as a therapeutic 
target. Previous work showed that targeting NK1R with the use of antagonist such as 
aprepitant can trigger a potent anti-cancer effect. However, very little is known about this 
complex in hepatoblastoma. The goal of this study was to: 
 
- investigate the effect of NK1R antagonism on human hepatoblastoma cells, 
- unravel the molecular mechanisms that lead to aprepitant-induced growth inhibition, 
- study the SP/NK1R complex from a clinical perspective. 
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MATERIALS  
1. Eukaryotic cell culture 
1.1 Cell lines 
HuH6 Homo sapiens (human), liver, hepatoblastoma 
HepT1 Homo sapiens (human), liver, hepatoblastoma 
HepG2 Homo sapiens (human), liver, hepatoblastoma 
HuH7 Homo sapiens (human), liver, hepatocellular carcinoma 
DLD1 Homo sapiens (human), colon, colorectal cancer 
LiM6 Homo sapiens (human), colon, colorectal cancer 
HEK293 Homo sapiens (humans), kidney 
L3.6pl Homo sapiens (humans), pancreas, pancreatic cancer 
JCRB, Osaka, Japan 
Pietsch et al.154 
ATCC, Manassas, USA 
ATCC, Manassas, USA 
ATCC, Manassas, USA 
Bresalier et al.155 
ATCC, Manassas, USA 
ATCC, Manassas, USA 
 
1.2 Cell culture reagents 
Dimethyl sulfoxide (DMSO), sterile 
Dulbecco's Phosphate-Buffered Saline (DPBS) 
Fetal Calf Serum (FCS), sterile 
Penicillin-Streptomycin (10,000 U/mL) 
Roswell Park Memorial Institute Medium (RPMI) 
Trypsin - EDTA 0.05 % 
Merck, Darmstadt, Germany  
Invitrogen, Karlsruhe, Germany 
Invitrogen, Karlsruhe, Germany  
Invitrogen, Karlsruhe, Germany 
Invitrogen, Karlsruhe, Germany 
Invitrogen, Karlsruhe, Germany 
 
1.3 Cell culture material 
Biosphere® Filtertips 1-10 μL, sterile 
 
Biosphere® Filtertips 1-100 μL, sterile 
Biosphere® Filtertips 100-1000 μL, sterile 
Cell scraper 
Costar® Stripette® Serologic Pipettes 5 mL, sterile 
 
Costar® Stripette® Serologic Pipettes 10mL, sterile 
Costar® Stripette® Serologic Pipettes 25mL, sterile 
EasyFlasksTM, Cell culture flasks, 25 cm2, non-pyrogenic 
DNase und RNase free 
Sarstedt AG & Co., Nümbrecht, 
Germany 
Sarstedt AG & Co., Nümbrecht 
Sarstedt AG & Co., Nümbrecht 
Sarstedt AG & Co., Nümbrecht 
Corning GmbH, Wiesbaden, 
Germany 
Corning GmbH, Wiesbaden  
Corning GmbH, Wiesbaden  
NUNC, Langenselbold, Germany 
NUNC, Langenselbold, Germany 
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EasyFlasksTM, Cell culture flasks, 75 cm2, non-pyrogenic 
DNase und RNase free 
Plastic tubes, 15 mL, sterile 
Plastic tubes, 50 mL, sterile 
Petri dishes 100 x 20 mm, non-pyrogenic, sterile 
6-Well Plates, non-pyrogenic, sterile BD 
12-Well Plates, non-pyrogenic, sterile BD 
24-Well Plates, non-pyrogenic, sterile BD 
96-Well Plates, non-pyrogenic, sterile BD 
Greiner bio-one, Frickenhausen, 
Germany 
Greiner bio-one, Frickenhausen, 
Germany 
NUNC, Langenselbold, Germany 
NUNC, Langenselbold, Germany 
NUNC, Langenselbold, Germany 
NUNC, Langenselbold, Germany 
NUNC, Langenselbold, Germany     
 
1.4 Spheres culture 
Human recombinant bFGF  
Human recombinant EGF  
L-Glutamine  
B27 serum free supplement 50X  
Methyl cellulose powder 
Minimum Essential Medium (MEM) Alpha Medium with 
Earle's salts without ribonucleosides, 
deoxyribonucleosides, and no L-glutamine 
Syringe Filter 0.45 µm SFCA 
 
96-well ultra-low attachment plates 
 
100 mm x 20 mm ultra-low attachment dishes 
Invitrogen, Karlsruhe, Germany 
Invitrogen, Karlsruhe, Germany 
Invitrogen, Karlsruhe, Germany 
Invitrogen, Karlsruhe, Germany 
Sigma, Steinheim, Germany 
VWR, Darmstadt, Germany 
 
 
Santa Cruz Biotechnology, 
Heidelberg, Germany 
Corning GmbH, Wiesbaden, 
Germany 
Corning GmbH, Wiesbaden, 
Germany  
 
2. Plasmids 
pRL-CMV Renilla luciferase plasmid 
TOPFlash Firefly luciferase reporter  
 
FOPFlash Firefly luciferase reporter  
 
Promega, Mannheim, Germany 
Prof. Dr. Frank Kolligs (LMU 
Munich) 
Prof. Dr. Frank Kolligs  
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3. Antibodies 
Rabbit anti-NK1R 
Rabbit anti-Substance P 
Mouse anti-human β-catenin  
 
Rabbit anti-human β-actin 
Rabbit anit-human β-catenin 
Rabbit anti-human LRP5 (Low-density lipoprotein receptor-
related protein 5)  
Rabbit anti-human MYC  
Rabbit anti-human PARP (Poly ADP Ribose Polymerase)  
Rabbit anti-human caspase 3  
Rabbit anti-human phospho-AKT (S473) 
Rabbit anti-human phospho-AKT (T308)  
Rabbit anti-human total AKT  
Rabbit anti-human phospho-P70S6K (S371)  
Rabbit anti-human total P70S6K  
Rabbit anti-human phospho-4EBP1 (S65)  
Rabbit anti-human total 4EBP1  
Rabbit anti-human phospho-mTOR (S2448)  
Rabbit anti-human total mTOR,  
Rabbit anti-human FOXM1  
Sigma, Steinheim, Germany 
Sigma, Steinheim, Germany 
BD transduction laboratories, 
Heidelberg, Germany 
Cell signaling technology, 
Danvers, USA 
Cell signaling technology, USA  
Cell signaling technology, USA 
Cell signaling technology, USA 
Cell signaling technology, USA 
Cell signaling technology, USA 
Cell signaling technology, USA 
Cell signaling technology, USA 
Cell signaling technology, USA 
Cell signaling technology, USA 
Cell signaling technology, USA 
Cell signaling technology, USA 
Cell signaling technology, USA 
Cell signaling technology, USA 
Cell signaling technology, USA 
Santa Cruz Biotechnology, 
Heidelberg, Germany 
 
4. Chemicals / Reagents 
6x DNA Loading Dye    
Acetic Acid     
Agarose  
Aprepitant     
Albumin Fraction V (BSA)    
Bio Rad Protein Assay  
Bromophenolblue     
Chloroform     
Fermentas GmbH, St. Leon-Rot, Germany 
Carl Roth, Karlsruhe, Germany 
PeQLab, Erlangen, Germany 
Selleck Chemicals, Munich, Germany 
Carl Roth, Karlsruhe, Germany 
Bio-Rad, Munich, Germany 
SERVA, Heidelberg, Germany 
Carl Roth, Karlsruhe, Germany 
MATERIALS 
23 
 
cOmplete Protease Inhibitor Cocktail Tablets 
Dithiothreitol DTT (0.1 M), 500 μL   
Ethylenediaminetetraacetic acid (EDTA)  
Ethanol, absolut, PA, 2.5 L     
Ethidium bromide, 10 mg /mL  
Glycerol      
Glycine, 1 kg     
Isopropyl alcohol, 1 L     
Igepal CA-630    
Magnesium chloride     
β-Mercaptoethanol, 100 mL  
MOPS SDS Running Buffer (20X) 
MTT formazan powder 
Paraformaldehyde, 0.5 kg   
Phenol      
Potassium chloride, 1 kg    
Powdered milk    
Propidium iodide 
Random primer     
Sodium acetat     
Sodium chloride, 1 kg    
Sodium dodecyl sulfat (SDS), 100 g  
Substance P     
TE-Buffer       
TRI Reagent® RNA Isolation Reagent  
Tris (hydroxymethyl)-aminomethane (TRIS) 
Triton X-100   
Tween       
Ultra Pure TM DNase/RNase-Free Distilled 
water  
Vectashield® with DAPI    
Roche, Mannheim, Germany 
Invitrogen, Karlsruhe, Germany 
Carl Roth, Karlsruhe, Germany 
Merck, Darmstadt, Germany 
Sigma, Steinheim, Germany 
Applichem, Darmstadt, Germany 
GERBU Biotechnik, Gaiberg, Germany 
Sigma-Aldrich, Steinheim, Germany 
Sigma-Aldrich, Steinheim, Germany 
Carl Roth, Karlsruhe, Germany  
Sigma-Aldrich, Steinheim, Germany 
Invitrogen, Karlsruhe, Germany 
Sigma-Aldrich, Steinheim, Germany 
Carl Roth, Karlsruhe, Germany 
Carl Roth, Karlsruhe, Germany 
Merck, Darmstadt, Germany 
Carl Roth, Karlsruhe, Germany 
Sigma-Aldrich, Steinheim, Germany 
Roche, Mannheim, Germany 
Carl Roth, Karlsruhe, Germany 
Carl Roth, Karlsruhe, Germany 
Carl Roth, Karlsruhe, Germany 
Sigma-Aldrich, Steinheim, Germany 
Upstate, Billerica, USA 
Sigma-Aldrich, Steinheim, Germany 
Carl Roth, Karlsruhe, Germany 
Sigma-Aldrich, Steinheim, Germany 
Sigma-Aldrich, Steinheim, Germany 
Invitrogen, Karlsruhe, Germany 
 
Vector Laboratories Inc., Burlingame,USA 
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5. Primers 
The primers used in this study are listed in Table 1. They were synthesized by Eurofins 
(Hamburg, Germany). 
 
gene name 
Reference sequence 
number forward reverse 
Full length NK1R NM_001058.3 5’AACCCCATCATCTACTGCTGC3’ 5’ATTTCCAGCCCCTCATAGTCG3’ 
Truncated NK1R NM_015727.2 5’GGGCCACAAGACCATCTACA3’ 5’AAGTTAGCTGCAGTCCCCAC3’ 
AKT1  NM_001014431 5’TGGACCACTGTCATCGAACG3’ 5’TGCTTCTTGAGGCCGTCAG3’ 
AKT2  NM_001243027 5’GAAGGCTGGCTCCACAAGC3’ 5’GGCCTCTCCTTGTACCCAATG3’ 
CD13  NM_001150 5’CTACCGCAGCGAGTACATGG3’  5’GCTCATCGAAGCATGGGAAG3’ 
CD133  NM_001145847 5’AAATGGGCCCTTCCTGAGG3’ 5’CCTGGTGATTTGCCACAAAAC3’ 
AFP  NM_001134 5’TGTGCTGGATTGTCTGCAGG3’ 5’GCAGCATTCTGTTATTTTGTTTGAC3’ 
DLK1  NM_001190703 5’GCAACCCCCAAAATGGATTC3’ 5’GAGGTCACGCACTGGTCACA3’ 
EPCAM  NM_002354 5’ATCGTCAATGCCAGTGTACTTCA3’ 5’TGAGCCATTCATTTCTGCCTT3’ 
GEP  NM_2087 5’CTGCCCAGTGGGAAGTATGG3’ 5’TGGATCAGGTCACACACAGTGTC3’ 
KRT19  NM_002276 5’GCCACTACTACACGACCATCCA3’ 5’AGCCAGACGGGCATTGTC3’ 
CTNNB1  NM_001904.2 5’ACGTCCATGGGTGGGACA3’ 5’CTAGGATGTGAAGGGCTCCG3’ 
FOXM1 NM_202002.2 5’CTCCCGCAGCATCAAGCAA3’ 5’GCCAGGACGCTGATGGTCTC3’ 
MYC NM_002467.3 5’CACCACCAGCAGCGACTCT3’ 5’CAGACTCTGACCTTTTGCCAGG3’ 
AXIN2  NM_004655.3 5’TATCCAGTGATGCGCTGACG3’ 5’TGTTTCTTACTGCCCACACGAT3’ 
LGR5  NM_003667.3 5’ACAGCAGTATGGACGACCTTCA3’ 5’CAGGTCTTCCTCAAAGTCAAGCA3’ 
NANOG  NM_024865 5’AGAACTCTCCAACATCCTGAACCT3’ 5’TCGGCCAGTTGTTTTTCTGC3’ 
SOX2  NM_003106.3 5’CCGTTCATCGACGAGGCTAA3’  5’TTCTTCATGAGCGTCTTGGTTTT3’ 
OCT4 NM_002701.5 5’CACTGCAGCAGATCAGCCA3’  5’GCTTGATCGCTTGCCCTTC3’ 
KLF4  NM_004235.4 5’ATCTCAAGGCACACCTGCG3’ 5’CCTGGTCAGTTCATCTGAGCG3’ 
TBP  NM_003194.3 5’GCCCGAAACGCCGAATAT3’ 5’CCGTGGTTCGTGGCTCTCT3’ 
Table 1: Specific primers used in this study 
6. Buffer and Solutions 
TBE-Buffer:  
- 89 mM Tris base, pH 8.0 
- 2 mM EDTA 
- 89 mM Boric acid 
 
Transfer-Buffer 10X 
- 25 mM Tris base 
- 192 mM Glycine 
 
Protein lysis buffer  
- 0.5% Triton X-100 
- 1 mM sodium orthovanadate 
- 1 protease inhibitor cocktail tablet  
- PBS 
 
Blocking solution 
- 5% BSA   
- 0.1% Tween-20 
- PBS 
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RPPA Lysis buffer  
- 1% Triton X-100  
- 50 mM HEPES pH 7.4  
- 150 mM NaCl  
- 1.5 mM MgCl2  
- 1 mM EGTA  
- 100 mM NaF  
- 10 mM Na pyrophosphate 
- 1 mM Na3VO4 
- 10% glycerol 
- protease and phosphatase inhibitors 
 
Staining buffer for FACS 
- PBS 
- 0.1% Triton X-100 
- 0.2 mg/mL RNAse A 
- 0.02 mg/mL propidium iodide 
 
MTT solution 
- 0.5 mg/mL  
- PBS 
 
Lysis buffer for proliferation assay 
- 10% SDS 
- 1M HCl 
 
7. Enzymes 
 
Super Script
 
ІІ Reverse Transcriptase
 
SsoAdvanced Universal SYBR Green Supermix  
Invitrogen, Karlsruhe, Germany 
Bio-Rad, Munich, Germany 
 
8. Kits 
 
Dual-Glo Luciferase Assay System 
FITC Annexin V Apoptosis Detection Kit II 
 
Promega, Mannheim, Germany 
BD Biosciences, Heidelberg, Germany 
9. Consumables 
 
Biosphere® Filtertips 
Coverglas 
Hybond-C extra Nitrocellulose membran 
Sarstedt AG & Co., Nümbrecht, Germany 
Menzel-Gläser, Braunschweig, Germany 
Amersham, Buckinghamshire, UK 
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HyperfilmTMMP 
Microwell Plates 
Multidishes NunclonTM 
Nalgene®  Cyrotube 
Nunc™ F96 MicroWell™ White Polystyrene Plate 
Object slide 
Pipette tips (10 µL, 100 μL, 1000 μL) 
8-Well PCR stripes 
PCR 96 Well Plates 
Quarz cuvette QS 10.00 mm 
8 - 12% Tris-Glycin Gels 
Whatman paper 
Safe-lock Eppendorf tube 
Amersham, Buckinghamshire, UK 
NUNC, Langenselbold, Germany 
NUNC, Langenselbold, Germany 
Schubert&Weiss, Iphofen, Germany 
NUNC, Langenselbold, Germany 
Menzel-Gläser, Braunschweig, Germany 
Sarstedt, Nümbrecht, Germany  
Eppendorf, Hamburg,Germany 
PeQLab, Erlangen, Germany 
Hellma, Müllheim, Germany 
Invitrogen, Karlsruhe, Germany 
Whatman, Maidstone, UK  
Eppendorf, Hamburg, Germany 
 
 
10. Equipment 
 
Agarose gel electrophoreses apparatus  
BD LSRFortessa cell analyzer  
Biofuge fresco, Heraeus 
Biofuge pico, Heraeus 
Bio Photometer 
Camera AxioCam MRm 
Camera Power Shot G6 
Cell screen Olympus IX50 
Centrifuge 5702 
Centrifuge J2-21 
Centrifuge LMC-3000 
CO2-Incubator MCO-20AIC 
Excella E24 Incubator Shaker Series 
Heat block MR 3001 
Heatblock Thermomixer comfort 
GelJet Imager Version 2004 
Bio-Rad, Munich, Germany 
BD Biosciences, Heidelberg, Germany 
Kendro, Langenselbold, Germany 
Kendro, Langenselbold, Germany 
Eppendorf, Hamburg, Germany 
Zeiss, Jena, Germany 
Canon, Krefeld, Germany 
Innovatis, Bielefeld, Germany 
Eppendorf, Hamburg, Germany 
Beckman Coulter, Krefeld, Germany 
G. Kisker, Steinfurt, Germany 
Sanyo, Tokio, Japan 
New Brunswick Scientific 
Heidolph, Kehlheim, Germany 
Eppendorf, Hamburg, Germany 
Intas, Göttigen, Germany 
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GENios Microplatereader 
Mastercycler ep gradient S 
Mastercycler personal 
Microlitercentrifuge MZ014 
Microscope Axiovert 40 CFL 
Microscope Axiovert 135 
Micro scales Te1245 
Microwave 
NanoDrop 1000 instrument 
FluoView™ FV1000 confocal microscope 
Incubator 
Shaker,  Rock-N-Roller 
Shaker, Unimax 1010 
Thermomixer Compact 
Vortexer Genie2 
Water bath GFL 1083 
Western-Blot Detection system „CP1000“ 
Work flow, Hera Safe 
XCell IITM Blot Module 
XCell SureLockTM Electrophoresis Cell  
Tecan, Crailsheim, Germany 
Eppendorf, Hamburg, Germany 
Eppendorf, Hamburg, Germany 
G. Kisker, Steinfurt, Germany 
Zeiss, Jena, Germany 
Zeiss, Jena, Germany 
Sartorius, Göttingen, Germany 
Panasonic, Hamburg, Germany 
Thermo Scientific, Wilmington, USA 
Olympus, Hamburg, Germany 
Memmert, Schwabach, Germany 
G. Kisker, Steinfurt, Germany 
Heidolph, Schwabach, Germany 
Eppendorf, Hamburg, Germany 
Scientific Industries, NY, USA 
GFL, Wien, Austria 
AGFA, Köln, Germany 
Kendro, Hanau, Germany 
Invitrogen, Karlsruhe, Germany 
Invitrogen, Karlsruhe, Germany 
 
11. Sofwares 
ImageJ software (NIH, Bethesda, MD, USA) 
FlowJo 7.6.3 Software (Tree Star, Inc., Ashland, OR, USA) 
GraphPad Prism (La Jolla, CA, USA) 
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METHODS 
1. Cell culture   
Three human hepatoblastoma cell lines (HuH6, HepT1 and HepG2), one human 
hepatocellular carcinoma cell line (HuH7), two colorectal cell lines (DLD1 and LiM6) as well 
as the pancreatic cell line L3.6pl were used in this study. All cell lines were grown in RPMI-
1640 medium supplemented with 10% FCS and 1% Penicillin/Streptomycin at 37°C in a 
humidified incubator with 5% CO2.  
2. RNA isolation and RT-PCR 
Total RNA was isolated from parental cells, spheres or tumor tissues using TRI-reagent. 
cDNA was synthesized from 2 µg of total RNA using random primers and SuperScript II 
Reverse Transcriptase according to the manufacturers instructions. For each PCR reaction 
we used 40 ng of cDNA, 500 nM of the primer pair and SsoAdvanced Universal SYBR 
Green Supermix for a total volume of 20 μL. Thermal cycling consisted of 40 cycles with 
denaturation at 95°C for 15 seconds, annealing at 55°C for 15 seconds, and elongation at 
72°C for 30 seconds using the Mastercycler ep gradient S. Each experimental condition 
was assayed in duplicate.  
 
3. Proliferation assays 
Cell proliferation was assessed using 1-(4,5-dimethylthiazol-2-yl)-3,5-diphenylformazan 
(MTT) assay. 10,000 cells/well were seeded into 96-well plates. After 24 hours, cells were 
treated with increasing doses of aprepitant for 48 hours or with DMSO. To assess cell 
viability, MTT solution was first added to each well followed by 4 hours incubation at 37°C. 
Finally, a lysis solution was added overnight in each well. For the readout, a multi scanner 
microplate reader was used to measure the absorbance at 595 nm. Each experiment was 
realized three times and each condition was performed in triplicates. 
4. In vitro analysis of apoptosis 
After treatment with the respective NK1R antagonist, the cells were fixed in 4% 
paraformaldehyde. After three rinses with PBS, microscope slides were mounted with 
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Vectashield containing 4,6-diamidino-2-pheylindole (DAPI). The pictures were taken using 
the Olympus FluoView™ FV1000 confocal microscope. Apoptotic cells were defined by 
chromatin condensation and nuclear fragmentation. We related the cell number of apoptotic 
cells to total cells of 10 randomly selected high power fields. Apoptosis was also assessed 
by flow cytometric analysis. After treatment, cells were stained for 15 minutes at room 
temperature with anti-Annexin V-FITC antibody and propidium iodide (PI). Then, 10,000 
cells were analyzed on a BD Fortessa Flow Cytometer and the results processed with the 
FlowJo 7.6.3 software.  
5. Western blot analysis  
Cells were treated for 24 hours, washed with ice-cold PBS and lysed with a lysis buffer. The 
protein concentration was determined by using the BIO-RAD protein assay. For each 
condition, 20 µg of proteins were loaded on 8-12%, separated by electrophoresis and 
electroblotted onto nitrocellulose membranes. The membranes were then incubated for 2 
hours in a blocking solution, followed by an overnight incubation with primary antibodies at 
a 1:1,000 dilution against β-catenin, LRP5 (low-density lipoprotein receptor-related protein 
5), MYC, PARP (poly ADP ribose polymerase), caspase 3, phospho-AKT (serine 473, 
threonine 308), total AKT, phospho-p70S6K (threonine 389), total p70S6K, phospho-4EBP1 
(serine 65), total 4EBP1, phospho-mTOR (serine 2448), total mTOR, β-actin and FOXM1. 
Finally, the blots were washed with TBS-0.1% Tween-20 and incubated for 1 hour at room 
temperature with a peroxidase–conjugated goat anti-rabbit IgG antibody at a dilution of 
1:2,000. The detection was realized with an enhanced chemiluminescence reaction and    
β-actin served as a loading control. 
Western blot band intensity was evaluated by ImageJ software and values of total proteins 
or ratios of phospho/total proteins were normalized to the housekeeping protein β-actin.  
6. Reverse-phase protein array (RPPA) 
Cells were treated for 24 hours with the indicated substrates. Samples were then washed in 
ice-cold PBS, denatured by a lysis buffer and stored at -80°C. Further processing of the 
samples was carried out by the functional proteomics RPPA core facility at MD Anderson 
cancer center as previously reported (14). Briefly, probes were spotted on nitrocellulose 
slides and a total of 172 different proteins were analyzed. Densitometry of these spots was 
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quantified and normalized for protein loading and transformed to linear values, which was 
used for the following calculations. For quantization, we calculated the ratios with the linear 
protein intensity values of the treated probes and the linear protein intensity values of their 
respective control probes.  
7. In vitro analysis of cell cycle  
Cells were seeded onto 6-well plates at a density of 200,000 cells/well. After 24 hours, cells 
were treated for 24 hours with 30 µM aprepitant or DMSO. Adherent cells were trypsinized 
and pooled together with non-adherent cells, rinsed with PBS and fixed with ice cold 
ethanol 70% for 2 hours minimum. Cells were washed with PBS and stained for 30 minutes 
with a staining buffer. Cells were analyzed by BD LSRFortessa cell analyzer. 
8. Immunofluorescence 
Cells were plated onto round cover slips with a diameter of 18 mm in 12-well plates at a 
density of 75,000 cells/well and treated as indicated in the results section. After 24 hours of 
treatment, cells were fixed in 4% paraformaldehyde for 15 minutes, permeabilized for 15 
minutes with 0.15% TritonX-100 in PBS and blocked for 30 minutes with 1% BSA in PBS. 
The cells were then incubated overnight at 4°C with rabbit primary antibodies against β-
catenin (monoclonal), phospho-AKT (polyclonal), phospho-mTOR or FOXM1 diluted in 
blocking solution at 1:80, 1:25, 1:80 and 1:25, respectively. After several washing steps, 
cells were then incubated for 1 hour in the dark with goat anti-rabbit antibody conjugated 
with Alexa Fluor 488 or goat anti-mouse antibody conjugated with Alexa Fluor 594 at a 
1:200 dilution. After three rinses with PBS, microscope slides were mounted with 
Vectashield containing 4,6-diamidino-2-pheylindole (DAPI). The pictures were taken using 
the Olympus FluoView™ FV1000 confocal microscope. 
9. Super TOP/FOP (STF) luciferase reporter assay  
Luciferase assays for reporters were carried out using the dual-luciferase reporter assay 
system. Cells were plated in 24-well plates at a density of 50,000 cells per well, 24 hours 
before treatment and transfection. Fugene HD reagent and alphaMEM medium was used to 
mediate co-transfection with inducible Firefly luciferase expressing SuperTOP or SuperFOP 
vectors and constitutively Renilla luciferase expressing normalization vector pRL-CMV at a 
METHODS 
31 
 
ratio of 50:1 as a control for transfection efficiency. The cells were simultaneously treated 
with different concentrations of aprepitant or DMSO. After 24 hours of incubation, total cell 
lysate was extracted using reporter lysis buffer and 5 µL of total extract was used to 
determine Firefly and Renilla luciferase activities using 25 µL of luciferase substrate LarII 
solution and 25 µL of Stop and glow 1X solution, respectively. The luminescence was 
measured with an integration time of 12 seconds. TCF-mediated transcriptional activity was 
determined by the ratio of SuperTOP/SuperFOP luciferase activities, each normalized to 
the respective luciferase activities of the pRL-TK reporter. Each experimental condition was 
assayed in triplicate. 
10. Sphere formation culture 
After trypsinization and rinses with PBS, 75,000 cells were seeded onto 100 mm * 20 mm 
ultra-low attachment dishes containing sphere formation medium composed of DMEM-F12, 
1% Penicillin/Streptomycin, 10 ng/mL human recombinant bFGF, 20 ng/mL human 
recombinant EGF, 1% glutamine and B27 serum free supplement 1X. Spheres were 
cultivated for 6 - 14 days and treated with aprepitant, SP or DMSO for further analysis. 
 
Sphere formation ability (SFA) was assessed in 96-well ultra-low attachment plates. Cells 
were seeded at a density of 500 cells per well in sphere formation medium supplemented 
with 1% methylcellulose that had been filtered with a 0.45 µm ultra cruz syringe filter. 100 
µL of media was added every three days. Sphere numbers and sizes were determined 
under a microscope after 6-11 days depending on the cell type. 
11. Patients and Tumor Tissues 
Tumor tissue samples were analyzed from patients with hepatoblastoma who were all part 
of the German Cooperative Pediatric Liver Tumor Study HB99 and its subsequent Registry 
for Pediatric Liver Tumors. Both were multicentric and initiated by the German Society for 
Pediatric Oncology and Hematology (GPOH). They were open to registration for patients 
from Germany, Austria, and Switzerland up to the age of 20 years with untreated 
hepatoblastoma. The registry protocols were assigned by the institutional Ethical 
Committees and written consent from the parents for treatment, data collection and analysis 
was obtained. 
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Clinical information including demographic, therapeutic, tumor and clinical outcome 
variables were retrieved in both clinical studies.  
All tumor specimens were reviewed by the local Pathology as well as the Institute of 
Pediatric Pathology, University of Kiel, which served as a reference center. Liver tissue 
samples from the surgical specimens without macroscopic as well as microscopic tumor 
served as tumor free controls. Clinical and molecular data such as sex, age of diagnosis, 
PRETEXT stadium, vascular invasion, multifocality, metastatic disease, histology, CTNNB1 
mutation, 16-gene signature and overall survival were retrieved from the HB99 database. 
12. Statistical analysis 
Results are expressed as the mean ± standard deviation (s.d.). All statistical comparisons 
were made with a standard t-test and Mann–Whitney-U-Test using the biostatistics software 
GraphPad Prism. The criterion for significance was p < 0.05 (*) and p < 0.01 (**) for all 
comparisons. 
Kaplan-Meier estimates of specific survival time were compared using the log-rank Mantel-
Cox test. 
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RESULTS 
1. Hepatoblastoma cells express NK1R and can be growth inhibited by aprepitant in 
vitro 
The results presented in this section are part of the publication: Hepatoblastoma cells express 
truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo. 
Journal of Hepatology (2014, 60(5):985-94) Berger M, Neth O, Ilmer M, Garnier A, Salinas-Martín 
MV, de Agustín Asencio JC, von Schweinitz D, Kappler R, Muñoz M. 
1.1 NK1R is expressed in human hepatoblastoma cell lines 
In order to characterize the expression of the NK1R in human hepatoblastoma cell lines, 
distinct RT-PCR were carried out for the full-length (fl-) and truncated (tr-) NK1R transcripts. 
The expression levels of hepatoblastoma cell lines were compared to human fibroblasts, 
and the HEK293 cell lines which is known to express NK1R (Figure 8). 
 
 
Figure 8: Expression pattern of NK1R in human hepatoblastoma cell lines  
In (A), mRNA expression for NK1R is shown as fold expression relative to human fibroblasts (FB) or (B) as 
relative gene expression (fl, full length; tr, truncated). Expression levels obtained by RT-PCR were normalized 
to the housekeeping gene TBP. (C) Western blot is shown for specific antibodies binding to either the fl-NK1R 
or both tr- and fl-NK1R. Shown is the mean and error bars represent s.d.. Significance levels are as follows: 
n.s.: not significant, * p < 0.05 and ** p < 0.01. Figure taken from Berger et al.
156
 
 
The HEK293 cell line expressed the highest level of fl-NK1R. Surprisingly, the three 
hepatoblastoma cell lines HuH6, HepT1 and HepG2 expressed very little mRNA coding for 
fl-NK1R. They predominantly overexpressed the shorter truncated splice variant while 
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human fibroblasts and HEK293 expressed only slight amounts (Figure 8A and 8B). These 
findings were verified by Western blot (Figure 8C). As no specific antibody for the truncated 
version of NK1R is commercially available at this time, a pair of specific antibodies against 
the full version alone as well as against both versions were used for the study, following the 
technique introduced by Gillespie et al.157. 
 
1.2 Aprepitant inhibits tumor growth in human hepatoblastoma cell lines 
In order to investigate cell survival after the antagonism of NK1R, the human 
hepatoblastoma cell lines as well as fibroblasts and HEK293 were treated with increasing 
concentrations of aprepitant for 48 hours, and an MTT assay was subsequently realized 
(Figure 9).  
 
Figure 9: Aprepitant triggers growth inhibition in hepatoblastoma cell lines 
MTT assays determining cell survival after treatment with aprepitant for 48 hours are shown for the cell lines 
HuH6, HepT1, HepG2, human fibroblasts, and HEK293 (left panel). Based on these data, IC50 (µM) were 
calculated and compared to fibroblasts for statistical analysis (right panel). Shown is the mean and error bars 
represent s.d.. Significance levels are as follows: n.s.: not significant, * p < 0.05 and ** p < 0.01. Figure taken 
from Berger et al.
156
 
 
 
Aprepitant induced a concentration dependent growth inhibition in all cell lines examined. 
However, human fibroblasts, which did not express NK1R, were significantly more resistant 
to this treatment compared to hepatoblastoma cell lines. The concentrations required for a 
50% growth reduction (IC50) were 57.5 µM for fibroblasts and 28.5 µM, 31.1 µM, 33.18 µM 
and 36.61 µM for HEK293, HepT1, HuH6 and HepG2, respectively (Figure 9, right panel).  
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Taken together, these results indicate that benign human fibroblasts express significantly 
less NK1R compared to hepatoblastoma cell lines and that the NK1R expression predicts 
the response rate to aprepitant. 
In order to complement the study, the inhibitory ability of aprepitant on proliferation of all 
hepatoblastoma cell lines was compared with that of other NK1R antagonists, namely L-
733,060 and L-732,138 (Figure 10). 
 
 
Figure 10: L-733,060 and L-732,138 induce growth inhibition in hepatoblastoma cell lines  
Similarly to figure 9, cell survival is shown for the small molecules L-733,060 and L-732,138 in comparison to 
aprepitant in HuH6, HepT1 and HepG2 cells.  Shown is the mean and error bars represent s.d.. Significance 
levels are as follows: n.s.: not significant, * p < 0.05 and ** p < 0.01. Figure taken from Berger et al.
156
 
 
 
L-733,060 was found to be significantly more potent and L-732,138 to be significantly less 
effective compared to aprepitant (p < 0.01).  
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1.3 SP reverses the anti-proliferative effect of NK1R antagonists 
SP is the natural agonist of NK1R and a mitogenic effect has been observed in several 
cancer cells however very little is known in hepatoblastoma. By blocking SP or NK1R with 
anti-SP or anti-NK1R antibodies, a significant growth reduction was observed for all three 
cell lines (Figure 11). This suggests that hepatoblastoma cell growth could be influenced by 
autocrine secretion of SP.  
 
 
Figure 11: Blocking SP or NK1R with monoclonal antibodies decreases cell survival of 
hepatoblastoma cell lines 
HepT1, HepG2, and HuH6 were treated with anti-SP, anti-NK1R and isotype antibodies at a final 
concentration of 1:100. Effects were analyzed with MTT proliferation assays. Shown is the mean and error 
bars represent s.d.. Significance levels are as follows: n.s.: not significant, * p < 0.05 and ** p < 0.01. Figure 
taken from Berger et al.
156
 
 
Further, when hepatoblastoma cells were treated with sub-lethal concentrations of either L-
733,060 or aprepitant, the addition of SP reversed the anti-proliferative effect of NK1R 
blockage in a dose-dependent manner: in the case of HepT1, 10 nM of SP were sufficient 
for a significant reduction of the anti-proliferative effect of L-733,060 (10 µM) and aprepitant 
(25 µM) whereas higher concentrations of SP (50 nM) were needed for HuH6 and HepG2 
cells (Figure 12).  
 
These findings, together with the observation that human fibroblast express little NK1R and 
were more resistant to treatment with NK1R antagonists, clearly indicate that the described 
effect of NK1R antagonists in hepatoblastoma cells is not generally toxic but specifically 
triggered via the SP/NK1R complex. 
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Figure 12: SP reverses the anti-proliferative effect of NK1R antagonism 
MTT assays determining cell survival after treatment with aprepitant or L-733,060 with SP for 48 hours. 
Shown is the mean and error bars represent s.d.. Significance levels are as follows: n.s.: not significant, * p < 
0.05 and ** p < 0.01. Figure taken from Berger et al.
156
 
 
1.4 Aprepitant and cytostatics synergistically induce cell death of 
hepatoblastoma cells 
The robust anti-proliferative effect of NK1R antagonists that we observed prompted us to 
perform a comparative study with cytostatic drugs commonly used in the treatment of 
hepatoblastoma. HepT1, HuH6, and HepG2 cells were treated with their respective IC50 
dose of aprepitant either separately or together with increasing doses of the cytostatics 
cisplatin and doxorubicin (Figure 13).  
 
For HepT1 cells, a statistically significant synergistic effect was found for high-dose 
doxorubicin (10 µM) in combination with aprepitant (Figure 13, lower panel), whereas 
similar synergisms for cisplatin and aprepitant in the same cell line were not detected 
(Figure 13, upper panel). For HepG2, a marked synergistic effect was found for high-dose 
doxorubicin (10 µM) and cisplatin (10 µM) with aprepitant (Figure 13, lower panel). 
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Interestingly, even a low-dose doxorubicin (1 µM) showed an interesting synergistic effect 
with aprepitant. Similar results could be obtained for HuH6.  
These results are consistent with the existence of a potent synergistic effect between the 
clinical drug aprepitant and cytostatics commonly used in hepatoblastoma therapy. 
 
 
Figure 13: Synergistic inhibition of human hepatoblastoma cells with cytostatics and aprepitant 
HepT1, HepG2, and HuH6 were treated either without or with IC50 aprepitant combined with increasing doses 
of the cytostatics cisplatin or doxorubicin. Cell viability (% survival) was determined by MTT assay. All 
experiments were realized in duplicates (n=3). Shown is the mean and error bars represent s.d.. Significance 
levels are as follows: n.s.: not significant, * p < 0.05 and ** p < 0.01. Figure taken from Berger et al.
156
 
 
 
1.5 NK1R antagonists induce apoptosis in hepatoblastoma cells 
In order to explain the observed decrease in survival of these cells, we performed 
experiments assessing whether these agents are apoptosis-inducing.  
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Figure 14: NK1R antagonism induces an increase of apoptotic cells in human hepatoblastoma cells 
Cells were treated for 18 hours with increasing doses of L-733,060 or aprepitant and DAPI staining was 
carried out. Quantitative analysis was subsequently performed in duplicate, apoptotic cells were defined by 
chromatin condensation and fragmentation. Shown is the mean and error bars represent s.d.. Significance 
levels are as follows: n.s.: not significant, * p < 0.05 and ** p < 0.01. Figure taken from Berger et al.
156
  
 
  
In all cell lines, a dose-dependent increase of apoptotic cells after 18 hours was observed 
for both L-733,060 and aprepitant (Figure 14). To characterize apoptosis in detail, 
hepatoblastoma cell lines were treated with SP or increasing doses of aprepitant for 24 
hours and Western Blot was carried against the apoptosic markers PARP and caspase-3 
(Figure 15). A dose-dependent increased expression of cleaved PARP as well as cleaved 
caspase-3 was detected, indicating an activation of the late apoptotic machinery. However, 
treatment with 100 nM of SP had no effect on apoptosis.  
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Figure 15: Dose-dependent increase of apoptosis markers after NK1R antagonism  
HepT1, HepG2, and HuH6 cells were treated with increasing doses of aprepitant (10 µM, 20 µM, 30 µM and 
40 µM), SP (100 nM) or DMSO (control) and Western blot analysis was performed for the apoptotic markers 
PARP and Caspase-3. β-actin served as a loading control. Figure taken from Berger et al.156 
 
Additionally, in order to better assess apoptosis, cells were treated with increasing doses of 
aprepitant and stained with anti Annexin V FITC antibody and propidium iodide (PI) (Figure 
16) followed by FACS analysis. 
 
Figure 16: Aprepitant triggers a dose dependent increase of early and late apoptosis 
HepT1 was treated with increasing doses of aprepitant (AP [10 µM], AP [20 µM], AP [30 µM], AP [40 µM] and 
AP [60 µM]) or with DMSO (control) and stained with Annexin V and propidium iodide (PI). Shown is the 
quantification of FACS analysis in the three hepatoblastoma cell lines HepT1, HepG2 and HuH6. Figure taken 
from Berger et al.
156
 
 
A dose-dependent increase of early and late apoptosis was observed in all cell lines as 
indicated by annexin V and the simultaneous staining of annexin V and PI, respectively 
(Figure 16). These results correlate with the overall action of NK1R antagonists on cell 
survival, indicating that the observed effects can be related to both apoptosis induction and 
growth inhibition in hepatoblastoma cells. 
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2. Targeting the NK1R compromises canonical Wnt signaling in hepatoblastoma 
The results presented in this section are part of the publication: Targeting the neurokinin-1 receptor 
compromises canonical Wnt signaling in hepatoblastoma. Molecular Cancer Therapeutics (2015 
Dec;14(12):2712-21) Ilmer M, Garnier A, Vykoukal J, Alt E, von Schweinitz D, Kappler R, Berger M. 
 
2.1 NK1R inhibition leads to downregulation of the PI3K/AKT/mTOR and Wnt 
signaling pathways 
In order to provide a mechanistic explanation for the effects of aprepitant on human 
hepatoblastoma cells, we next used reverse-phase protein array (RPPA) as a screening 
tool to identify proteins regulated by aprepitant treatment. The human hepatoblastoma cell 
lines HepT1, HepG2, and HuH6 (harboring β-catenin mutations) were treated with 20 µM 
and 40 µM aprepitant and subsequently screened for changes in expression level of 172 
proteins and phosphoproteins associated with common cancer pathways. After averaging 
over all three cell lines, it was observed that most proteins did not change significantly 
compared to the untreated control (in black); few samples changed significantly with 
downregulation (in green) or upregulation (in red) (Figure 17).  
 
 
Figure 17: Pattern of regulation of 172 proteins analyzed by RPPA in the three hepatoblastoma cell 
lines 
Hepatoblastoma cells (HepT1, HepG2, HuH6) were cultured in monolayer, treated with DMSO (control), 
aprepitant (20 μM or 40 μM) or substance P (SP) for 24 hours and protein lysates were analyzed by RPPA. 
The averaged changes after aprepitant treatment of all three hepatoblastoma cell lines for all the proteins 
investigated compared to untreated controls are shown. Ratios > 1.2 in red to the left, ratios < 0.8 in green to 
the right. In black, proteins with no significant changes in expression. The cut-offs were chosen according to 
the standard deviation of the values. Figure taken from Ilmer et al.
158
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Significantly altered protein ratios after treatment are shown in Figure 18. By classifying 
proteins according to their pathway affiliation, we found several candidate proteins that 
belong to the PI3K/AKT/mTOR and Wnt group (Figure 18).  
 
More particularly, in the PI3K/AKT/mTOR pathway, total AKT, 4E-BP1/2 (S65), p70S6K 
(T389), and S6 (S235/236 and S240/244) were downregulated. Additionally, 4E-BP1 
(T37/T46) and PRAS40 (T246), a member of mTORC1, were upregulated upon aprepitant 
treatment. Furthermore, calculations of phospho/total protein ratios of the investigated 
proteins revealed that aprepitant treatment resulted in upregulation of AKT (S473 and 
T308) and mTOR (S2448) as well as downregulation of Rictor (T1135) (Supplemental 
Figure 1). 
 
Concerning the Wnt associated proteins, FOXM1 in its total form was found downregulated. 
On the other hand, p-GSK3α/β (pS21/S9), an important part of the β-catenin destruction 
complex, was found upregulated (Figure 18). Similar to the AKT pathway, phospho/total 
ratios for Wnt pathway associated proteins were calculated and confirmed the findings 
(Supplemental Figure 1). Overall, a dose-dependent effect with more drastic changes after 
treatment with 40 μM (lower rows) than with 20 μM was detected.   
 
 
Figure 18: Heatmap of protein changes in the three hepatoblastoma cell lines compared to control  
Red indicates an increased signal and green a decreased signal in treated samples normalized against the 
control sample. Shown are all proteins with significant changes. Figure taken from Ilmer et al.
158
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Taken together, these data indicate a strong downregulation of both the PI3K/AKT/mTOR 
and the canonical Wnt signaling pathways at the protein level upon NK1R inhibition with 
aprepitant. 
2.2 NK1R antagonism leads to differential expression of the PI3K/AKT/mTOR 
pathway 
 To validate the findings of the RPPA analysis, the PI3K/AKT/mTOR pathway was 
first analyzed in greater detail (Figure 19).  
 
Figure 19: Analysis of the PI3K/AKT/mTOR pathway by Western blot  
(A) Cells were treated with increasing doses of aprepitant for 24 hours and protein lysates probed for total and 
p-AKT (S473 and T308), total and p-4EBP1/2 (S56), total and p-p70S6 (T389), total and p-mTOR (S2448) 
and β-actin. (B) Cells were treated with IC50 aprepitant, protein lysates harvested after 1, 3, 6, 12 and 24 
hours and probed for p-AKT (ser473), total AKT and β-actin. Western blots were carried out at least twice and 
representative pictures are shown. Numbers on top of each band indicate the fold induction or decrease as 
determined by total and phospho-specific signals. Figure taken from Ilmer et al.
158
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Hepatoblastoma cell lines (HepT1, HepG2 and HuH6) were treated with aprepitant for 24 
hours and Western blot analysis was performed for AKT, 4E-BP1/2, p70S6K and mTOR in 
their phosphorylated and non-phosphorylated form (Figure 19A). Short time treatment were 
also realized in the three hepatoblastoma cell lines and phospho-AKT (ser473) and total 
AKT were analyzed (Figure 19B). 
 
This experiment confirmed a robust decrease of p-4E-BP1 (S65) and p-p70S6K (T389)  in 
all cell lines, but not in their total form. Interestingly, AKT activity was increased after 
aprepitant treatment as shown by increased p-AKT (S473, T308) to total AKT ratios as well 
as increased presence of p-mTOR (S2448) (Figure 19A and Supplemental Figure 1).  
 
To analyze more in depth this pathway, mRNA expression levels of AKT1 and AKT2 were 
analyzed and immunofluorescence staining of p-AKT (S473) and p-mTOR (S2448) were 
realized in the three hepatoblastoma cell lines. With the exception of AKT2 in HuH6, 
increasing doses of aprepitant led to decreasing mRNA levels of AKT1 and AKT2 in all the 
three hepatoblastoma cell lines analyzed so far (Figure 20).  
 
 
Figure 20: Analysis of AKT1 and AKT2 expression by qRT-PCR 
Hepatoblastoma cell lines were subjected to mRNA analysis for AKT1 and AKT2 after aprepitant treatment 
(Ap 10 µM, Ap 20 µM and Ap 30 µM) or DMSO (0).  All experiments were performed independently at least 
two times. Shown is the mean and error bars represent s.d.. Significance levels are as follows: * p < 0.05 and 
** p < 0.01. Figure taken from Ilmer et al.
158
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Immunofluorescence staining with p-AKT (S473) revealed that high doses of aprepitant led 
to an elevated number of cells with nuclear/paranuclear accumulation of p-AKT, which 
suggests an augmented activated AKT signaling in these cells (white arrow head in Figure 
21, left panel). Even more impressive, we found that mTOR was activated, too, as 
evidenced by the translocation of p-mTOR (Ser2448) to the nucleus (white arrow head in 
Figure 21, right panel).  
 
These results indicate that aprepitant treatment leads to an increased activity of AKT, a 
nuclear translocation of p-AKT (S473) and p-mTOR (S2448) after 24 hours, while 
downstream AKT targets, such as 4EBP1 or p70S6K, are significantly downregulated. 
 
Figure 21: Nulcear translocation of p-AKT (S473) and p-mTOR (S2448) upon aprepitant treatment 
Hepatoblastoma cells were treated for 24 hours with DMSO (Control), aprepitant (APIC50) or SP (70 nM). 
Subsequently, cells were fixed and stained for p-AKT (S473) or p-mTOR (S2448). Nuclei were stained with 
DAPI (blue). Shown are representative pictures of at least 4 randomly evaluated view fields. Figure taken from 
Ilmer et al.
158
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2.3 NK1R inhibition compromises FOXM1 expression and subsequently 
diminishes canonical Wnt signaling 
 
FOXM1 has recently been shown to play an essential role in enhancing nuclear 
translocation of β-catenin as a shuttle protein, and in the subsequent increased activation of 
the canonical Wnt signaling cascade in glioma cells159. Data from RPPA (Figure 18) 
suggested a decrease in FOXM1 expression upon aprepitant treatment which was 
subsequently confirmed by Western blot (Figure 22A) and qPCR analysis (Figure 22B). In 
line with that, analysis of total β-catenin in the three hepatoblastoma cell lines revealed a 
decreased expression in HepT1 and HuH6 corroborating our data from RPPA analysis and 
indicating decreased activation of the Wnt pathway (Figure 22A). 
 
 
Figure 22: Aprepitant induces a downregulation of  β-catenin and FOXM1 expression 
(A) Western blot analysis of FOXM1 and β-catenin shows decreasing protein expression upon increasing 
doses of aprepitant (0, 10, 20, 30, 40 μM). Numbers on top of each band indicate the fold induction or 
decrease as determined by protein of interest to β-Actin signals. (B) qRT-PCR of FOXM1 shows dose-
dependent decrease of gene expression after 24 hours of treatment with increasing doses of aprepitant. 
Experiment was performed independently three times. Shown is the mean and error bars represent s.d.. 
Significance levels are as follows: * p < 0.05 and ** p < 0.01. Figure taken from Ilmer et al.
158
  
 
 
To further analyze the effects of aprepitant on Wnt signaling, untreated cells were first 
stained for β-catenin and FOXM1 and subsequently analyzed by confocal microscopy. 
FOXM1 was found to colocalize in the cytoplasm and nucleus of HepG2 and HUH6 (Figure 
23). 
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Figure 23: β-catenin and FOXM1 colocalize in hepatoblastoma cells 
Untreated cells were stained for β-catenin (green) and FOXM1 (red), and analyzed by confocal microspcoy. 
Nuclei were stained with DAPI (blue). 
 
Cells were then treated with aprepitant (IC50) or SP (70 nM) for 24 hours, stained for         
β-catenin and analyzed by confocal microscopy. Interestingly, aprepitant induced a 
depletion of nuclear and cytosolic β-catenin as well as a strong accumulation of membrane-
bound β-catenin (green) (Figure 24, left panel, white arrow), indicating an inactivation of 
canonical Wnt signaling. In contrast, stimulation with SP did not alter Wnt signaling 
significantly, presumably due to the high baseline Wnt activity in β-catenin mutated 
hepatoblastoma cell lines.  
In order to investigate the role of FOXM1, the same treatments were repeated and cells 
were stained for FOXM1 (red). In contrast to β-catenin, FOXM1 increasingly translocated to 
the nucleus upon aprepitant treatment (Figure 24, right panel, white arrows), thereby 
moving in the opposite direction to β-catenin.  
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Figure 24: Immunofluorescence of β-catenin and FOXM1 in hepatoblastom cell lines 
Aprepitant (IC50), SP (70 nM) and DMSO (control) treatments were carried out and immunofluorescent 
stainings for β-catenin (green) or FOXM1 (red) were performed. Nuclei were stained with DAPI (blue). Figure 
taken from Ilmer et al.
158
 
  
To support these important findings, quantification analysis of the immunofluorescence data 
was subsequently realized (Figure 25). 
 
Figure 25: Aprepitant induces membrane-bound β-catenin and nuclear accumulation of FOXM1 
For each condition indicated in Figure 24, 100 cells from at least 9 random fields were analyzed regarding the 
localization (membranous and/or nuclear) and the signal intensity (from very high +++ to very low -) of           
β-catenin and FOXM1 staining. Aprepitant treatment increases membrane-bound β-catenin and depletes 
cytosolic/nuclear β-catenin accumulation (left panel). On the contrary, FOXM1 (red) is shifted into the nucleus 
(right panel). Figure taken from Ilmer et al.
158
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To further investigate the action of aprepitant on canonical Wnt signaling, we then included 
the hepatocellular carcinoma cell line HuH7 for subsequent experiments that doesn't carry 
mutations in the canonical Wnt signaling pathway, as opposed to the other hepatoblastoma 
cells that harbor β-catenin mutations. In accordance with this, a significant activation of Wnt 
signaling in HepT1, HepG2 and HuH6, but not in HuH7 was detected by Super TOP/FOP 
(STF) reporter luciferase assays (Figure 26A).  
 
In a next step, STF assays were carried out after treatment with increasing doses of 
aprepitant in the four cell lines. A robust inhibition of Wnt activity was detected in all            
β-catenin mutated hepatoblastoma cell lines, whereas Wnt activity in HuH7 remained 
unaffected (Figure 26B). 
 
 
Figure 26: Aprepitant induces a decrease of Wnt activity in hepatoblastoma cell lines 
Cells were treated with increasing doses of aprepitant (Ap 10 µM, Ap 20 µM and Ap 40 µM) or DMSO (0) and 
Super TOP/FOP (STF) assay was conducted. Measurements of Wnt activity were realized after 24 hours of 
treatment. Shown are the relative values to the untreated control sample (black column), the mean and error 
bars represent s.d.. Figure taken from Ilmer et al.
158
 
 
These results could be corroborated by findings with qRT-PCR in which the Wnt target 
genes LGR5, CTNNB1 and AXIN2 were dose dependently downregulated upon aprepitant 
treatment in all hepatoblastoma cell lines. Interestingly, even HuH7 exhibited a 
downregulation of Wnt target genes (Figure 27). 
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Overall, these data indicate that antagonism to the SP/NK1R complex by aprepitant leads 
to reduced expression of the β-catenin shuttle protein FOXM1, which in turn potentially 
contributes to the observed decreased canonical Wnt signaling in hepatoblastoma cells 
harboring β-catenin mutations. 
 
 
 
Figure 27: Aprepitant induces a decrease of Wnt target genes expression in hepatoblastoma  
qRT-PCR on Wnt target genes (LGR5, AXIN2, CTNNB1) in HepT1, HepG2, HUH6 and HUH7. Shown are the 
relative values to the untreated control sample (black column) as fold changes after normalization to TATA-
box binding protein (TBP). Cells were treated for 24 hours with 10 μM (dark grey bars), 20 μM (light grey bars) 
or 30 μM aprepitant (white bars). Shown is the mean and error bars represent s.d.. Significance levels are 
shown as follows: * p < 0.05 and ** p < 0.01. Figure taken from Ilmer et al.
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2.4 Wnt pathway inhibition by aprepitant is effective downstream of β-catenin 
and disrupts the FOXM1-β-catenin interaction 
 
In order to investigate how aprepitant might block the Wnt signaling pathway, HEK293 cells 
were stimulated with lithium chloride (LiCl) which activates canonical Wnt signaling by 
inhibiting GSK3β160. Wnt activity levels were subsequently analyzed by STF assays (Figure 
28A). As expected, LiCl alone increased Wnt activity significantly, whereas additional 
aprepitant then lowered Wnt levels almost back to baseline, suggesting that the functional 
inhibition of Wnt occurs at the level of or downstream to the β-catenin disruption complex. 
Likewise, upon LiCl treatment, Wnt signaling increased in the β-catenin wild type cell line 
HuH7 as indicated by STF and β-catenin immunofluorescence staining (Figure 28A-B). In 
both cases, aprepitant treatment reduced the effects provoked by LiCl significantly. 
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FOXM1 reportedly builds an interaction with β-catenin that facilitates the translocation of the 
latter to the nucleus - hence, it is critical for enhanced Wnt signaling159. To further analyze 
how aprepitant acts on this interaction in hepatoblastoma, HuH7 cells were treated with 
LiCl, aprepitant or a combination of both for 24 hours. Cells were subsequently co-stained 
for FOXM1 and β-catenin (Figure 28C). Similar to Figure 23, a co-localization of FOXM1 
(red) and β-catenin (green) in the cytoplasm of unstimulated HuH7 was observed (DMSO). 
Upon LiCl treatment, a significantly increase of cytosolic β-catenin was noted, whereas 
aprepitant treatment or a combination of both induced a depletion of cytosolic β-catenin with 
an increase of free cytosolic FOXM1 (Figure 28C). 
 
 
Figure 28: Aprepitant disrupts FOXM1/β-catenin complex 
(A) STF in HEK293 (293T) and HuH7: cells were treated with DMSO (black bar), 20 mM Lithium Chloride 
(LiCl) (dark grey bar) or a combination of 20 mM LiCl and 20 μM aprepitant (Ap) (light grey bar) n = 3 (B) 
HEK293 cells were stained for β-catenin (green) and counterstained with DAPI (blue). (C) HuH7 cells were 
treated with DMSO, 20 mM LiCl, 20 µM Ap or a combination (Ap + LiCl) and co-stained for FOXM1 (red) and 
β-catenin (green). Counterstaining was performed with DAPI (blue). Shown is the mean and error bars 
represent s.d.. Figure taken from Ilmer et al.
158
 
 
Taken together, these findings suggest that treatment with aprepitant inhibits canonical Wnt 
signaling downstream of GSK3β most likely by disrupting proper FOXM1-β-catenin 
interaction in hepatoblastoma cells. However, co-immunoprecipitation experiments should 
be realized in order to validate this hypothesis. 
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2.5 NK1R antagonism inhibits growth of hepatoblastoma cancer stem-like 
cells 
The Wnt pathway is known to be highly activated in cancer stem cells (CSCs)161, 162. This is 
particularly interesting, because therapeutics that specifically target CSCs could potentially 
alter current treatment strategies. Therefore, in a next step, it was investigated whether 
such cells indeed show high activity of Wnt signaling and whether their growth could be 
inhibited by aprepitant. CSC-like cells were grown as non-adherent sphere cultures that 
were previously reported to enrich for CSCs163. First, activity of Wnt signaling in sphere 
cultures was measured and compared to parental cell lines by measuring Wnt target gene 
expression. HepT1 spheres overexpressed LGR5 and AXIN2, HepG2 spheres as well as 
their parental counterparts expressed similar levels for these markers, and the β-catenin 
wild type HuH7 spheres revealed a lower expression of AXIN2 and CTNNB1 (Figure 29).  
 
 
Figure 29: qRT-PCR of Wnt target genes in HepT1, HepG2, and HuH7 spheres 
Shown are the relative values to adherent cells (black bars): HepT1 spheres in dark grey, HepG2 spheres in 
light grey, and HuH7 spheres in white. The error bars represent s.d.. Figure taken from Ilmer et al.
158
 
 
 
In order to assess their stemness, cells were analyzed for their expression of embryonic 
stem cell markers SOX2, OCT4, and NANOG163. Expression of NK1R-tr and NK1R-fl was 
also analyzed. The results displayed an increased expression of NANOG in all spheres, an 
increased expression of SOX2 in HepT1 and HepG2 spheres and an increased expression 
of OCT4 in HepT1 and HuH7 spheres (Figure 30). A striking observation was that in HepT1 
spheres, SOX2 was overexpressed 7-fold while OCT4 and NANOG were overexpressed 8-
fold indicating increased stemness properties of these cells (Figure 30). Accordingly, HepT1 
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spheres also revealed the highest relative Wnt target gene overexpression (Figure 29). A 
noteworthy observation was that spheres overexpressed the truncated version of NK1R 
(NK1R-tr) compared to parental cells, whereas full length NK1R (NK1R-fl) was grossly 
unchanged (Figure 30). 
 
Figure 30: qRT-PCR on embryonic stemness markers in spheres compared to adherent cells 
qRT-PCR of embryonic stem cell markers SOX2, OXT4, and NANOG as well as NK1R (NK1R-tr and NK1R-fl) 
in untreated adherent cells (black bars) and untreated spheres. Shown is the mean and error bars represent 
s.d.. Figure taken from Ilmer et al.
158
 
 
In order to investigate whether the expression pattern of stem cell markers may change 
following the inhibition of the NK1R receptor, CSC-like cells and their parental counterparts 
were treated with aprepitant and analyzed by qRT-PCR (Figure 31). First, a dose 
dependent downregulation of Wnt target genes LGR5, AXIN2, and CTNNB1 was detected 
in spheres of all hepatoblastoma cell lines.  
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Figure 31: Aprepitant inhibits Wnt target genes expression in hepatoblastoma spheres 
(A) qRT-PCR of Wnt target genes in spheres. Spheres were treated for 24 hours with DMSO (black bars), 10 
µM aprepitant (light grey bars) or 20 μM aprepitant (white bars). Data are normalized to TBP expression and 
presented as fold change in gene expression relative to DMSO treated controls. Shown is the mean and error 
bars represent s.d.. * p < 0.05 and ** p < 0.01 (n = 2). Figure taken from Ilmer et al.
158
 
 
Furthermore, mRNA expression of pluripotency markers as well as NK1R were analyzed in 
spheres upon aprepitant treatment. These markers were found downregulated in HepT1 
and HepG2 parentals and spheres, whereas in HUH7 they tend to increase (Figure 32). In 
this regard, it seems the β-catenin mutated cell lines (HepT1 and HepG2) were more 
susceptible to aprepitant treatment than the β-catenin wild-type cell line HuH7.  
 
Figure 32: Inhibition of SP/NK1R compromises cancer stemness-associated traits in hepatoblastoma  
qRT-PCR of embryonic stem cell markers SOX2, OXT4, and NANOG as well as NK1R (NK1R-tr and NK1R-
fl). Left panel: adherent cells were treated for 24 hours with DMSO (black bars) or 20 µM aprepitant. Data are 
normalized to TBP expression and presented as fold change in gene expression relative to DMSO-treated 
controls. HepT1 (dark gray bars), HepG2 (light gray bars), and HuH7 (white bars). Right panel: qRT-PCR 
analysis of stemness markers similar to the left panel in spheres. Shown is the mean and error bars represent 
s.d.. * p < 0.05 and ** p < 0.01 (n = 2). Figure taken from Ilmer et al.
158
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Due to the modest changes in HuH7 cells, gene expression analysis of previously 
described liver-specific CSC markers (CD13164, CD133165, CK19166, EPCAM167, and 
GEP168)  as well as AFP, the serum marker of hepatoblastoma, were included in this study 
(Figure 33). AFP and CD13 were found downregulated in all hepatoblastoma spheres upon 
aprepitant treatment as well as CD133, CK19, EPCAM, and GEP in either HepT1 or HepG2 
spheres (Figure 33).  
 
 
Figure 33: Aprepitant targets liver specific cancer stem cell markers in hepatoblastoma 
Spheres were treated as indicated in Figure 32. qRT-PCR of liver-specific CSC markers. Shown is the mean 
and error bars represent s.d.. Significance levels are as follows: * p < 0.05 and ** p < 0.01 (n = 2). Figure 
taken from Ilmer et al.
158
  
 
 
Finally, FOXM1 expression was also analyzed in spheres. Its expression decreased in a 
dose-dependent manner in all hepatoblastoma spheres (Figure 34) similar to the findings in 
the respective parental cell lines (Figure 22B).  
 
RESULTS 
56 
 
 
Figure 34: Aprepitant induces a downregulation of FOXM1 expression in spheres  
Spheres were treated with aprepitant for 24 hours (Ap 10 µM or 20 µM) or DMSO (0) and qRT-PCR analysis 
for FOXM1 was performed. Shown are the relative values standardized to TBP. Shown is the mean and error 
bars represent s.d.. Significance levels are as follows: * p < 0.05 and ** p < 0.01 (n = 2). Figure taken from 
Ilmer et al.
158
 
 
Having seen a decreased activity of the Wnt pathway as well as a downregulation of 
defined liver stem cell markers upon inhibition of NK1R by aprepitant, the next step was to 
investigate whether self-renewal of CSC-like cells could be targeted with aprepitant. In 
order to do so, sphere formation ability (SFA) assays were performed, which assess 
functional anoikis-resistant self-renewal behavior of CSCs in vitro.  
 
Aprepitant induced a robust inhibition of sphere formation with simultaneous treatment 
(Figure 35A) in HepT1, HepG2  and the β-catenin wild-type cell line HuH7. Because 
aprepitant induced apoptosis in parental hepatoblastoma cells, Western blot analysis for 
PARP were realized in the same cell lines after aprepitant treatment. Similarly, apoptosis 
induction was detected in spheres as evidenced by increased PARP cleavage upon 
aprepitant treatment (Figure 35C).  
 
To rule out that inhibition of sphere formation is only executed by apoptosis induction, cells 
were pretreated in adherent conditions and only seeded viable cells were seeded for SFA 
assays. Intriguingly, a single pretreatment with aprepitant was sufficient to significantly 
diminish their sphere formation capacity (Figure 35B) indicating that aprepitant might not 
only exert its effect by reducing three-dimensional cell growth or inducing cell death in CSC-
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like cells, but moreover sustainably influences CSC properties in cancer cells, which 
support the data obtained by qRT-PCR (Figure 31 and 32). 
 
 
Figure 35: Aprepitant impairs sphere formation ability and triggers apoptosis in spheres 
(A) Simultaneous treatment: sphere formation ability (SFA) assays in hepatoblastoma cell lines HepT1 and 
HepG2 as well as in the hepatocellular carcinoma cell line HuH7. Spheres were cultures for several days in 
1% methylcellulose media. Treatment was realized every three days with the addition of 100 µL of 1% methyl 
cellulose media supplemented with 20 µM aprepitant (grey bars), 70 nM SP (white bars) or DMSO (black 
bars). Shown is the relative number of spheres per 500 seeded cells in an ultra low-attachment 96-well plate. 
(n = 2) (B) Pretreatment: Adherent cells were pretreated with 20 µM aprepitant or 70 nM SP for 24 hours, then 
viable cells seeded into SFA assays, and grown without any further treatment for 10 days. Shown is the 
relative number of spheres per 500 seeded cells. (n = 2) (C) Western blot analysis of PARP in HepT1, HepG2 
and HuH7 spheres after treatment with 10 µM or 20 µM aprepitant, or 70 nM SP. Fold changes of protein 
expression compared to control and standardized to β-actin is shown on top of each band. Shown is the mean 
and error bars represent s.d.. (n = 1). Figure taken from Ilmer et al.
158
 
 
Taken together, these findings illustrate that in addition to conventional human 
hepatoblastoma, hepatoblastoma cells with stem cell-like properties (CSC-like cells) can be 
growth inhibited by targeting the NK1R. 
 
Altogether, our study uncovered the effect of aprepitant on hepatoblastoma cells at a 
molecular level identifying a downregulation of PI3K/AKT/mTOR pathway and inhibition of 
Wnt activity possibly through the downregulation of FOXM1 as the major components of 
this inhibition (Figure 36). 
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Figure 36: Graphical illustration of crosstalk between NK1R, PI3K/AKT/mTOR pathway, and canonical 
Wnt signaling. 
According to our data, the SP/NK1R system seems to positively influence downstream PI3K/AKT/mTOR (right 
side of the illustration) and Wnt signaling (left side of the illustration). Upon blockage of NK1R with aprepitant, 
both phosphorylation sites of AKT (S473 and T308) as well as mTOR (S2448) (in red) become increasingly 
phosphorylated after 24 hours indicating an activation of upstream PI3K/AKT/mTOR signaling, whereas 
downstream actors of PI3K/AKT/mTOR (p70S6K and 4E-BP1/2) appear to be down-regulated (in green). On 
the other hand, aprepitant treatment increases GSK3β phosphorylation (in red), but robustly inhibits canonical 
Wnt signaling as evidenced by decreased β-catenin as well as downregulated Wnt target genes AXIN2 and 
LGR5 (all in green). The key mechanism for the latter seems to be disruption of the FOXM1-β-catenin 
interaction. Figure taken from Ilmer et al.
158
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3. Targeting the NK1R inhibits growth of human colon cancer cells 
The results presented in this section are part of the publication: Targeting the neurokinin-1 receptor 
inhibits growth of human colon cancer cells. International Journal of Oncology (2015 Jul;47(1):151-
60) Garnier A, Vykoukal J, Hubertus J, Alt E, von Schweinitz D, Kappler R, Berger M, Ilmer M. 
In the previous sections, we studied the consequences of blocking the NK1R using 
aprepitant in hepatoblastoma cell lines. Globally, we observed both growth reduction and 
apoptosis of the treated cells. At the intracellular level, we discovered that aprepitant 
disrupts the Wnt and PI3K/AKT/mTOR pathways, which possibly explains some of its 
effects. In this section, we investigated the effects of aprepitant on human colon cancer cell 
lines in order to extrapolate our results in another model harboring a deregulation of Wnt 
signaling as well.  
 
3.1 NK1R blocking leads to the regulation of specific proteins involved in 
PI3K/AKT/mTOR and canonical Wnt signaling 
First, human colorectal cancer (CRC) cell lines LiM6 (CTNNB1 mutation169) and DLD1 
(APC mutation170) were treated with increasing doses of aprepitant for 48 hours and 
standard MTT assays were subsequently realized. As observed with the hepatoblastoma 
cell lines, aprepitant induced a dose-dependent reduction of cell growth in both cell lines 
(Figure 37). 
 
Figure 37: Aprepitant triggers growth inhibition in colorectal cancer cells 
(A) MTT assay in DLD1 and LiM6. Cells were treated with increasing concentration of aprepitant or with 
DMSO (control) for 48 hours to assess cell survival. Shown is the mean and error bars represent s.d.. Figure 
taken from Garnier et al.
171
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In order to have a better understanding of the downstream molecular mechanisms 
responsible for these observed effects, RPPA was also realized in these cells. Similarly to 
hepatoblastoma cells, CRC cell lines LiM6 and DLD1 were treated with 20 µM or 40 µM 
aprepitant for 24 hours and 172 proteins were screened for changes in protein expression. 
To better scrutinize the regulation pattern in the two cell lines, we again averaged the 
changes after aprepitant treatment over the two cell lines conditions and for each protein 
(Figure 38). According to the cut off values, only a small number of proteins exhibited an 
upregulation (red) or downregulation (green) common in the two cell lines. However, 
compared to hepatoblastoma cells, aprepitant seemed to have a more potent effect on 
changes in expression in CRC cells (Figure 38). 
  
 
Figure 38: Pattern of regulation of 172 proteins analyzed by RPPA in two CRC cell lines 
CRC cells (LiM6 and DLD1) were cultured in monolayer, treated with DMSO (control), aprepitant (20 μM or 40 
μM) or substance P (SP) for 24 hours and protein lysates were analyzed by RPPA. The averaged changes 
after aprepitant treatment of all two CRC cell lines for all the proteins investigated compared to untreated 
controls are shown. The cut-offs were chosen according to the standard deviation of the values. In red, the 
selected proteins with a relative fold-change ≥ 1.163 and in green, the selected proteins with a relative fold-
change ≤ 0.836 are shown. In black, proteins with no significant changes in expression. Figure taken from 
Garnier et al.
171
 
 
A key outcome of this experiment is the finding of a similar intracellular pattern of regulation 
after aprepitant treatment between human hepatoblastoma and CRC cells. Indeed, some of 
the proteins which were significantly regulated could be associated to the PI3K/AKT/mTOR 
pathway and the Wnt signaling. Among the latter, the target gene MYC and the β-catenin 
interacting factor FOXM1 were found downregulated. Interestingly, β-catenin was not found 
significantly altered (Figure 39). 
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Figure 39: Aprepitant alters expression of Wnt associated proteins in CRC cells  
Graphical representation of relative fold-changes of proteins associated with Wnt pathway (β-catenin, MYC, 
FOXM1) after aprepitant treatment (20 µM or 40 µM). Cells were treated with 20 µM or 40 µM aprepitant, 
values were put into relation with the control (DMSO) and normalized to 1. Figure taken from Garnier et al.
171
 
 
Concerning the PI3K/AKT/mTOR pathway, its downstream proteins 4E-BP1/2 (S65), 
p70S6K (T389) (grey bars) were also found downregulated compared to their total forms 
(black bars). Total AKT was also dose-dependently downregulated upon aprepitant 
treatment in the two cell lines, whereas no clear trend could be extracted from its 
phosphorylated form at T308. In contrast, phosphorylation of AKT at S473 was upregulated 
along with its substrate PRAS40 at T246 (Figure 40).  
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Figure 40: RPPA reveals an inhibition of PI3K/AKT/mTOR pathway in CRC cells 
Relative fold-changes of proteins involved in PI3K/AKT/mTOR pathway. Cells were treated with 20 µM or 40 
µM aprepitant, values were put into relation with the control (DMSO) and normalized to 1. For AKT (S473), 
AKT (T308), PRAS (T246), p70S6K (T389) and 4E-BP1/2 (S65) the phosphorylated proteins are shown in 
grey bars and the total proteins in black bars. Figure taken from Garnier et al.
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3.2 NK1R antagonism induces apoptosis and a G2 arrest 
In the earlier sections, it was shown that aprepitant induced apoptosis in human 
hepatoblastoma cells. Therefore, as a next step it was investigated whether this held true in 
CRC cells. First, data obtained by RPPA were screened for alterations in apoptosis 
markers. For instances, cleaved caspase 7 and phospho-c-Jun (S73), two well known 
mediators of apoptosis172, 173 were upregulated upon aprepitant treatment (Figure 41A). In 
order to confirm the RPPA data, DLD1 cells were treated for 24 hours with increasing 
concentration of aprepitant and Western blot analysis for PARP was performed. As 
expected, aprepitant induced a dose-dependent increase of cleaved PARP indicating an 
activation of apoptosis, whereas SP had no effect (Figure 41B). Moreover, HER3 was found 
to be downregulated and targeting this receptor in CRC cells has been described to induce 
a G2 arrest as well as apoptosis174 (Figure 41A).  
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Figure 41: Aprepitant induces a G2 arrest and apoptosis in colorectal cancer cells 
(A) Relative fold-change of selected up and downregulated proteins involved in apoptosis or (C) in cell cycle 
regulation are shown. (B) Western blot analysis of total and cleaved PARP after treatment with increasing 
doses of aprepitant for 24 hours. (D) Analysis of the cell cycle by flow cytometry in DLD1. Cells were treated 
with 30 µM aprepitant or DMSO for 24 hours and stained with propidium iodide. The data are represented as 
the percentage of cells at different stages: subG1 (black), G1/G0 (black and grey), S (grey) or G2 (white). 
Values are shown in percent and n=2. Figure taken from Garnier et al.
171
 
 
In order to scrutinize the molecular basis of aprepitant-induced growth inhibition, cell cycle 
analysis was realized. The RPPA data revealed a downregulation of cyclin B1 and 
Checkpoint kinase 1 (CHK1), whereas p53 was slightly upregulated (Figure 41C). These 
proteins are known to regulate the G2-M transition175. To take a step further, DLD1 cells 
were treated with aprepitant for 24 hours with 30 µM aprepitant and cell cycle profile by 
propidium iodide staining and FACS analysis was performed. As shown in Figure 41D, 
aprepitant induced a G2 arrest (33% compared with 26% for DMSO-treated cells, white bar) 
and an increase of cells in the subG1 phase (12.7% compared with 1.63% for DMSO-
treated cells, black bar) indicating either late apoptosis or necrosis. 
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3.3 NK1R antagonism inhibits canonical Wnt signaling 
RPPA data in CRC cells suggested that aprepitant might induce a reduction of Wnt activity 
as observed in hepatoblastoma cell lines. In order to confirm this hypothesis, STF assays 
were performed first in non-treated cells to assess the baseline Wnt activity in DLD1 and 
LiM6, and in the pancreatic cancer cell line L3.6pl, a cell line known to express little Wnt176. 
As expected, both colon cancer cell lines displayed high levels of Wnt activity with 
approximately a 500-fold increased activity compared to L3.6pl (Figure 42A). However, 
upon aprepitant treatment, a robust inhibition of Wnt activity in both colorectal cell lines was 
observed (Figure 42B).  
 
Figure 42: Aprepitant induces a robust inhibition of Wnt activity in CRC cells.  
(A) Baseline Wnt activity was assessed using the TOP/FOP flash reporter system. Cells were transfected with 
TOPflash (non mutated TCF/LEF binding sites) or FOPflash (mutated TCF/LEF binding sites) for 24 hours. 
Results are represented by the ratio of TOP on FOP Firefly luciferase and normalized to Renilla luciferase. (B) 
Ratio of TOP to FOP after 24 hours of treatment with different concentrations of aprepitant (10, 20 or 40 µM) 
or DMSO (0) in LiM6 and DLD1.(C) qRT-PCR of Wnt target genes (AXIN2, MYC, CTNNB1) and Wnt-
associated gene (FOXM1). Cells were treated with increasing doses of aprepitant (10 µM, 20 µM or 30 µM, 
gray and black columns), SP (black columns) or DMSO (white columns) for 24 hours. (D) Selected proteins of 
the Wnt pathway were validated by Western blot analysis (β-catenin, LRP5, MYC). Cells were treated with 30 
µM aprepitant or DMSO (0) for 24 hours followed by extraction of total cell lysates. Figure taken from Garnier 
et al.
171
 
 
RESULTS 
65 
 
These results were corroborated by qRT-PCR data in DLD1. The Wnt target gene MYC 
was dose-dependently downregulated upon aprepitant treatment along with AXIN2 and 
FOXM1 (Figure 42C). Intriguingly, in contrast to the RPPA data, CTNNB1 was 
downregulated, too, although the trend was not as convincing as observed in the other 
genes. Finally, cells were treated with 30 µM aprepitant and Western blot analysis was 
performed. The Wnt co-receptor LRP5 as well as the Wnt target MYC were expressed at 
markedly lower levels upon aprepitant treatment compared to the respective control. In the 
same experiment, the expression of β-catenin following aprepitant treatment was analyzed. 
Similar to the RPPA data, no changes of total β-catenin could be noted in whole cell lysates 
of LiM6 or DLD1 (Figure 42D). 
 
In order to investigate this hypothesis as well as the downregulation of the β-catenin/Wnt 
signaling pathway following aprepitant treatment, cells were cultured with 30 µM aprepitant 
or 70 nM SP for 24 hours, stained for β-catenin and analyzed by confocal microscopy. 
Similarly to hepatoblastoma cells, aprepitant induced a strong accumulation of membrane-
bound β-catenin whereas SP did not affect β-catenin/Wnt signaling when compared to the 
control (Figure 43).  
 
 
Figure 43: Aprepitant promotes membrane-bound β-catenin in colorectal cancer cells 
Immunofluorescent staining of β-catenin (green) in DLD1 and nuclear staining with DAPI (blue). Cells were 
treated with 30 µM aprepitant (AP 30 µM), 70 nM SP or DMSO for 24 hours. The staining was examined by 
confocal microscopy. Figure taken from Garnier et al.
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In a next step, SFA assays were performed with both DLD1 and LiM6 in order to confirm 
the potential of aprepitant to reduce three-dimensional cell growth of CSC-like spheres. 
RESULTS 
66 
 
Aprepitant induced a striking decrease in sphere number and size. A noteworthy fact is that 
activation of the SP/NK1R system with recombinant SP significantly increased the SFA of 
DLD1 CSCs in number and size, whereas in LiM6, such effects could not be detected 
(Figure 44). 
 
  
 
Figure 44: Aprepitant induces a robust inhibition of Wnt activity and promotes membrane-bound        
β-catenin in colorectal cancer cells 
Sphere formation ability (SFA) assays in DLD1 and LiM6 with simultaneous treatment with aprepitant (AP) or 
SP. Shown are the number of spheres per 500 seeded cells in an ultra-low attachment 96-well plate after 10 
days. Sphere sizes were evaluated and categorized as follows: >250 µm (black) >150 µm (black and grey) 
and >75 µm (grey) n=3. Figure taken from Garnier et al.
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In conclusion, the inhibition of the SP/NK1R system with aprepitant induced a decrease of 
canonical Wnt signaling in colorectal cancer cells, likely by arresting β-catenin in its 
membrane-bound localization, and affected negatively the growth of CSC-like colorectal 
spheres. 
 
3.4 The inactivation of the Wnt pathway is independent from initial Wnt 
baseline activity 
 
In order to better understand the inhibitory effect of aprepitant on Wnt signaling, it was 
investigated whether differences exist regarding the response rate to aprepitant treatment 
within cell populations that are constitutively active with respect to the Wnt pathway. Such 
cells with high constitutive Wnt activation have been described to have higher stemness 
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properties177. In order to have comparable findings to those from Vermeulen et al.177, the 
colorectal cell lines LiM6 and DLD1 were transduced with a 7xTCF-eGFP/SV40-mCherry 
(7TGC) lentiviral construct178 allowing cell separation regarding their Wnt activities by single 
cell sorting via FACS (Figure 45A). Wnt activity in cells with the same level of mCherry 
intensity then correlates with their GFP intensity. After separation, Wnthigh and Wntlow 
expressing cells were independently cultured and subsequently treated with increasing 
doses of aprepitant for 48 hours (Figure 45B). Interestingly, no differences in cell survival 
were observed for any of the doses tested between cells with high or low Wnt activity.  
 
Figure 45: Aprepitant affects the cell viability of GFP/Wnt
high
 and GFP/Wnt
low
 cells to the same degree 
(A) CRC cells were transduced with the lentiviral construct 7xTCF-eGFP/SV40-mCherry (7TGC). The 5% 
GFP
high
 and 5% GFP
low
 cells were sorted via FACS and used for further evaluation. Shown are representative 
FACS plots with DLD1 in the upper panel and LiM6 in the lower panel. The left panels show cell counts on the 
y-axis and eGFP intensities on the x-axis; the right panels show mCherry intensities on the y-axis and eGFP 
intensities on the x-axis. (B) GFP
high
 or GFP
low
 cells from (A) were treated for 24 hours with increasing doses 
of aprepitant or with DMSO. Subsequently, MTT cell viability assays were carried out and relative cell viability 
compared to DMSO treated cells is shown (n = 3). Figure taken from Garnier et al.
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These findings suggest that the apoptosis-inducing property of NK1R targeting is 
maintained even in cells with supposedly increased cancer stemness potential (Wnthigh). 
Furthermore, these data indicate that in a particular cell line or population, the observed 
inhibitory effects caused by NK1R antagonism are independent of the initial Wnt baseline 
activation. 
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Taken together, these data clearly demonstrate that the anti-cancer effect of aprepitant is 
not limited to hepatoblastoma but concern also CRC cell lines. Interestingly, aprepitant 
seems to triggers identical molecular responses by targeting PI3K/AKT/mTOR and 
canonical Wnt pathways, which implies that this molecule could be used in a broad variety 
of cancers harboring these two types of deregulations.  
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4. The NK1R is an ubiquitous anti-tumor target in hepatoblastoma and its 
expression is independent from tumor biology and stage 
The results presented in this section are part of the publication: The neurokinin-1 receptor is an 
ubiquitous anti-tumor target in hepatoblastoma and its expression is independent from tumor 
biology and stage. Oncology Letters (2015, 11:870-878) Garnier A, Ilmer M, Becker K, Häberle B, 
von Schweinitz D, Kappler R, Berger M. 
 
4.1 NK1R is overexpressed in human hepatoblastoma 
The final step of this study in the assessment of NK1R as an interesting anti-tumor target 
was to evaluate its expression in tumor samples, and determine whether its expression 
correlate with clinical, histological and biological parameters. In order to address this 
question, the gene expression pattern of NK1R-fl as well as NK1R-tr was first analyzed in 
tumor tissue samples of hepatoblastoma and non-tumorous liver tissue. NK1R-tr was 
significantly overexpressed in hepatoblastoma compared to the control specimens (Figure 
46A). Although not statistically significant, the expression of NK1R-fl also tended to be 
higher in tumor specimens (Figure 46B). These results correlated with the previous findings 
in vitro (Figure 8) in which NK1R-tr is overexpressed in malignant hepatoblastoma cells, 
which in turn correlates with the responsiveness to treatment with NK1R antagonists such 
as aprepitant. 
 
Figure 46: Hepatoblastoma tumors overexpress NK1R compared to normal liver tissue 
(A) Statistically significant different relative gene expression (p=0.0301) of NK1R-tr in hepatoblastoma (n=47, 
black triangles) compared to normal liver tissue (n=9, white squares). (B) Gene expression of NK1R-fl in the 
same samples as in (A); no significant difference could be detected. Figure taken from Garnier et al.
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4.2 Expression of NK1R-tr correlates with NK1R-fl 
 
Because of the wide range of gene expressions, the results were displayed as ratio of 
NK1R-tr vs. NK1R-fl. The ratios were found to be comparable between the tumor and the 
control specimens (Figure 47A), suggesting a positive correlation of the two splice variants. 
When analyzed in depth, a statistically significant weak correlation (r=0.3542) between 
NK1R-tr and NK1R-fl was found, potentially indicating a mutual dependency (Figure 47B). 
 
 
Figure 47: Expression of NK1R-tr correlates with NK1R-fl 
(A) The ratio of the gene expression values of NK1R-tr (Figure 46A) vs. NK1R-fl (Figure 46B) was calculated 
for hepatobmastoma tumors and liver tissue. (B) The correlation of the gene expression values of NK1R-tr 
(Figure 46A) vs. NK1R-fl (Figure 46B) was calculated and graphically illustrated (black squares). P=0.0074, 
r=0.3542. Figure taken from Garnier et al
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4.3 NK1R expression does not correlate with biological features 
For a better understanding of whether the expression level of either splice variant or their 
ratio correlates with the biological features of the tumor, NK1R expression was analyzed 
accordingly.  
The first analysis focused on the truncated variant due to its significance in hepatoblastoma 
as a potential therapeutic target as demonstrated in this work. The presence of a correlation 
was investigated between the relative expression of NK1R-tr with a recently described 16-
gene molecular signature known to associate with prognosis55. Similarly to the original 
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description of this signature, the cohort of this study could be separated into 29 
hepatoblastoma belonging to the C1 signature (61.7%) and 18 hepatoblastoma grouped 
into the adverse C2 signature (38.2%) (Table 2).  
Relative gene expression of NK1R-tr revealed no significant difference between C1 and C2 
(Figure 48, upper left panel). Next, the same features were analyzed in correlation to the 
gene expression of NK1R-fl (Figure 49, upper left panel). Here, a significant correlation was 
found of low NK1R-fl with the C2 population of the 16-gene signature (p = 0.0222). Of note, 
55.6% of the specimen grouped into the C2 population displayed very low levels of NK1R-fl. 
Next, the ratio of both variants – truncated vs. full length – was used to see whether it could 
be correlated with the 16-gene signature. Intriguingly, very low ratios were found in the 
favorable C1 population and very high ratios were found within the C2 population, but this 
effect was not statistically significant (Figure 50, upper left panel).  
 
Table 2: Classification of the cohort  
 
4.4 Expression of NK1R does not correlate with clinical features 
In a next step, the expression patterns of both NK1R-fl and NK1R-tr was correlated with 
clinical, biological and histological features such as metastasis, vascular invasion, histology, 
multifocality, CTNNB1 mutations, sex and the preoperative classification PRETEXT 
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(Figures 48 and 49). Over the entire cohort, 63.8% had no metastasis at the time of 
diagnosis, 82.9% had no vascular invasion, while only 27.7% were multifocal. Sex was 
equally distributed (female 51.1% vs. male 48.9%) and most tumors had a fetal histology 
(74.5% vs. 25.5% embryonal). As expected, 70.2% of tumors possessed a β-catenin 
mutation (CTNNB1 mutation). The age of diagnosis was mainly within the first 24 months of 
life (68.1%) and the specimen were distributed among PRETEXT 1-2 (36.2%), PRETEXT 3 
(40.4%), and PRETEXT 4 (23.4%) (Table 2).  
 
After analyzing NK1R-tr expression, no statistically relevant differences could be detected 
with respect to the above-mentioned clinical features. An interesting observation was that 
high expressions of NK1R-tr correlated with a better overall survival (Figure 48, lower left 
panel), although this was only a trend and did not reach statistically significant levels. 
 
Similarly, when analyzing the pattern of NK1R-fl expression with metastasis, PRETEXT, 
vascular invasion, histology, age of diagnosis, multifocality, CTNNB1 mutations or sex, no 
significant correlation was found (Figure 49). When clustered into groups according to high 
versus low expression of NK1R-fl, overall survival curves did not deviate from each other 
contrary to the finding for NK1R-tr (Figure 48 and 49, lower left panels). 
 
When considering the ratio of both variants – truncated vs. full length – again, no statically 
significant differences could be found with regards to most of the characteristics, with the 
only exception that higher truncated to full-length ratio was found predominantly in 
PRETEXT 1-2 compared to PRETEXT 3 (Figure 50, upper right panel). Similarly to the 
analysis considering NK1R-tr alone, overall survival was worse with a low ratio of NK1R-
tr/NK1R-fl (Figure 50). 
 
Because the original description of the 16-gene signature by Cairo et al.55 suggested a 
worse prognosis for the C2 signature, it was interesting to investigate whether either factor 
(NK1R-tr, NK1R-fl or the ratio thereof) could refine the predictive value in the set of tumors 
of this study. Therefore, the overall survival was reanalyzed within the C2 hepatoblastoma 
tumors and their outcome was analyzed with respect to high vs. low expression of NK1R or 
its ratio. Low NK1R-tr predicted a bad prognosis for C2 tumors with a higher significance 
than NK1R-tr alone (Figure 48, lower right panel). Although not significant, high NK1R-fl 
suggested a worse outcome (Figure 49, lower right panel) and the ratio of both variants 
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showed the same trend as the truncated variant alone and as analyzed in the whole cohort, 
but with a clear tendency to a worse prognosis for low NK1R-tr/NK1R-fl in the C2 group 
(Figure 50, lower right panel). 
 
To sum up, a strong correlation of either gene expression of NK1R-tr, NK1R-fl or the ratio 
thereof with clinical and histological data could not be found. However, and especially when 
added to the C2 signature, a low NK1R-tr expression level or a low truncated-vs-full ratio 
was associated to a worse prognosis, whereas no significance could be found in NK1R-fl 
with a slight trend to worse outcomes in the C2 and high NK1R-fl expression cases.  
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Figure 48: NK1R-tr expression is not associated with clinical parameters.  
Relative gene expression of NK1R-tr was correlated to the 16-gene signature, metastasis, the preoperative 
staging system PRETEXT, vascular invasion, histology, age of diagnosis, multifocality, CTNNB1 mutation 
status (no = wild type, yes = mutated β-Catenin), and sex (no significant differences). Overall survival is 
shown for high and low NK1R-tr expressers with a difference in survival (p=0.0551). High expression is 
defined as > 3-fold of the mean of 9 normal liver tissues. Low expression of NK1R-tr significantly lowers 
overall survival in hepatoblastoma tumors harboring the C2 signature (p=0.0377). n.s. = not significant. Figure 
taken from Garnier et al
179
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Figure 49: NK1R-fl expression displays no difference in biological, clinical, and histological features. 
Analogous to Figure 48, relative gene expression of NK1R-fl was compared to the same 10 parameters. The 
C2 signature (upper left) significantly correlated with a low gene expression of NK1R-fl. All other calculation of 
the p-values did not reveal any statistically relevant differences. High expression of NK1R-fl worsens outcome 
in hepatoblastoma tumors harboring the C2 signature, but the trend is not significant. n.s. = not significant. 
Figure taken from Garnier et al
179
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Figure 50: The ratio of NK1R-tr and NK1R-fl does not predict clinical prognosis.  
As in Figures 48 and 49, ten different clinical features were analyzed with regards to the ratio of NK1R-tr vs. 
NK1R-fl gene expression. No significant difference could be detected in the 16-gene signature, metastasis, 
vascular invasion, histology, age of diagnosis, multifocality, CTNNB1 status, sex or overall survival. PRETEXT 
1-2 significantly correlated with a higher ratio compared to PRETEXT 3 (upper right panel). Low expression of 
the ratio of truncated / full length lowers overall survival in hepatoblastoma tumors harboring the C2 signature 
but the results are not significant. n.s. = not significant. Figure taken from Garnier et al
179
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DISCUSSION 
1. Hepatoblastoma cells express NK1R and can be growth inhibited by aprepitant in 
vitro 
This study reports on a completely new approach for the treatment of hepatoblastoma 
based on the blockage of NK1R. We found that this receptor was highly expressed in 
hepatoblastoma cell lines and its inhibition by small molecules was responsible for a robust 
inhibition of proliferation with induction of apoptosis in vitro. However, aprepitant alone was 
not enough to eradicate HuH6 tumor in vivo but was efficient in significantly reducing tumor 
growth156.   
Combining aprepitant with cytostatics revealed very promising results: a synergistic effect 
was observed with the addition of aprepitant with doses as low as 1 µM of doxorubicin. In 
line with these observations, osteosarcoma cell lines showed a similar effect with NK1R 
antagonists for mitomycin, ifosphamide, adriamycin and cisplatin153. However, in this study 
results were obtained after one single treatment and are not representative of the clinical 
setting where several chemotherapy courses are needed. In a next step, it would be 
interesting to further investigate how combinations of low dose chemotherapy agents with 
aprepitant affect tumor growth in vivo. The ultimate goal would be to decrease the 
concentration of cytostatics because these molecules are responsible for severe side 
effects when given at high doses. Particularly, doxorubicin is responsible for 
cardiotoxicity124, whereas cisplatin causes nephrotoxicity and ototoxicity8. Furthermore, 
aprepitant has successfully been used for the treatment of pain, migraine, and some 
psychiatric disorders including depression152. Therefore, the use of this molecule for future 
treatment strategies would be very interesting knowing that many patients with cancer 
suffer from these symptoms. Altogether these findings emphasize the relevance of 
conducting a clinical study with aprepitant in combination with cytostatics currently used for 
the treatment of hepatoblastoma.  
Despite being highly expressed in neoplastic cells, the SP/NK1R complex has been 
recently incriminated as an important actor of the tumor microenvironment. For instance, 
high expression of NK1R in capillaries was recently linked to tumor neovascularization, 
which participates in the angiogenesis process180. More precisely, SP which is highly 
expressed by the tumor itself but also by other structures such as peripheral terminal 
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nerves or infiltrated immune cells127, was shown to induce the growth of capillary vessels in 
vivo and trigger the proliferation of endothelial cells in vitro. Additionally, SP acts as a pro-
inflammatory compound, which potentially could contribute to tumor-promoted 
inflammations, a previously described hallmark of cancer181. The fact that cancer cells 
produce SP also suggests the presence of an autocrine growth stimulus pattern. 
Mayordomo et al. used a monoclonal, specific antibody against this agonist in isolated 
cultures of breast cancer and other cancer cell lines and observed an inhibition of cell 
growth and an increase of apoptosis182. Similarly, when using anti-SP or anti-NK1R 
antibodies, a significant growth inhibition was noted in our study. These findings converge 
to the fact that hepatoblastoma cells are capable of auto-stimulation, which therefore 
reinforces the preeminence of NK1R as a driver of hepatoblastoma growth.  
Nevertheless, there are many unresolved questions concerning the true role of the 
SP/NK1R system in the development of cancer. For instance, until recently few attention 
has been given to the different splice variants of NK1R. Previous studies pointed out the 
central role of NK1R-tr in breast cancer183, 184. Likewise, Gillespie et al. analyzed NK1R-tr 
and NK1R-fl in colitis-associated cancer and found that it was the expression of NK1R-tr 
alone that predicted the progression from quiescent colitis to high-grade dysplasia and 
cancer157. Compared to NK1R-fl, the truncated variant is lacking residues at the 
cytoplasmic end of the receptor. Nonetheless, it seems to be able to couple to G proteins 
but shows reduced efficiency with respect to internalization and desensitization. The 
analysis of NK1R expression in hepatoblastoma cells revealed an overexpression of the 
truncated isoform whereas NK1R-fl was very little expressed. In comparison, human 
fibroblasts and non-malignant HEK293 cells expressed negligible levels of NK1R-tr. This 
receptor system seems to be of minor importance in human fibroblasts, since both splice 
variants were barely detectable. Interestingly, these cells showed the strongest resistance 
to aprepitant when analyzing cell survival whereas HEK293 cells, which expressed higher 
levels of NK1R-fl, displayed an increased response to aprepitant. Taking these results into 
account, it seems that the response to NK1R antagonists is selective and relies on the 
differential expression of the receptor within these cells. However, at the moment, these 
results do not permit us to establish clearly a causal relationship between the expression 
level of splice variants and the sensitivity to aprepitant. Nevertheless, as NK1R-tr is 
believed to be resistant to desensitization and internalization, one could suggest that this 
isoform is responsible for a constitutive growth stimulus.  
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This part of the study uncovered the SP/NK1R complex as an interesting therapeutic target 
in human hepatoblastoma. Aprepitant and other NK1R antagonists are capable of inducing 
a potent growth inhibition with induction of apoptosis in malignant cells harboring high level 
of NK1R-tr. Therefore, it would be interesting to realize complementary experiments such 
as NK1R knockdown, in order to investigate in detail the functional role of this specific 
isoform in hepatoblastoma development. 
2. Targeting the NK1R compromises PI3K/AKT/mTOR pathway in hepatoblastoma 
The next step of this study was to investigate the downstream mechanisms following 
inhibition of NK1R by aprepitant on hepatoblastoma cells. First, a robust inhibition of 4EBP1 
and p70S6K was identified, which are both downstream members of the PI3K/AKT/mTOR 
pathway. This is really promising because this pathway is known to be involved in 
tumorigenesis and was identified as a potent target for the development of future anticancer 
strategies185. In particular, previous work showed that the inhibition of hepatoblastoma cell 
growth could be achieved with the use of rapamycin through inhibition of the 
PI3K/AKT/mTOR pathway by dephosphorylating and deactivating p70S6K186. Furthermore, 
the inhibition of both p70S6K and 4EBP1 in our study is in accordance with Mayordomo et 
al.182. This group treated breast, prostate and colon cancer cells with SP antibodies, which 
led to the inhibition of mTOR. Likewise, Garcia-Recio et al. showed that SP induced an 
activation of the pathway with an early increased expression of p-AKT in breast cancer 
cells187.  
When analyzing more in details the effect of aprepitant at the molecular level, we came 
across discrepancies by finding an unexpected increase of AKT phosphorylation (S473 and 
T308) suggesting an activation of the PI3K/AKT/mTOR pathway. This was confirmed by an 
increase of AKT substrate-specific phosphorylation of PRAS40 (T-246)188 and GSK3β 
(S9)81. However, activation of mTORC1 following aprepitant treatment is questionable for 
several reasons. Firstly, 4EBP1 was found phosphorylated at T37/T46 and although it is 
admitted that mTORC1 mediates this phosphorylation189, other kinases have this ability. For 
instance, phosphorylation of 4EBP1 at these two distinct sites can be performed by CDK1 
under conditions of reduced mTOR signaling190. Likewise, PLK1 was shown to have similar 
effects in HepG2191. Furthermore, our data also indicated an increase in phosphorylation of 
mTOR at S2448 which, in this form, is known to be associated with mTORC1 complex192. 
At first, we speculated that it was an indicator of mTORC1 activity. However, mutation of 
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S2448 to A2448 has no discernible effect on the ability of mTOR to activate its downstream 
effectors. More interestingly, deletion of this region resulted in enhanced mTOR kinase 
activity suggesting that this region may actually act as a repressor domain193. Therefore, 
the more grounded hypothesis would consider that mTORC1 is inhibited after aprepitant 
treatment (Figure 51).  
 
Figure 51: Schematic representation of aprepitant action on PI3K/AKT/mTOR pathway in 
hepatoblastoma based on RPPA and Western blot data  
Following aprepitant treatment, mTORC1 is inhibited as proved by decrease of its downstream target p70S6K 
(T389) and 4EBP1 (S65). AKT becomes activated due to the loss of negative feedback of p70S6K on Rictor 
(decrease of phosphorylation at T1135), and on IRS protein. Activated AKT phosphorylates GSK3β (S9) and 
PRAS40 (T246) and promotes for instance cell survival. 
 
Another indicator of mTORC1 inhibition is hyperactivation of mTORC2 as illustrated by 
increased phosphorylation of AKT at S473 and decreased phosphorylation of Rictor at 
T113597. We speculate as others that inhibition of mTORC1 complex suppresses the 
negative feedback of mTOR/p70S6K activation on IRS198, 194, 195 and Rictor (T1135)95 
(Figure 51). In the same manner, Western blots of AKT after short time treatment revealed 
first a decreased expression of phospho-AKT (S473) followed by a subsequent increase 
probably due to the loss of these negative feedbacks. Late AKT activation would therefore 
represent a rescue reaction of the tumor cells to escape cell death. This phenomenon was 
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already described after everolimus treatment where the negative feedback via p70S6K on 
mTORC2 is inhibited allowing AKT phosphorylation at S473 by mTORC2 complex196. 
Importantly, it has been suggested that increased AKT signaling following mTORC1 
inhibition could attenuate anticancer efficacy or over time, contribute to the development of 
resistance196, 197. 
Furthermore, we identified upon aprepitant treatment a nuclear localization of phospho-
mTOR (S2448) and phospho-AKT (S473). mTOR is believed to be cytoplasmic198 however 
our immunofluorescence staining in untreated cells revealed that mTOR was present in the 
cytoplasm but also to a lesser degree in the nucleus. Although no classic nuclear 
localization sequences have been found in mTOR, we think that this particular localization 
could be explained by the presence of a rapid nuclear export mechanism compared to the 
nuclear import, which could explain the strong nuclear accumulation of mTOR, AKT and 
FOXM1. Interestingly, Kim et al.199 reported the same atypical localization of mTOR.  
Additionally, they observed an accumulation of nuclear mTOR upon Leptomycin B 
treatment, an inhibitor of CRM1-dependent nuclear export, which was associated with a 
decrease of p70S6K and 4EBP1 phosphorylation. It is possible to speculate that a perfect 
balance beetwen cytoplasmic and nuclear mTOR is needed for maximal mTOR activity200. 
By dysrupting a shuttling mechanism, aprepitant could induce a strong accumulation of 
mTOR in the nucleus, which therefore would inhibit cytoplasmic mTORC1 downstream 
targets such as p70S6K and 4EBP1.  
Appart from this, increase of nuclear AKT was also detected upon aprepitant treatment. In 
the nucleus, active AKT can phosphorylate several intracellular substrates to promote cell 
survival or DNA repair201. Furthermore, strong nuclear presence of AKT (S473) has been 
described in several cancer types, which corroborates the potential role of AKT in the 
development of drug resistance. Importantly, this phenomenon could explain our in vivo 
data. Despite the fact that aprepitant induced a significant reduction of tumor growth, we 
observed a slight increase in tumor volume over time growing from 75 to 200 mm3 after 20 
days of treatment156. 
In sum, these findings clearly identify the PI3K/AKT/mTOR pathway as one major 
downstream mechanism responsible for NK1R-triggered growth inhibition in 
hepatoblastoma. However, several efforts have to be made in order to clearly understand 
the mechanisms involved in upregulation of AKT. This could lead to the developpment of 
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new approches to abrogate completely this pathway pivotal in drug resistance. For 
instance, Wan et al. successfuly suppressed reactivation of AKT by targeting mTOR but 
also IGF1R202.  
3. Targeting the NK1R compromises canonical Wnt signaling in hepatoblastoma 
3.1 Aprepitant induces a downregulation of Wnt signaling 
In this study, we also observed a striking reduction of Wnt activity as confirmed by reduced 
luciferase activity in SuperTOP/FOP assays and by decrease of Wnt target gene 
expression. Firstly, this effect seemed to be limited to cells with mutations of the Wnt 
pathway or cells in which the pathway was extrinsically activated, as demonstrated with the 
β-catenin wild-type cell lines HuH7 and HEK293 after lithium chloride stimulation. Further, 
the cell lines used in this study harbor β-catenin mutations indicating that the molecules 
upstream of the destruction complex should not be needed for pathway 
activation/modulation. Therefore, knowing that aprepitant more likely acts at the level of β-
catenin, we made several assumptions on how NK1R inhibition could modulate Wnt 
signaling.  
 Modulation of β-catenin/E-cadherin phosphorylation status 
One of our intriguing results was the discovery of increased membrane bound β-catenin 
upon aprepitant treatment, that we believe could be the cause of Wnt inhibition. It is well 
established that E-cadherin/β-catenin complex association is tightly regulated by a complex 
interplay of phosphorylations. Indeed, previous work reported that E-cadherin 
phosphorylation at specific sites promotes cell adhesion by increasing the E-cadherin/β-
catenin203 binding affinity. Particularly, the cytoplasmic domain of E-cadherin contains 
several phosphorylation sites for CKII and GSK3β203. However we found an increase of 
AKT dependent phosphorylation of GSK3β (S9), which is known to completely suppress its 
kinase activity204. Therefore, it is unlikely that GSK3β is responsible for the observed effect. 
Other phosphorylation sites have been characterized in β-catenin as being central for the 
binding to E-cadherin. Particularly, Y142, Y489 and Y654 are phosphorylated by Fyn/c-Met, 
Abl/Fer, and EGFR/Src, respectively, and enhanced activity of these kinases has been 
linked to a decrease of E-cadherin/β-catenin binding affinity37. However, our RPPA data 
revealed that total and phosphorylation levels of c-Met (Y1235), EGFR (Y1068/Y1173) and 
Src (Y416/Y527) were not affected. Therefore, at the moment our RPPA data doesn't allow 
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us to understand the underlying mechanisms responsible for the heightened level of          
β-catenin at the membrane. To perform this task, it would be worth investigating E-cadherin 
and β-catenin phosphorylation status and realize accordingly knockdown experiments of 
specific kinases coupled with co-immunoprecipitation and immunofluorescence 
experiments.  
 Disruption of FOXM1/β-catenin complex 
In our study, we showed that FOXM1, a recognized shuttle protein for the translocation of 
β-catenin to the nucleus159, was found inhibited at the mRNA and protein levels. 
Intriguingly, we also observed a loss of colocalization between these two proteins reflected 
by an increase of nuclear FOXM1 and membrane bound β-catenin. Disruption of this 
complex could therefore be the cause of Wnt inhibition in Wnt-dependent cancer cells 
leading to enhanced susceptibility for apoptosis and growth arrest. In accordance, Zhang et 
al. mentioned that FOXM1 mutation or nuclear import prevented β-catenin nuclear 
accumulation in tumor cells leading to decrease of Wnt activity159. Nevertheless, these 
findings do not explain how exactly β-catenin accumulates at the membrane and further 
experiments need to be realized in this direction. This is indeed very interesting because it 
leads to the assumption that NK1R inhibition fortifies epithelial states of the cell, therefore 
indicating a potential role of NK1R in the regulation of epithelial-mesenchymal transition 
(EMT). This process confers mesenchymal properties on epithelial cells and has been 
associated with the acquisition of aggressive traits participating in the outgrowth of 
metastasis205. For this reason, approaches to reverse or inhibit this phenomenon in cancer 
cells are still intensively researched206. Additional experiments should thus focus on 
analyzing EMT regulation following aprepitant treatment, especially as Wnt and 
PI3K/AKT/mTOR pathways are important drivers206, 207. For instance, an inquiry of EMT 
markers by qRT-PCR (TWIST, SLUG, SNAIL, E-cadherin)208, wound healing assay or 
Boyden chamber assays to assess invasiveness could be envisaged209. 
 
3.2 Aprepitant targets cancer stem-like cells 
Wnt signaling has been associated with stemness property161, which is considered as the 
final acquisition conferred by EMT210. We were able to show in vitro that aprepitant not only 
diminished the sphere formation ability of hepatoblastoma cells when treated 
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simultaneously, but also sustainably altered their stemness potential as shown by sphere 
formation ability assays of pretreated hepatoblastoma cells and decreased expression of 
embryonic stemness genes. Interestingly, we found that high expression of embryonic 
stemness markers correlated with high expression of NK1R-tr in HepT1 and HuH7 spheres 
suggesting a mutual dependency. However, It seems unlikely that this mechanism solely 
rely on Wnt signaling as, contrary to HepT1, HuH7 spheres didn't overexpress members of 
the Wnt pathway (LGR5, CTNNB1, AXIN2). More interestingly, treatment of spheres with 
aprepitant only affected Wnt mutated cell lines when considering embryonic markers and 
NK1R expression. This suggests the presence of a positive retroaction loop in Wnt mutated 
cells between NK1R-tr and Wnt signaling, which is potentially pivotal in the acquisition of 
stem-like features. This highlights once again the central role of this isoform as a driver of 
hepatoblastoma and indicates that it could be used as a marker of agressiveness. Taken 
together, we provide evidence that NK1R antagonism decreases canonical Wnt signaling 
and stemness property, especially in Wnt-dependent CSC-like cells. These results are of 
particular importance considering the assumption that CSC are responsible for cancer 
relapse and resistance211.  
However, this is not to say that growth inhibition following treatment with NK1R antagonists 
in hepatoblastoma cells is necessarily triggered exclusively through this mechanism. For 
example, cancer cells that express little Wnt activity, such as HuH7 cells, still show a 
therapeutic effect in response to aprepitant. Often, this therapeutic response is in the same 
magnitude as in cancer cells with high Wnt activity. This goes along with our findings, which 
identify other important cancer pathways being significantly inhibited by NK1R antagonists, 
such as PI3K/AKT/mTOR. Overall, we find these results encouraging, because targeting 
two pathways involved in tumorigenesis might delay the development of escape 
mechanisms in the cancer cell.  
 
3.3 Crosslinks between PI3K/AKT/mTOR and canonical Wnt signaling 
Crosslinks between PI3K/AKT/mTOR and Wnt signaling have been well described, 
although not in the setting of NK1R inhibition. Wnt can inhibit GSK3β in order to activate 
mTOR in the absence of β-catenin during regular cell growth. Inoki et al. reported that the 
kinases GSK3β and AMPK cooperate in the activation of TSC2 to inhibit mTOR activity212. 
This work clearly showed that the phosphorylation of TSC2 by GSK3β is significantly 
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suppressed by Wnt signaling. Furthermore, mTORC1 activity has been shown to facilitate 
nuclear translocation of Forkhead Box K1 (FOXK1), another member of the forkhead family 
which is predicted to contain an mTOR phosphorylation motif213. We speculate here that 
FOXM1 might be modulated in a similar way since they share a common forkhead 
domain214. Increase of nuclear mTOR (S2448) could therefore induce the sequestration of 
FOXM1 in the nucleus, which ultimately would inhibit Wnt signaling. Unfortunately, at this 
time our data do not permit us to fully answer this intriguing query. Inhibition of mTORC1 
with rapamycin followed by immunofluorescence and phosphorylation status analysis of 
FOXM1 could be envisaged to elucidate this point. 
Another crosslink between PI3K/AKT/mTOR and Wnt has been recently described. Gao et 
al. showed that autophagy negatively regulates Wnt signaling by promoting Dishevelled 2 
degradation215. Autophagy is an early mechanism set up by the cells under nutrient 
starvation, stress or reduced availability of growth factors to adjust the metabolism to 
survive. It is essentially activated upon mTORC1 inhibition216, 217. However, we exclude this 
possibility as hepatoblastoma cells harbor β-catenin mutation and should theoretically be 
independent of upstream signals.  
Taken together, these findings suggest that components of the PI3K/AKT/mTOR pathway 
can potentially be targets for diseases linked to hyperactive Wnt signaling, including 
cancer212, 218.  
4. Targeting the NK1R inhibits growth of human colon cancer cells 
Colorectal cancer was found to be the consequence of an accumulation of genetic 
abnormalities including an overactivation of Wnt signaling in the early stages of 
tumorigenesis47. New drugs have been developed to block this pathway. The use of 
antibody-based therapy, small molecules219 or other direct and indirect inhibitors220 have all 
been studied in depth, but until now, no component has succeeded at a clinical level. We 
used colorectal cancer cell lines to assess whether aprepitant would have a similar effect, 
therefore reinforcing the action of aprepitant as a broad anti-cancer agent targeting Wnt 
signaling, and also providing new insights for the treatment of CRC.   
Firstly, this work revealed that aprepitant triggered a robust inhibition of Wnt signaling 
activity and a growth inhibition of the two CRC cell lines DLD1 and LiM6. Aprepitant didn't 
clearly downregulate β-catenin at the protein or mRNA level, but  induced an accumulation 
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in its membrane-bound state, as observed in the hepatoblastoma cell lines. These findings 
were confirmed by a significant inhibition of Wnt activity as measured by the luciferase 
reporter assay, and by the decrease of Wnt target genes MYC, AXIN2 and CCND1 at 
mRNA level and/or protein level. 
With the results at hand, it is difficult to make other assumptions than the ones already 
exposed in the previous parts. Particularly, our work showed that FOXM1 was significantly 
downregulated following treatment with aprepitant. Therefore, as observed in 
hepatoblastoma cells, FOXM1 could also be responsible for the decreased Wnt activity in 
CRC cells. Indeed, in accordance with Zhang et al.159, previous work showed that β-catenin 
activation directly correlates with FOXM1 expression221. They suggested also that FOXM1 
might be crucial for Wnt activity. This could be demonstrated in Foxm1 knockout mice in 
which Wnt signaling was significantly reduced in Foxm1-/- colon tumors222. Furthermore, 
aprepitant also reduced sphere formation ability in CRC cell lines indicating that the 
inhibition effect of aprepitant on CSC is not restricted to hepatoblastoma cells, but englobes 
other Wnt-mutated cancers. 
On the other hand, we found that aprepitant treatment resulted in growth inhibition of cells 
independently of their constitutional Wnt activity. For example, we observed the same 
therapeutic effect after separating colon cancer cells in Wnthigh and Wntlow expressing cells. 
The treatment of pancreatic cancer cell line L3.6pl known to express minimal Wnt176 
showed furthermore a strong growth inhibition. One can give several explanations of these 
facts. Wnt signaling has a critical role for any cancer cell and its abrogation merely has 
detrimental effects on the cell, independently of its constitutional Wnt activity. Further, 
aprepitant has not only an anti-cancer effect by inhibiting Wnt but also by a downregulation 
of the PI3K/AKT/mTOR pathway, also observed in CRC cells. Therefore, aprepitant could 
actually be used as a broad spectrum anti-cancer agent, as already demonstrated in vitro in 
other cancer models152. The striking resemblance of aprepitant action with that of 
rapamycin, and the fact that even non Wnt-mutated cells are particularly susceptible to 
aprepitant, let us assume that NK1R inhibition modulates the PI3K/AKT/mTOR pathway at 
the level of mTORC1 and that the downregulation of Wnt signaling would be a fortunate 
side effect in a context of hyperactive Wnt (e.g. LiCl stimulated cells, hepatoblastoma cells, 
CRC cells). Therefore, understanding more in depth the crosslinks between 
PI3K/AKT/mTOR and Wnt signaling but also with other pathways (e.g. MAPK, p38) is 
essential in order to tackle the molecular basis of NK1R inhibition.  
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5. The NK1R is an ubiquitous anti-tumor target in hepatoblastoma and independent 
from tumor biology and stage 
Very little is known regarding the expression profile of NK1R and its association with clinical 
outcome. NK1R is a crucial component of cancer development and progression and a 
promising anticancer target in a multitude of cancers152, including hepatoblastoma and 
colorectal cancer as demonstrated in this work. Here, we performed in depth analysis of the 
expression pattern of NK1R in hepatoblastoma and correlated our findings with patients’ 
clinical tumor stage, biology and outcome.  
We found that compared to tumor free liver tissue, tumorous tissue expressed significantly 
more truncated NK1R-tr, which is in accordance with our findings in vitro. Although not 
significant, hepatoblastoma tissues also tended to express slightly more of the full-length 
variant of NK1R. Within the tumorous tissues, expression of the full-length version 
correlated with the expression of the truncated version. Overall, our data provide evidence 
that hepatoblastoma ubiquitously expresses NK1R, supporting recent evidence that NK1R 
antagonist could be a promising anticancer agents against a wide variety of 
hepatoblastoma subsets223.  
It has recently been suggested that a correlation exists between the expression rate of the 
SP/NK1R complex and prognosis187, 224-226. Garcia-Recio et al. found that SP contributes to 
persistent transmodulation of the ErbB receptors, EGFR and HER2, in breast cancer, acting 
to enhance malignancy and therapeutic resistance187. Both NK1R and TAC1 (SP) were 
highly expressed in HER2+ primary breast tumors and correlated with poor prognosis 
factors. These findings are therefore in contradiction to our findings in hepatoblastoma, 
which showed worse prognosis with low expression of NK1R-tr. However, it must be noted 
that two completely separate tumor entities were investigated, and in their study, no 
distinction is made between the truncated and the full variant of the receptor. Interestingly, 
in their study, upon treatment of xenografted mice bearing HER2+ or HER2- human breast 
carcinoma, they found a therapeutic effect only for HER2+ tumors, suggesting that the anti-
tumor effects of NK1R inhibition in carcinoma of the breast depended on the modulatory 
properties of NK1R signaling on the activity of HER2 and EGFR187. 
Cairo et al. recently described two tumor subclasses within hepatoblastoma resembling 
distinct phases of liver development and a discriminating 16-gene signature55, 227. 
Intriguingly, when separated into the two groups by this 16-gene signature namely C1 and 
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C2, clinical prognosis could be predicted for these children with very high accuracy55. By 
retrieving the C1/C2-status from our hepatoblastoma data base that classified each tumor 
according to this specific 16-gene signature, we found that NK1R-fl was lower in the C2 
signature compared to C1. Further, we saw worse prognosis with low expression of NK1R-
tr (P = 0.0551), although this was only a trend. Intriguingly, when further analyzing the C2 
signature population separately, we again found worse prognosis with low expression of 
NK1R-tr (P = 0.0377). Therefore, in hepatoblastoma, NK1R alone cannot be used as a 
pronostic factor. However, NK1R-tr could possibly help to identify tumors with an advanced 
stage, potentially by itself and especially within the C2 signature patient population. More in 
depth analysis of such a C2 NK1R-tr low tumor cohort will be necessary in order to 
demonstrate the value of this distinction. Also, when making such a distinction, it needs to 
be understood that "low" expression here is in reference to "high", as a NK1R-tr low 
expressing tumor will on average express still significantly more NK1R-tr than non-
tumorous tissue.  
Another point, which has to be taken into account is that tumors, and especially tumors of 
the liver, have been shown to be significantly heterogeneous228. Typically, in our analysis 
we only analyzed one sample per tumor, which might not be representative for other areas 
of the cancer. Further, gene expression does not always correlate with the actual protein 
expression. It would be interesting to see whether an immunohistochemistry-based 
classification of hepatoblastoma could indicate prognosis. With regards to the SP/NK1R 
complex, immunohistochemical staining of its different splice variants remains a challenge 
and presents a major obstacle as no antibodies are currently available which distinguish 
both isoforms. Also, according to our current understanding of the SP/NK1R complex, 
having SP as its high affinity ligand is critical for its function125. Here, we did not investigate 
SP gene expression within the tumor, which might be an interesting task for the future. And 
last, all but 4 patients enrolled into this retrospective study had received chemotherapy prior 
to surgery. Cairo et al. observed that the signature is stable irrespective of pretreatment, 
however we do not know in our setting if NK1R expression was altered. This is important to 
consider because the exposure to chemotherapy could potentially alter the expression 
pattern of NK1R and its splice variants. Therefore, the influence of systemic chemotherapy 
on the expression of the NK1R complex remains an unsolved question to this point. 
In conclusion, our findings do not show that the NK1R expression pattern depends on or 
predicts the clinical stage and behavior, but that the two splice variants of NK1R are 
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ubiquitously overexpressed in hepatoblastoma. Overall, our data further support the 
potential of the SP/NK1R complex as an ideal target in a wide variety of hepatoblastoma. 
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HUH6 Ap20 0.87 1.21 1.64 1.13 1.22 1.31 1.08 0.84 1.17 1.07 1.09 1.18 0.93 1.06 1.08 0.98 1.15 0.95 0.84 0.96 0.98 1.00 1.32 0.89 1.00 1.04 1.02 0.98 0.99 1.09 1.30 1.17 1.30 0.92 1.01
Ap40 0.71 1.02 1.70 1.43 1.66 1.41 1.08 0.99 1.21 1.15 1.08 0.98 1.13 1.41 1.36 1.07 1.35 1.17 0.90 1.01 1.05 0.98 1.76 0.91 0.84 1.08 0.93 0.99 0.84 1.03 1.43 0.90 1.45 1.07 0.96
SP 1.03 1.01 1.08 0.96 0.99 1.23 1.04 1.00 0.99 1.10 1.11 0.98 1.04 1.06 1.10 0.94 1.00 1.05 0.95 0.95 1.01 1.03 1.05 1.01 0.94 1.06 1.02 1.01 1.09 1.03 0.95 1.02 1.05 0.97 0.86
Table S1: Ratio of phospho / total protein values (RPPA) in comparison to untreated cells
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ABSTRACT 
 
The neurokinin-1 receptor (NK1R) has recently been described as being pivotal in the 
development of cancer. NK1R antagonists, such as the clinical drug aprepitant, are 
therefore under current investigation as future innovative anticancer agents. However, little 
is known about the NK1R complex as a potential target in hepatoblastoma and colon 
cancer cells. Thus, we aimed at investigating the impact of NK1R inhibition with aprepitant 
on cell growth, apoptosis, downstream mechanims and cancer stem cells in three human 
hepatoblastoma cell lines HepT1, HepG2 and HuH6 and the human colon cancer cell lines 
LiM6 and DLD1. Finally, mRNA from 47 children with hepatoblastoma were analysed 
regarding both full length and truncated forms of NK1R. 
NK1R is highly expressed in human hepatoblastoma cell lines predominantly in its 
truncated version. Following NK1R blockage by aprepitant, a significant growth inhibition of 
hepatoblastoma cells and colon cancer cells as well as induction of apoptosis was 
detected, which was associated with the downregulation of two critical signaling pathways, 
namely Wnt and PI3K/AKT/mTOR. Further, treatment of colon cancer or hepatoblastoma 
cells grown under cancer stem cell conditions reduced sphere formation in number and size 
as well as expression of the stemness markers SOX2, NANOG, and OCT4. From a clinical 
perspective, both forms of NK1R were generally overexpressed in hepatoblastoma cases, 
without any correlation with clinicopathological parameters indicating that aprepitant might 
be used in a wide variety of hepatoblastoma.  
Taken together, these findings give important insight into the molecular mechanisms of the 
NK1R as a critical component in tumorigenesis and can help in the development of future 
anticancer therapies for Wnt-activated cancers such as hepatoblastoma and colon cancer. 
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ZUSAMMENFASSUNG 
 
Der Neurokinin-Rezeptor 1 spielt eine wichtige Rolle in der Tumorentwicklung. Daher 
besteht gegenwärtig ein großes Forschungsinteresse an der Untersuchung von NK1R-
Antagonisten wie z.B. Aprepitant, welches bereits klinisch angewendet wird, als mögliche 
neue innovative Anti-Krebstherapie.  Allerdings ist aktuell noch wenig bekannt über den 
NK1-R Komplex als potentieller Zielkandidat bei Hepatoblastomen und Kolonkarzinomen. 
Ziel dieser Arbeit war deshalb, die Auswirkungen einer NK1R-Inhibierung bei den drei 
humanen Hepatoblastomzelllinien HepT1, HepG2 und HUH6 sowie den 
Kolonkarzinomzelllinien LiM6 und DLD1 zu untersuchen. Schließlich sollte auch die 
Genexpression der full length und truncated Formen von NK1R in 47 Hepatoblastoma-
Fällen gemessen werden.  
Als Resultat fanden wir in den Hepatoblastoma-Fällen eine Überexpression des NK1R vor 
allem in der truncated Form. Aprepitant als NK1R Antagonist bewirkt sowohl eine 
signifikante Wachstumsinhibierung als auch Apoptoseinduktion bei Hepatoblastom- und 
Kolonkarzinomzellen, was mit der Herunterregulierung zweier entscheidender Signalwege, 
dem WNT und PI3K/AKT/mTOR Signalweg, assoziiert ist. Nach Behandlung der 
Hepatoblastom- und Kolonkarzinomzelllinien mit Aprepitant unter Tumorstammzell-
Wachstumsbedingungen zeigten diese sowohl eine generell verringerte Anzahl und Größe 
der Sphären als auch eine reduzierte Expression der Tumorstammzellmarker SOX2, 
NANOG und OCT4. Betrachtet man die Forschungsergebnisse zusammen mit dem 
Krankheitsverlauf der einzelnen Patienten, werden zwar in den HB-Fällen beide Formen 
des NKR-1 Rezeptors überexprimiert, jedoch ohne mit klinisch-pathologischen Parametern 
zu korrelieren. Daraus ließe sich ableiten, dass Aprepitant bei einer Vielzahl von 
Hepatobastom-Fällen Anwendung finden könnte. Zusammenfassend geben die 
Forschungsergebnisse einen wichtigen Einblick in die molekularen Mechanismen von 
NK1R als wichtiger Faktor in der Tumorgenese des Hepatoblastoms und dessen 
Bedeutung für die zukünftige Entwicklung von Krebstherapien bezüglich Wnt-aktivierter 
Tumoren wie dem Hepatoblastom- und des Kolonkarzinoms. 
 
   
ACKNOWLEDGMENT 
93 
 
ACKNOWLEDGMENT 
 
 
Thanks, first and foremost, must go to Prof. Dr. med. Dietrich von Schweinitz, the director of 
the Department of Pediatric Surgery at the Dr. von Hauner Children's Hospital in Munich 
where I realized my PhD. 
I am deeply grateful to Prof. Dr. rer. nat. Roland Kappler for accepting me as a member of 
his lab and for introducing me to the fascinating field of hepatoblastoma, for helpful 
discussions and guidance during my PhD project. 
I am indebted to PD Dr. med. Michael Berger for giving me the opportunity to start this 
exciting and challenging project in the Pediatric Surgery Research Laboratories. Thank you 
for your friendship, your patience and unremitting help in many scientific, technical and 
personal matters. 
Further, I would like to thank Dr. med. Matthias Ilmer for providing important scientific input 
during my thesis and for his guidance during my stay in MD Anderson Cancer Center in 
Houston. I take this opportunity to thank the Translational Molecular Pathology group of MD 
Anderson and Prof. Dr. med. Eckhard Alt for their generous support.  
Special thanks to Corinna Weber, a fellow PhD student, who helped me several times 
during my project and to Fatemeh Promoli for technical support of qPCR and cell culture. 
I am particularly grateful to all the members of the Kappler lab (Corinna Weber, Alexander 
Beck, Björn Krietemeyer, Fatemeh Promoli, Tatiana Schmid, Iva Mikulić and Jakob 
Mühling) for the warm and open welcome, for their numerous assistance, for providing a 
stimulating and joyful lab atmosphere and for all the shared activities. 
I am very grateful to my family, particularly to my brother Dr. Ilias Garnier, and my friends 
for their unlimited help, support and understanding during this long journey in Munich. 
 
 
 
REFERENCES 
94 
 
REFERENCES 
 
1. Allan, B.J. et al. Predictors of survival and incidence of hepatoblastoma in the paediatric population. 
HPB : the official journal of the International Hepato Pancreato Biliary Association 15, 741-746 
(2013). 
2. Schnater, J.M., Kohler, S.E., Lamers, W.H., von Schweinitz, D. & Aronson, D.C. Where do we stand 
with hepatoblastoma? A review. Cancer 98, 668-678 (2003). 
3. DeBaun, M.R. & Tucker, M.A. Risk of cancer during the first four years of life in children from The 
Beckwith-Wiedemann Syndrome Registry. The Journal of pediatrics 132, 398-400 (1998). 
4. Hughes, L.J. & Michels, V.V. Risk of hepatoblastoma in familial adenomatous polyposis. American 
journal of medical genetics 43, 1023-1025 (1992). 
5. Ikeda, H., Matsuyama, S. & Tanimura, M. Association between hepatoblastoma and very low birth 
weight: a trend or a chance? The Journal of pediatrics 130, 557-560 (1997). 
6. von Schweinitz, D. et al. [Results of the HB-89 Study in treatment of malignant epithelial liver tumors 
in childhood and concept of a new HB-94 protocol]. Klinische Padiatrie 206, 282-288 (1994). 
7. Perilongo, G. et al. Hepatoblastoma presenting with lung metastases: treatment results of the first 
cooperative, prospective study of the International Society of Paediatric Oncology on childhood liver 
tumors. Cancer 89, 1845-1853 (2000). 
8. Herzog, C.E., Andrassy, R.J. & Eftekhari, F. Childhood cancers: hepatoblastoma. The oncologist 5, 
445-453 (2000). 
9. Haas, J.E., Feusner, J.H. & Finegold, M.J. Small cell undifferentiated histology in hepatoblastoma may 
be unfavorable. Cancer 92, 3130-3134 (2001). 
10. Maibach, R. et al. Prognostic stratification for children with hepatoblastoma: the SIOPEL experience. 
Eur J Cancer 48, 1543-1549 (2012). 
11. Hishiki, T. Current therapeutic strategies for childhood hepatic tumors: surgical and interventional 
treatments for hepatoblastoma. International journal of clinical oncology 18, 962-968 (2013). 
12. Haeberle, B. & Schweinitz, D. Treatment of hepatoblastoma in the German cooperative pediatric 
liver tumor studies. Front Biosci (Elite Ed) 4, 493-498 (2012). 
13. Malogolowkin, M.H., Katzenstein, H.M., Krailo, M. & Meyers, R.L. Treatment of hepatoblastoma: the 
North American cooperative group experience. Front Biosci (Elite Ed) 4, 1717-1723 (2012). 
14. Czauderna, P. et al. Hepatoblastoma state of the art: pathology, genetics, risk stratification, and 
chemotherapy. Current opinion in pediatrics 26, 19-28 (2014). 
15. Roebuck, D.J. et al. 2005 PRETEXT: a revised staging system for primary malignant liver tumours of 
childhood developed by the SIOPEL group. Pediatric radiology 37, 123-132; quiz 249-150 (2007). 
16. Khaderi, S. et al. Role of liver transplantation in the management of hepatoblastoma in the pediatric 
population. World journal of transplantation 4, 294-298 (2014). 
17. Purcell, R. et al. Potential biomarkers for hepatoblastoma: results from the SIOPEL-3 study. Eur J 
Cancer 48, 1853-1859 (2012). 
18. Klaus, A. & Birchmeier, W. Wnt signalling and its impact on development and cancer. Nature 
reviews. Cancer 8, 387-398 (2008). 
19. Nusse, R. & Varmus, H.E. Many tumors induced by the mouse mammary tumor virus contain a 
provirus integrated in the same region of the host genome. Cell 31, 99-109 (1982). 
20. Rijsewijk, F. et al. The Drosophila homolog of the mouse mammary oncogene int-1 is identical to the 
segment polarity gene wingless. Cell 50, 649-657 (1987). 
21. Nusse, R. et al. A new nomenclature for int-1 and related genes: the Wnt gene family. Cell 64, 231 
(1991). 
22. Barker, N. & Clevers, H. Mining the Wnt pathway for cancer therapeutics. Nature reviews. Drug 
discovery 5, 997-1014 (2006). 
23. Liu, C. et al. Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 
108, 837-847 (2002). 
REFERENCES 
95 
 
24. Aberle, H., Bauer, A., Stappert, J., Kispert, A. & Kemler, R. beta-catenin is a target for the ubiquitin-
proteasome pathway. The EMBO journal 16, 3797-3804 (1997). 
25. Daniels, D.L. & Weis, W.I. Beta-catenin directly displaces Groucho/TLE repressors from Tcf/Lef in 
Wnt-mediated transcription activation. Nature structural & molecular biology 12, 364-371 (2005). 
26. Bilic, J. et al. Wnt induces LRP6 signalosomes and promotes dishevelled-dependent LRP6 
phosphorylation. Science 316, 1619-1622 (2007). 
27. Behrens, J. et al. Functional interaction of beta-catenin with the transcription factor LEF-1. Nature 
382, 638-642 (1996). 
28. He, T.C. et al. Identification of c-MYC as a target of the APC pathway. Science 281, 1509-1512 (1998). 
29. Leyns, L., Bouwmeester, T., Kim, S.H., Piccolo, S. & De Robertis, E.M. Frzb-1 is a secreted antagonist 
of Wnt signaling expressed in the Spemann organizer. Cell 88, 747-756 (1997). 
30. Glinka, A. et al. Dickkopf-1 is a member of a new family of secreted proteins and functions in head 
induction. Nature 391, 357-362 (1998). 
31. Mao, B. et al. Kremen proteins are Dickkopf receptors that regulate Wnt/beta-catenin signalling. 
Nature 417, 664-667 (2002). 
32. Kazanskaya, O. et al. R-Spondin2 is a secreted activator of Wnt/beta-catenin signaling and is required 
for Xenopus myogenesis. Developmental cell 7, 525-534 (2004). 
33. Jamora, C. & Fuchs, E. Intercellular adhesion, signalling and the cytoskeleton. Nature cell biology 4, 
E101-108 (2002). 
34. Orsulic, S., Huber, O., Aberle, H., Arnold, S. & Kemler, R. E-cadherin binding prevents beta-catenin 
nuclear localization and beta-catenin/LEF-1-mediated transactivation. Journal of cell science 112 ( Pt 
8), 1237-1245 (1999). 
35. Huber, O., Bierkamp, C. & Kemler, R. Cadherins and catenins in development. Current opinion in cell 
biology 8, 685-691 (1996). 
36. Huber, A.H., Stewart, D.B., Laurents, D.V., Nelson, W.J. & Weis, W.I. The cadherin cytoplasmic 
domain is unstructured in the absence of beta-catenin. A possible mechanism for regulating 
cadherin turnover. The Journal of biological chemistry 276, 12301-12309 (2001). 
37. Lilien, J. & Balsamo, J. The regulation of cadherin-mediated adhesion by tyrosine 
phosphorylation/dephosphorylation of beta-catenin. Current opinion in cell biology 17, 459-465 
(2005). 
38. Monga, S.P. et al. Hepatocyte growth factor induces Wnt-independent nuclear translocation of beta-
catenin after Met-beta-catenin dissociation in hepatocytes. Cancer research 62, 2064-2071 (2002). 
39. Apte, U. et al. beta-Catenin is critical for early postnatal liver growth. American journal of physiology. 
Gastrointestinal and liver physiology 292, G1578-1585 (2007). 
40. Tan, X. et al. Beta-catenin deletion in hepatoblasts disrupts hepatic morphogenesis and survival 
during mouse development. Hepatology 47, 1667-1679 (2008). 
41. Monga, S.P. Role and regulation of beta-catenin signaling during physiological liver growth. Gene 
expression 16, 51-62 (2014). 
42. Monga, S.P., Pediaditakis, P., Mule, K., Stolz, D.B. & Michalopoulos, G.K. Changes in WNT/beta-
catenin pathway during regulated growth in rat liver regeneration. Hepatology 33, 1098-1109 
(2001). 
43. Michalopoulos, G.K. Liver regeneration after partial hepatectomy: critical analysis of mechanistic 
dilemmas. The American journal of pathology 176, 2-13 (2010). 
44. Michalopoulos, G.K. & DeFrances, M.C. Liver regeneration. Science 276, 60-66 (1997). 
45. Polakis, P. Wnt signaling and cancer. Genes & development 14, 1837-1851 (2000). 
46. Bodmer, W.F. et al. Localization of the gene for familial adenomatous polyposis on chromosome 5. 
Nature 328, 614-616 (1987). 
47. Fearnhead, N.S., Britton, M.P. & Bodmer, W.F. The ABC of APC. Human molecular genetics 10, 721-
733 (2001). 
48. Rubinfeld, B. et al. Binding of GSK3beta to the APC-beta-catenin complex and regulation of complex 
assembly. Science 272, 1023-1026 (1996). 
REFERENCES 
96 
 
49. Ikeda, S. et al. Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-
3beta and beta-catenin and promotes GSK-3beta-dependent phosphorylation of beta-catenin. The 
EMBO journal 17, 1371-1384 (1998). 
50. Koch, A. et al. Childhood hepatoblastomas frequently carry a mutated degradation targeting box of 
the beta-catenin gene. Cancer research 59, 269-273 (1999). 
51. Koesters, R. & von Knebel Doeberitz, M. The Wnt signaling pathway in solid childhood tumors. 
Cancer letters 198, 123-138 (2003). 
52. Jeng, Y.M., Wu, M.Z., Mao, T.L., Chang, M.H. & Hsu, H.C. Somatic mutations of beta-catenin play a 
crucial role in the tumorigenesis of sporadic hepatoblastoma. Cancer letters 152, 45-51 (2000). 
53. Takayasu, H. et al. Frequent deletions and mutations of the beta-catenin gene are associated with 
overexpression of cyclin D1 and fibronectin and poorly differentiated histology in childhood 
hepatoblastoma. Clinical cancer research : an official journal of the American Association for Cancer 
Research 7, 901-908 (2001). 
54. Wei, Y. et al. Activation of beta-catenin in epithelial and mesenchymal hepatoblastomas. Oncogene 
19, 498-504 (2000). 
55. Cairo, S. et al. Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in 
aggressive childhood liver cancer. Cancer cell 14, 471-484 (2008). 
56. Taniguchi, K. et al. Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular 
carcinomas and hepatoblastomas. Oncogene 21, 4863-4871 (2002). 
57. Koch, A. et al. Mutations and elevated transcriptional activity of conductin (AXIN2) in 
hepatoblastomas. The Journal of pathology 204, 546-554 (2004). 
58. Oda, H., Imai, Y., Nakatsuru, Y., Hata, J. & Ishikawa, T. Somatic mutations of the APC gene in sporadic 
hepatoblastomas. Cancer research 56, 3320-3323 (1996). 
59. Aretz, S. et al. Should children at risk for familial adenomatous polyposis be screened for 
hepatoblastoma and children with apparently sporadic hepatoblastoma be screened for APC 
germline mutations? Pediatric blood & cancer 47, 811-818 (2006). 
60. Koch, A. et al. Elevated expression of Wnt antagonists is a common event in hepatoblastomas. 
Clinical cancer research : an official journal of the American Association for Cancer Research 11, 
4295-4304 (2005). 
61. Cavard, C. et al. Wnt/beta-catenin pathway in hepatocellular carcinoma pathogenesis and liver 
physiology. Future Oncol 4, 647-660 (2008). 
62. Burke, Z.D. et al. Liver zonation occurs through a beta-catenin-dependent, c-Myc-independent 
mechanism. Gastroenterology 136, 2316-2324 e2311-2313 (2009). 
63. Testa, J.R. & Tsichlis, P.N. AKT signaling in normal and malignant cells. Oncogene 24, 7391-7393 
(2005). 
64. Hartmann, W. et al. Activation of phosphatidylinositol-3'-kinase/AKT signaling is essential in 
hepatoblastoma survival. Clinical cancer research : an official journal of the American Association for 
Cancer Research 15, 4538-4545 (2009). 
65. Polivka, J., Jr. & Janku, F. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. 
Pharmacology & therapeutics 142, 164-175 (2014). 
66. Altomare, D.A. & Testa, J.R. Perturbations of the AKT signaling pathway in human cancer. Oncogene 
24, 7455-7464 (2005). 
67. Engelman, J.A. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nature 
reviews. Cancer 9, 550-562 (2009). 
68. Lemmon, M.A. & Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell 141, 1117-1134 
(2010). 
69. Gschwind, A., Fischer, O.M. & Ullrich, A. The discovery of receptor tyrosine kinases: targets for 
cancer therapy. Nature reviews. Cancer 4, 361-370 (2004). 
70. Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell 103, 211-225 (2000). 
71. Cantley, L.C. The phosphoinositide 3-kinase pathway. Science 296, 1655-1657 (2002). 
REFERENCES 
97 
 
72. Sun, X.J. et al. Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction 
protein. Nature 352, 73-77 (1991). 
73. Wymann, M.P., Zvelebil, M. & Laffargue, M. Phosphoinositide 3-kinase signalling--which way to 
target? Trends in pharmacological sciences 24, 366-376 (2003). 
74. Katso, R. et al. Cellular function of phosphoinositide 3-kinases: implications for development, 
homeostasis, and cancer. Annual review of cell and developmental biology 17, 615-675 (2001). 
75. Engelman, J.A., Luo, J. & Cantley, L.C. The evolution of phosphatidylinositol 3-kinases as regulators of 
growth and metabolism. Nature reviews. Genetics 7, 606-619 (2006). 
76. Klippel, A., Kavanaugh, W.M., Pot, D. & Williams, L.T. A specific product of phosphatidylinositol 3-
kinase directly activates the protein kinase Akt through its pleckstrin homology domain. Molecular 
and cellular biology 17, 338-344 (1997). 
77. Alessi, D.R. et al. Characterization of a 3-phosphoinositide-dependent protein kinase which 
phosphorylates and activates protein kinase Balpha. Current biology : CB 7, 261-269 (1997). 
78. Stokoe, D. et al. Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein 
kinase B. Science 277, 567-570 (1997). 
79. Sarbassov, D.D., Guertin, D.A., Ali, S.M. & Sabatini, D.M. Phosphorylation and regulation of Akt/PKB 
by the rictor-mTOR complex. Science 307, 1098-1101 (2005). 
80. Calnan, D.R. & Brunet, A. The FoxO code. Oncogene 27, 2276-2288 (2008). 
81. Cross, D.A., Alessi, D.R., Cohen, P., Andjelkovich, M. & Hemmings, B.A. Inhibition of glycogen 
synthase kinase-3 by insulin mediated by protein kinase B. Nature 378, 785-789 (1995). 
82. Datta, S.R. et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death 
machinery. Cell 91, 231-241 (1997). 
83. Ashworth, R.E. & Wu, J. Mammalian target of rapamycin inhibition in hepatocellular carcinoma. 
World journal of hepatology 6, 776-782 (2014). 
84. Ma, X.M. & Blenis, J. Molecular mechanisms of mTOR-mediated translational control. Nature 
reviews. Molecular cell biology 10, 307-318 (2009). 
85. Peterson, T.R. et al. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma 
cells and required for their survival. Cell 137, 873-886 (2009). 
86. Wang, L., Harris, T.E., Roth, R.A. & Lawrence, J.C., Jr. PRAS40 regulates mTORC1 kinase activity by 
functioning as a direct inhibitor of substrate binding. The Journal of biological chemistry 282, 20036-
20044 (2007). 
87. Huang, J. & Manning, B.D. A complex interplay between Akt, TSC2 and the two mTOR complexes. 
Biochemical Society transactions 37, 217-222 (2009). 
88. Pullen, N. & Thomas, G. The modular phosphorylation and activation of p70s6k. FEBS letters 410, 78-
82 (1997). 
89. Richter, J.D. & Sonenberg, N. Regulation of cap-dependent translation by eIF4E inhibitory proteins. 
Nature 433, 477-480 (2005). 
90. Buchkovich, N.J., Yu, Y., Zampieri, C.A. & Alwine, J.C. The TORrid affairs of viruses: effects of 
mammalian DNA viruses on the PI3K-Akt-mTOR signalling pathway. Nature reviews. Microbiology 6, 
266-275 (2008). 
91. Sabatini, D.M. mTOR and cancer: insights into a complex relationship. Nature reviews. Cancer 6, 729-
734 (2006). 
92. Yang, Q., Inoki, K., Ikenoue, T. & Guan, K.L. Identification of Sin1 as an essential TORC2 component 
required for complex formation and kinase activity. Genes & development 20, 2820-2832 (2006). 
93. Huang, J., Dibble, C.C., Matsuzaki, M. & Manning, B.D. The TSC1-TSC2 complex is required for proper 
activation of mTOR complex 2. Molecular and cellular biology 28, 4104-4115 (2008). 
94. Guertin, D.A. et al. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that 
mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Developmental cell 11, 
859-871 (2006). 
95. Julien, L.A., Carriere, A., Moreau, J. & Roux, P.P. mTORC1-activated S6K1 phosphorylates Rictor on 
threonine 1135 and regulates mTORC2 signaling. Molecular and cellular biology 30, 908-921 (2010). 
REFERENCES 
98 
 
96. Huang, J., Wu, S., Wu, C.L. & Manning, B.D. Signaling events downstream of mammalian target of 
rapamycin complex 2 are attenuated in cells and tumors deficient for the tuberous sclerosis complex 
tumor suppressors. Cancer research 69, 6107-6114 (2009). 
97. Treins, C., Warne, P.H., Magnuson, M.A., Pende, M. & Downward, J. Rictor is a novel target of p70 S6 
kinase-1. Oncogene 29, 1003-1016 (2010). 
98. Tzatsos, A. & Kandror, K.V. Nutrients suppress phosphatidylinositol 3-kinase/Akt signaling via raptor-
dependent mTOR-mediated insulin receptor substrate 1 phosphorylation. Molecular and cellular 
biology 26, 63-76 (2006). 
99. Goel, A. et al. Frequent inactivation of PTEN by promoter hypermethylation in microsatellite 
instability-high sporadic colorectal cancers. Cancer research 64, 3014-3021 (2004). 
100. Samuels, Y. et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 304, 
554 (2004). 
101. Carpten, J.D. et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. 
Nature 448, 439-444 (2007). 
102. Gray, S.G. et al. Altered expression of members of the IGF-axis in hepatoblastomas. British journal of 
cancer 82, 1561-1567 (2000). 
103. Rosen, C.J. & Pollak, M. Circulating IGF-I: New Perspectives for a New Century. Trends in 
endocrinology and metabolism: TEM 10, 136-141 (1999). 
104. Rainier, S., Dobry, C.J. & Feinberg, A.P. Loss of imprinting in hepatoblastoma. Cancer research 55, 
1836-1838 (1995). 
105. Akmal, S.N., Yun, K., MacLay, J., Higami, Y. & Ikeda, T. Insulin-like growth factor 2 and insulin-like 
growth factor binding protein 2 expression in hepatoblastoma. Human pathology 26, 846-851 
(1995). 
106. Li, X. et al. Expression, promoter usage and parental imprinting status of insulin-like growth factor II 
(IGF2) in human hepatoblastoma: uncoupling of IGF2 and H19 imprinting. Oncogene 11, 221-229 
(1995). 
107. Regel, I. et al. IGFBP3 impedes aggressive growth of pediatric liver cancer and is epigenetically 
silenced in vascular invasive and metastatic tumors. Molecular cancer 11, 9 (2012). 
108. Eichenmuller, M. et al. Blocking the hedgehog pathway inhibits hepatoblastoma growth. Hepatology 
49, 482-490 (2009). 
109. Litten, J.B. et al. Activated NOTCH2 is overexpressed in hepatoblastomas: an immunohistochemical 
study. Pediatric and developmental pathology : the official journal of the Society for Pediatric 
Pathology and the Paediatric Pathology Society 14, 378-383 (2011). 
110. Lopez-Terrada, D. et al. Histologic subtypes of hepatoblastoma are characterized by differential 
canonical Wnt and Notch pathway activation in DLK+ precursors. Human pathology 40, 783-794 
(2009). 
111. Sakamoto, L.H., B, D.E.C., Cajaiba, M., Soares, F.A. & Vettore, A.L. MT1G hypermethylation: a 
potential prognostic marker for hepatoblastoma. Pediatric research 67, 387-393 (2010). 
112. Weber, R.G., Pietsch, T., von Schweinitz, D. & Lichter, P. Characterization of genomic alterations in 
hepatoblastomas. A role for gains on chromosomes 8q and 20 as predictors of poor outcome. The 
American journal of pathology 157, 571-578 (2000). 
113. Ortega, J.A. et al. Randomized comparison of cisplatin/vincristine/fluorouracil and 
cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: A report from 
the Children's Cancer Group and the Pediatric Oncology Group. Journal of clinical oncology : official 
journal of the American Society of Clinical Oncology 18, 2665-2675 (2000). 
114. Aronson, D.C., Czauderna, P., Maibach, R., Perilongo, G. & Morland, B. The treatment of 
hepatoblastoma: Its evolution and the current status as per the SIOPEL trials. Journal of Indian 
Association of Pediatric Surgeons 19, 201-207 (2014). 
115. Meyers, R.L., Tiao, G., de Ville de Goyet, J., Superina, R. & Aronson, D.C. Hepatoblastoma state of the 
art: pre-treatment extent of disease, surgical resection guidelines and the role of liver 
transplantation. Current opinion in pediatrics 26, 29-36 (2014). 
REFERENCES 
99 
 
116. Kremer, N., Walther, A.E. & Tiao, G.M. Management of hepatoblastoma: an update. Current opinion 
in pediatrics 26, 362-369 (2014). 
117. Malogolowkin, M.H. et al. Complete surgical resection is curative for children with hepatoblastoma 
with pure fetal histology: a report from the Children's Oncology Group. Journal of clinical oncology : 
official journal of the American Society of Clinical Oncology 29, 3301-3306 (2011). 
118. D'Antiga, L. et al. Features predicting unresectability in hepatoblastoma. Cancer 110, 1050-1058 
(2007). 
119. Browne, M. et al. Survival after liver transplantation for hepatoblastoma: a 2-center experience. 
Journal of pediatric surgery 43, 1973-1981 (2008). 
120. Meyers, R.L. et al. Predictive power of pretreatment prognostic factors in children with 
hepatoblastoma: a report from the Children's Oncology Group. Pediatric blood & cancer 53, 1016-
1022 (2009). 
121. Warmann, S. et al. The role of the MDR1 gene in the development of multidrug resistance in human 
hepatoblastoma: clinical course and in vivo model. Cancer 95, 1795-1801 (2002). 
122. Kimura, Y., Morita, S.Y., Matsuo, M. & Ueda, K. Mechanism of multidrug recognition by 
MDR1/ABCB1. Cancer science 98, 1303-1310 (2007). 
123. Morland, B. Commentary on hepatoblastoma minisymposium. Pediatric radiology 36, 175 (2006). 
124. Ichikawa, Y. et al. Cardiotoxicity of doxorubicin is mediated through mitochondrial iron 
accumulation. The Journal of clinical investigation 124, 617-630 (2014). 
125. Pennefather, J.N. et al. Tachykinins and tachykinin receptors: a growing family. Life sciences 74, 
1445-1463 (2004). 
126. Tsuchida, K., Shigemoto, R., Yokota, Y. & Nakanishi, S. Tissue distribution and quantitation of the 
mRNAs for three rat tachykinin receptors. European journal of biochemistry / FEBS 193, 751-757 
(1990). 
127. Ho, W.Z., Lai, J.P., Zhu, X.H., Uvaydova, M. & Douglas, S.D. Human monocytes and macrophages 
express substance P and neurokinin-1 receptor. J Immunol 159, 5654-5660 (1997). 
128. Patacchini, R. & Maggi, C.A. Peripheral tachykinin receptors as targets for new drugs. European 
journal of pharmacology 429, 13-21 (2001). 
129. Saffroy, M., Torrens, Y., Glowinski, J. & Beaujouan, J.C. Autoradiographic distribution of tachykinin 
NK2 binding sites in the rat brain: comparison with NK1 and NK3 binding sites. Neuroscience 116, 
761-773 (2003). 
130. Page, N.M. Characterization of the gene structures, precursor processing and pharmacology of the 
endokinin peptides. Vascular pharmacology 45, 200-208 (2006). 
131. Otsuka, M. & Yoshioka, K. Neurotransmitter functions of mammalian tachykinins. Physiological 
reviews 73, 229-308 (1993). 
132. Almeida, T.A. et al. Tachykinins and tachykinin receptors: structure and activity relationships. Current 
medicinal chemistry 11, 2045-2081 (2004). 
133. Gerard, N.P. et al. Human substance P receptor (NK-1): organization of the gene, chromosome 
localization, and functional expression of cDNA clones. Biochemistry 30, 10640-10646 (1991). 
134. Roush, E.D. & Kwatra, M.M. Human substance P receptor expressed in Chinese hamster ovary cells 
directly activates G(alpha q/11), G(alpha s), G(alpha o). FEBS letters 428, 291-294 (1998). 
135. Mitsuhashi, M. et al. Multiple intracellular signaling pathways of the neuropeptide substance P 
receptor. Journal of neuroscience research 32, 437-443 (1992). 
136. Sagan, S., Chassaing, G., Pradier, L. & Lavielle, S. Tachykinin peptides affect differently the second 
messenger pathways after binding to CHO-expressed human NK-1 receptors. The Journal of 
pharmacology and experimental therapeutics 276, 1039-1048 (1996). 
137. Takeda, Y. et al. Ligand binding kinetics of substance P and neurokinin A receptors stably expressed 
in Chinese hamster ovary cells and evidence for differential stimulation of inositol 1,4,5-
trisphosphate and cyclic AMP second messenger responses. Journal of neurochemistry 59, 740-745 
(1992). 
REFERENCES 
100 
 
138. Khawaja, A.M. & Rogers, D.F. Tachykinins: receptor to effector. The international journal of 
biochemistry & cell biology 28, 721-738 (1996). 
139. Holst, B., Hastrup, H., Raffetseder, U., Martini, L. & Schwartz, T.W. Two active molecular phenotypes 
of the tachykinin NK1 receptor revealed by G-protein fusions and mutagenesis. The Journal of 
biological chemistry 276, 19793-19799 (2001). 
140. Ramkissoon, S.H., Patel, H.J., Taborga, M. & Rameshwar, P. G protein-coupled receptors in 
haematopoietic disruption. Expert opinion on biological therapy 6, 109-120 (2006). 
141. Nakajima, Y., Tsuchida, K., Negishi, M., Ito, S. & Nakanishi, S. Direct linkage of three tachykinin 
receptors to stimulation of both phosphatidylinositol hydrolysis and cyclic AMP cascades in 
transfected Chinese hamster ovary cells. The Journal of biological chemistry 267, 2437-2442 (1992). 
142. Mantyh, P.W. et al. Rapid endocytosis of a G protein-coupled receptor: substance P evoked 
internalization of its receptor in the rat striatum in vivo. Proceedings of the National Academy of 
Sciences of the United States of America 92, 2622-2626 (1995). 
143. Garland, A.M. et al. Mechanisms of desensitization and resensitization of G protein-coupled 
neurokinin1 and neurokinin2 receptors. Molecular pharmacology 49, 438-446 (1996). 
144. Roosterman, D., Cottrell, G.S., Schmidlin, F., Steinhoff, M. & Bunnett, N.W. Recycling and 
resensitization of the neurokinin 1 receptor. Influence of agonist concentration and Rab GTPases. 
The Journal of biological chemistry 279, 30670-30679 (2004). 
145. Fong, T.M., Anderson, S.A., Yu, H., Huang, R.R. & Strader, C.D. Differential activation of intracellular 
effector by two isoforms of human neurokinin-1 receptor. Molecular pharmacology 41, 24-30 
(1992). 
146. Page, N.M. New challenges in the study of the mammalian tachykinins. Peptides 26, 1356-1368 
(2005). 
147. Li, H. et al. A substance P (neurokinin-1) receptor mutant carboxyl-terminally truncated to resemble 
a naturally occurring receptor isoform displays enhanced responsiveness and resistance to 
desensitization. Proceedings of the National Academy of Sciences of the United States of America 94, 
9475-9480 (1997). 
148. Tuluc, F., Lai, J.P., Kilpatrick, L.E., Evans, D.L. & Douglas, S.D. Neurokinin 1 receptor isoforms and the 
control of innate immunity. Trends in immunology 30, 271-276 (2009). 
149. Harrison, S. & Geppetti, P. Substance p. The international journal of biochemistry & cell biology 33, 
555-576 (2001). 
150. Tattersall, F.D. et al. The novel NK1 receptor antagonist MK-0869 (L-754,030) and its water soluble 
phosphoryl prodrug, L-758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets. 
Neuropharmacology 39, 652-663 (2000). 
151. Dando, T.M. & Perry, C.M. Aprepitant: a review of its use in the prevention of chemotherapy-
induced nausea and vomiting. Drugs 64, 777-794 (2004). 
152. Munoz, M., Rosso, M. & Covenas, R. A new frontier in the treatment of cancer: NK-1 receptor 
antagonists. Current medicinal chemistry 17, 504-516 (2010). 
153. Munoz, M. et al. Antitumor activity of neurokinin-1 receptor antagonists in MG-63 human 
osteosarcoma xenografts. International journal of oncology 44, 137-146 (2014). 
154. Pietsch, T. et al. Characterization of the continuous cell line HepT1 derived from a human 
hepatoblastoma. Laboratory investigation; a journal of technical methods and pathology 74, 809-818 
(1996). 
155. Bresalier, R.S. et al. Mucin production by human colonic carcinoma cells correlates with their 
metastatic potential in animal models of colon cancer metastasis. The Journal of clinical investigation 
87, 1037-1045 (1991). 
156. Berger, M. et al. Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth 
inhibited by aprepitant in vitro and in vivo. Journal of hepatology 60, 985-994 (2014). 
157. Gillespie, E. et al. Truncated neurokinin-1 receptor is increased in colonic epithelial cells from 
patients with colitis-associated cancer. Proceedings of the National Academy of Sciences of the 
United States of America 108, 17420-17425 (2011). 
REFERENCES 
101 
 
158. Ilmer, M. et al. Targeting the Neurokinin-1 Receptor Compromises Canonical Wnt Signaling in 
Hepatoblastoma. Molecular cancer therapeutics 14, 2712-2721 (2015). 
159. Zhang, N. et al. FoxM1 promotes beta-catenin nuclear localization and controls Wnt target-gene 
expression and glioma tumorigenesis. Cancer cell 20, 427-442 (2011). 
160. Stambolic, V., Ruel, L. & Woodgett, J.R. Lithium inhibits glycogen synthase kinase-3 activity and 
mimics wingless signalling in intact cells. Current biology : CB 6, 1664-1668 (1996). 
161. Reya, T. & Clevers, H. Wnt signalling in stem cells and cancer. Nature 434, 843-850 (2005). 
162. Rattis, F.M., Voermans, C. & Reya, T. Wnt signaling in the stem cell niche. Current opinion in 
hematology 11, 88-94 (2004). 
163. Lonardo, E. et al. Nodal/Activin signaling drives self-renewal and tumorigenicity of pancreatic cancer 
stem cells and provides a target for combined drug therapy. Cell stem cell 9, 433-446 (2011). 
164. Haraguchi, N. et al. CD13 is a therapeutic target in human liver cancer stem cells. The Journal of 
clinical investigation 120, 3326-3339 (2010). 
165. Akita, M. et al. Detection of CD133 (prominin-1) in a human hepatoblastoma cell line (HuH-6 clone 
5). Microscopy research and technique 76, 844-852 (2013). 
166. Kim, H. et al. Human hepatocellular carcinomas with "Stemness"-related marker expression: keratin 
19 expression and a poor prognosis. Hepatology 54, 1707-1717 (2011). 
167. de Boer, C.J., van Krieken, J.H., Janssen-van Rhijn, C.M. & Litvinov, S.V. Expression of Ep-CAM in 
normal, regenerating, metaplastic, and neoplastic liver. The Journal of pathology 188, 201-206 
(1999). 
168. Cheung, S.T., Cheung, P.F., Cheng, C.K., Wong, N.C. & Fan, S.T. Granulin-epithelin precursor and ATP-
dependent binding cassette (ABC)B5 regulate liver cancer cell chemoresistance. Gastroenterology 
140, 344-355 (2011). 
169. Brabletz, T. et al. Variable beta-catenin expression in colorectal cancers indicates tumor progression 
driven by the tumor environment. Proceedings of the National Academy of Sciences of the United 
States of America 98, 10356-10361 (2001). 
170. Yang, J. et al. Adenomatous polyposis coli (APC) differentially regulates beta-catenin 
phosphorylation and ubiquitination in colon cancer cells. The Journal of biological chemistry 281, 
17751-17757 (2006). 
171. Garnier, A. et al. Targeting the neurokinin-1 receptor inhibits growth of human colon cancer cells. 
International journal of oncology 47, 151-160 (2015). 
172. Bossy-Wetzel, E., Bakiri, L. & Yaniv, M. Induction of apoptosis by the transcription factor c-Jun. The 
EMBO journal 16, 1695-1709 (1997). 
173. Leppa, S. & Bohmann, D. Diverse functions of JNK signaling and c-Jun in stress response and 
apoptosis. Oncogene 18, 6158-6162 (1999). 
174. Gespach, C. Increasing potential of HER3 signaling in colon cancer progression and therapy. Clinical 
cancer research : an official journal of the American Association for Cancer Research 18, 917-919 
(2012). 
175. Taylor, W.R. & Stark, G.R. Regulation of the G2/M transition by p53. Oncogene 20, 1803-1815 (2001). 
176. Ilmer, M. et al. RSPO2 Enhances Canonical Wnt Signaling to Confer Stemness-Associated Traits to 
Susceptible Pancreatic Cancer Cells. Cancer research 75, 1883-1896 (2015). 
177. Vermeulen, L. et al. Wnt activity defines colon cancer stem cells and is regulated by the 
microenvironment. Nature cell biology 12, 468-476 (2010). 
178. Fuerer, C. & Nusse, R. Lentiviral vectors to probe and manipulate the Wnt signaling pathway. PloS 
one 5, e9370 (2010). 
179. Garnier, A. et al. Truncated neurokinin-1 receptor is an ubiquitous antitumor target in 
hepatoblastoma, and its expression is independent of tumor biology and stage. Oncology Letters 11 
(2015). 
180. Rosso, M., Munoz, M. & Berger, M. The role of neurokinin-1 receptor in the microenvironment of 
inflammation and cancer. TheScientificWorldJournal 2012, 381434 (2012). 
REFERENCES 
102 
 
181. Colotta, F., Allavena, P., Sica, A., Garlanda, C. & Mantovani, A. Cancer-related inflammation, the 
seventh hallmark of cancer: links to genetic instability. Carcinogenesis 30, 1073-1081 (2009). 
182. Mayordomo, C. et al. Targeting of substance P induces cancer cell death and decreases the steady 
state of EGFR and Her2. Journal of cellular physiology 227, 1358-1366 (2012). 
183. Patel, H.J., Ramkissoon, S.H., Patel, P.S. & Rameshwar, P. Transformation of breast cells by truncated 
neurokinin-1 receptor is secondary to activation by preprotachykinin-A peptides. Proceedings of the 
National Academy of Sciences of the United States of America 102, 17436-17441 (2005). 
184. Ramkissoon, S.H., Patel, P.S., Taborga, M. & Rameshwar, P. Nuclear factor-kappaB is central to the 
expression of truncated neurokinin-1 receptor in breast cancer: implication for breast cancer cell 
quiescence within bone marrow stroma. Cancer research 67, 1653-1659 (2007). 
185. Alayev, A. & Holz, M.K. mTOR signaling for biological control and cancer. Journal of cellular 
physiology 228, 1658-1664 (2013). 
186. Wagner, F. et al. Rapamycin blocks hepatoblastoma growth in vitro and in vivo implicating new 
treatment options in high-risk patients. Eur J Cancer 48, 2442-2450 (2012). 
187. Garcia-Recio, S. et al. Substance P autocrine signaling contributes to persistent HER2 activation that 
drives malignant progression and drug resistance in breast cancer. Cancer research 73, 6424-6434 
(2013). 
188. Kovacina, K.S. et al. Identification of a proline-rich Akt substrate as a 14-3-3 binding partner. The 
Journal of biological chemistry 278, 10189-10194 (2003). 
189. Gingras, A.C. et al. Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism. Genes & 
development 13, 1422-1437 (1999). 
190. Shuda, M. et al. CDK1 substitutes for mTOR kinase to activate mitotic cap-dependent protein 
translation. Proceedings of the National Academy of Sciences of the United States of America 112, 
5875-5882 (2015). 
191. Shang, Z.F. et al. 4E-BP1 participates in maintaining spindle integrity and genomic stability via 
interacting with PLK1. Cell Cycle 11, 3463-3471 (2012). 
192. Copp, J., Manning, G. & Hunter, T. TORC-specific phosphorylation of mammalian target of rapamycin 
(mTOR): phospho-Ser2481 is a marker for intact mTOR signaling complex 2. Cancer research 69, 
1821-1827 (2009). 
193. Sekulic, A. et al. A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and 
the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer research 
60, 3504-3513 (2000). 
194. Shah, O.J., Wang, Z. & Hunter, T. Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette 
induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Current biology : CB 14, 
1650-1656 (2004). 
195. Harrington, L.S. et al. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of 
IRS proteins. The Journal of cell biology 166, 213-223 (2004). 
196. Breuleux, M. et al. Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent 
and does not predict tumor cell response to PI3K/mTOR inhibition. Molecular cancer therapeutics 8, 
742-753 (2009). 
197. Chen, K.F. et al. Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired 
resistance to sorafenib in hepatocellular carcinoma cells. The Journal of pharmacology and 
experimental therapeutics 337, 155-161 (2011). 
198. Betz, C. & Hall, M.N. Where is mTOR and what is it doing there? The Journal of cell biology 203, 563-
574 (2013). 
199. Kim, J.E. & Chen, J. Cytoplasmic-nuclear shuttling of FKBP12-rapamycin-associated protein is 
involved in rapamycin-sensitive signaling and translation initiation. Proceedings of the National 
Academy of Sciences of the United States of America 97, 14340-14345 (2000). 
200. Bachmann, R.A., Kim, J.H., Wu, A.L., Park, I.H. & Chen, J. A nuclear transport signal in mammalian 
target of rapamycin is critical for its cytoplasmic signaling to S6 kinase 1. The Journal of biological 
chemistry 281, 7357-7363 (2006). 
REFERENCES 
103 
 
201. Martelli, A.M. et al. The emerging multiple roles of nuclear Akt. Biochimica et biophysica acta 1823, 
2168-2178 (2012). 
202. Wan, X., Harkavy, B., Shen, N., Grohar, P. & Helman, L.J. Rapamycin induces feedback activation of 
Akt signaling through an IGF-1R-dependent mechanism. Oncogene 26, 1932-1940 (2007). 
203. Lickert, H., Bauer, A., Kemler, R. & Stappert, J. Casein kinase II phosphorylation of E-cadherin 
increases E-cadherin/beta-catenin interaction and strengthens cell-cell adhesion. The Journal of 
biological chemistry 275, 5090-5095 (2000). 
204. McCubrey, J.A. et al. GSK-3 as potential target for therapeutic intervention in cancer. Oncotarget 5, 
2881-2911 (2014). 
205. Scheel, C. & Weinberg, R.A. Cancer stem cells and epithelial-mesenchymal transition: concepts and 
molecular links. Seminars in cancer biology 22, 396-403 (2012). 
206. Larue, L. & Bellacosa, A. Epithelial-mesenchymal transition in development and cancer: role of 
phosphatidylinositol 3' kinase/AKT pathways. Oncogene 24, 7443-7454 (2005). 
207. Heuberger, J. & Birchmeier, W. Interplay of cadherin-mediated cell adhesion and canonical Wnt 
signaling. Cold Spring Harbor perspectives in biology 2, a002915 (2010). 
208. Lamouille, S., Xu, J. & Derynck, R. Molecular mechanisms of epithelial-mesenchymal transition. 
Nature reviews. Molecular cell biology 15, 178-196 (2014). 
209. Hulkower, K.I. & Herber, R.L. Cell migration and invasion assays as tools for drug discovery. 
Pharmaceutics 3, 107-124 (2011). 
210. Wu, K.J. & Yang, M.H. Epithelial-mesenchymal transition and cancer stemness: the Twist1-Bmi1 
connection. Bioscience reports 31, 449-455 (2011). 
211. Yu, Y., Ramena, G. & Elble, R.C. The role of cancer stem cells in relapse of solid tumors. Front Biosci 
(Elite Ed) 4, 1528-1541 (2012). 
212. Inoki, K. et al. TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK 
and GSK3 to regulate cell growth. Cell 126, 955-968 (2006). 
213. Bowman, C.J., Ayer, D.E. & Dynlacht, B.D. Foxk proteins repress the initiation of starvation-induced 
atrophy and autophagy programs. Nature cell biology 16, 1202-1214 (2014). 
214. Partridge, L. & Bruning, J.C. Forkhead transcription factors and ageing. Oncogene 27, 2351-2363 
(2008). 
215. Gao, C. et al. Autophagy negatively regulates Wnt signalling by promoting Dishevelled degradation. 
Nature cell biology 12, 781-790 (2010). 
216. Jung, C.H., Ro, S.H., Cao, J., Otto, N.M. & Kim, D.H. mTOR regulation of autophagy. FEBS letters 584, 
1287-1295 (2010). 
217. Noda, T. & Ohsumi, Y. Tor, a phosphatidylinositol kinase homologue, controls autophagy in yeast. 
The Journal of biological chemistry 273, 3963-3966 (1998). 
218. Vadlakonda, L., Pasupuleti, M. & Pallu, R. Role of PI3K-AKT-mTOR and Wnt Signaling Pathways in 
Transition of G1-S Phase of Cell Cycle in Cancer Cells. Frontiers in oncology 3, 85 (2013). 
219. Lepourcelet, M. et al. Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein 
complex. Cancer cell 5, 91-102 (2004). 
220. Moon, R.T., Kohn, A.D., De Ferrari, G.V. & Kaykas, A. WNT and beta-catenin signalling: diseases and 
therapies. Nature reviews. Genetics 5, 691-701 (2004). 
221. Gong, A. & Huang, S. FoxM1 and Wnt/beta-catenin signaling in glioma stem cells. Cancer research 
72, 5658-5662 (2012). 
222. Yoshida, Y., Wang, I.C., Yoder, H.M., Davidson, N.O. & Costa, R.H. The forkhead box M1 transcription 
factor contributes to the development and growth of mouse colorectal cancer. Gastroenterology 
132, 1420-1431 (2007). 
223. Munoz, M. & Covenas, R. Neurokinin-1 receptor: a new promising target in the treatment of cancer. 
Discovery medicine 10, 305-313 (2010). 
224. Esteban, F., Munoz, M., Gonzalez-Moles, M.A. & Rosso, M. A role for substance P in cancer 
promotion and progression: a mechanism to counteract intracellular death signals following 
oncogene activation or DNA damage. Cancer metastasis reviews 25, 137-145 (2006). 
REFERENCES 
104 
 
225. Castro, T.A., Cohen, M.C. & Rameshwar, P. The expression of neurokinin-1 and preprotachykinin-1 in 
breast cancer cells depends on the relative degree of invasive and metastatic potential. Clinical & 
experimental metastasis 22, 621-628 (2005). 
226. Misawa, K. et al. Frequent promoter hypermethylation of tachykinin-1 and tachykinin receptor type 
1 is a potential biomarker for head and neck cancer. Journal of cancer research and clinical oncology 
139, 879-889 (2013). 
227. Cairo, S., Armengol, C. & Buendia, M.A. Activation of Wnt and Myc signaling in hepatoblastoma. 
Front Biosci (Elite Ed) 4, 480-486 (2012). 
228. Nault, J.C. & Villanueva, A. Intratumor molecular and phenotypic diversity in hepatocellular 
carcinoma. Clinical cancer research : an official journal of the American Association for Cancer 
Research 21, 1786-1788 (2015). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
LIST OF ABBREVIATIONS 
105 
 
LIST OF ABBREVIATIONS 
 
4EBP1 
AC 
AFP 
AMPK 
APC 
bFGF 
BWS 
BSA 
cAMP 
CDK1 
CHK1 
CK1 α 
CKII 
COG 
CSC 
DAG 
DAPI 
DEPTOR 
DKK 
DLK1 
DTT 
DMSO 
EDTA  
EGF  
EGFR 
EGTA 
EMT 
EpCAM 
FACS 
FAP 
FCS 
4E binding protein 1 
Adenylate cyclase 
Alpha feto protein 
AMP-activated protein kinase 
Adenomatous polyposis coli 
Basic fibroblast growth factor 
Beckwith-Wiedemann syndrome 
Bovine serum albumin 
Cyclic adenosine monophosphate 
Cyclin-dependent kinase 1 
Checkpoint kinase 1 
Casein kinase 1α 
Casein kinase II 
Children's oncology group 
Cancer stem cells 
Diacylglycerol 
4,6-diamidino-2-pheylindole 
DEP domain-containing mTOR-interacting protein 
Dickkopfs 
Delta-Like 1 Homolog 
Dithiothreitol 
Dimethyl sulfoxide  
Ethylendiamintetraacetate 
Epidermal growth factor 
Epidermal growth factor receptor 
ethylene glycol tetraacetic acid 
Epithelial-mesenchymal transition 
Epithelial cell adhesion molecule 
Fluorescence activated cell sorting 
Familial adenomatosis polyposis 
Fetal calf serum 
LIST OF ABBREVIATIONS 
106 
 
FDA 
FOXM1 
FOXK1 
GAP 
GDP 
GEP 
GFP 
GPCR 
GPOH 
GSK3β 
GTP 
HGF 
IGF 
IGF1R 
IGFBP 
HHIP 
Int1 
IRS 
KLF4 
LEF 
LiCl 
LRP 
MAPK 
MDR 
mLST8 
MnK1 
mTOR 
mTORC 
MTT 
NK1R 
NK2R 
NK3R 
NK1R-fl 
Food and drug administration 
Forkhead box M1 
Forkhead box K1 
GTPase activating protein 
Guanosine 5'-diphosphate 
Granulin/epithelin precursor 
Green fluorescent protein 
G-protein coupled receptors 
German pediatric oncology hematology group 
Glycogen synthase kinase 3β 
Guanosine 5'-triphosphate 
Hepatocyte growth factor 
Insulin like growth factor 
Insulin-like growth factor 1 receptor 
Insulin-like growth factor binding proteins 
Hedgehog-interacting protein 
Integration 1 
Insulin receptor substrate 
Kruppel-like factor 4 
Lymphoid enhancer-binding factor  
Lithium chloride 
Low-density lipoprotein receptor-related protein 
Mitogen-activated protein kinases 
Multidrug resistance 
Mammalian Sec13 protein with lethal 8 
Mitogen-activated protein kinase-interacting kinase 1 
Mammalian target of rapamycin 
Mammalian target of rapamycin complex  
1-(4,5-dimethylthiazol-2-yl)-3,5-diphenylformazan 
Neurokinin-1 receptor 
Neurokinin-2 receptor 
Neurokinin-3 receptor 
Full length form of NK1R 
LIST OF ABBREVIATIONS 
107 
 
NK1R-tr 
OCT4 
p70S6K 
PARP 
PBS 
PDK1 
PH 
PI 
PI3K 
PIKK 
PIP2 
PIP3 
PKA 
PKCα 
PLC 
PLK1 
POSTTEXT 
PRAS40 
PRETEXT 
PTEN 
JAK 
JPLT 
RAPTOR 
Rheb 
Rictor 
RPPA 
RTK 
SDS 
SFA 
SFRP 
SGK1 
SH2 
SIN1 
Truncated form of NK1R 
Octamer-binding transcription factor 4 
p70 ribosomal S6 kinase 
poly ADP ribose polymerase 
Phosphate-buffered saline 
Phosphoinositide-dependent kinase-1 
Pleckstrin homology 
Propidium iodide 
Phosphatidylinositol 3-kinase 
Phosphatidylinositol 3-kinase-related kinase 
Phosphatidylinositol-4,5-diphosphate 
Phosphatidylinositol-3,4,5-triphosphate 
Protein kinase A 
Protein kinase Cα 
Phospholipase C 
Polo-Like Kinase 1 
POST-Treatment EXTent of Tumor 
Proline-rich AKT substrate of 40kDa 
PRE-Treatment tumor EXTension 
Phosphatase and tensin homologue 
Janus kinase 
Japanese study group for pediatric liver tumor 
Regulatory-associated rotein to mTOR 
Ras homolog enriched in brain 
Rapamycin-insensitive companion of TOR 
Reverse-phase protein array 
Receptor tyrosine kinase 
Sodium dodecyl sulfate 
Sphere formation ability 
Secreted frizzled-related proteins 
Serum and glucocorticoid-induced protein kinase 1 
Src Homology 2 
Stress-activated map kinase-interacting protein 1 
LIST OF ABBREVIATIONS 
108 
 
SIOPEL 
SOX2 
SP 
STAT 
STF 
TBE 
TBP 
TCF 
TSC 
International society of pediatric oncology group 
SRY-related HMG-box 2 
Substance P 
Signal transducer and activator of transcription 
Super TOP/FOP 
Tris, Borate, EDTA 
TATA box binding protein 
T-cell factor 
Tuberous sclerosis complex 
 
 
 
 
 
 
 
 
 
 
 
109 
 
 
Eidesstattliche Versicherung 
 
Garnier, Agnès 
Ich erkläre hiermit an Eides statt, dass ich die vorliegende Dissertation mit dem Thema 
 
Neurokinin-1 receptor as a therapeutic target in hepatoblastoma 
 
selbständig verfasst, mich außer der angegebenen keiner weiteren Hilfsmittel bedient und 
alle Erkenntnisse, die aus dem Schrifttum ganz oder annähernd übernommen sind, als 
solche kenntlich gemacht und nach ihrer Herkunft unter Bezeichnung der Fundstelle 
einzeln nachgewiesen habe. 
 
Ich erkläre des Weiteren, dass die hier vorgelegte Dissertation nicht in gleicher oder in 
ähnlicher Form bei einer anderen Stelle zur Erlangung eines akademischen Grades 
eingereicht wurde. 
 
 
 
Ort, Datum      Unterschrift Doktorand 
 
